https://trial.medpath.com/news/7388f2f143f6206a/virginia-approves-incentive-packages-for-astrazeneca-and-eli-lilly-manufacturing-plants 2025-08-27T05:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/30f8687e28cb0e5c/umass-chan-medical-school-partners-with-hongene-biotech-to-expand-access-to-exna-oligonucleotide-technology 2025-08-27T05:55:40+00:00 hourly 0.9 https://trial.medpath.com/news/b4904aa0a595b8bb/verily-shuts-down-medical-device-program-as-alphabet-pivots-to-ai-driven-healthcare-strategy 2025-08-27T05:55:37+00:00 hourly 0.9 https://trial.medpath.com/news/544a193b607b5397/antiva-biosciences-reports-positive-phase-1b-2-results-for-abi-2280-in-high-risk-hpv-treatment 2025-08-27T04:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/9853af4ca2a80a95/psycho-oncology-emerges-as-essential-component-of-comprehensive-cancer-care 2025-08-27T03:09:54+00:00 hourly 0.9 https://trial.medpath.com/news/353812976de93e6c/er-kim-secures-exclusive-distribution-rights-for-cnx-therapeutics-oncology-portfolio-in-central-eastern-europe-and-turkey 2025-08-27T02:01:57+00:00 hourly 0.9 https://trial.medpath.com/news/0186d530dbbc0a9e/zentalis-pharmaceuticals-appoints-james-b-bucher-as-chief-legal-officer-to-support-azenosertib-s-advancement 2025-08-27T02:00:55+00:00 hourly 0.9 https://trial.medpath.com/news/efcee63bd59ea17f/light-based-therapy-shows-cognitive-improvements-in-alzheimer-s-clinical-trials 2025-08-27T02:00:48+00:00 hourly 0.9 https://trial.medpath.com/news/0ef0954b7146620b/avapritinib-shows-durable-long-term-response-in-indolent-systemic-mastocytosis-as-pipeline-expands 2025-08-27T02:00:28+00:00 hourly 0.9 https://trial.medpath.com/news/89d7843cd6929c15/eris-lifesciences-receives-anvisa-approval-for-sterile-injectable-facility-enabling-brazil-market-entry 2025-08-27T02:00:20+00:00 hourly 0.9 https://trial.medpath.com/news/4f1962a85585462d/singapore-s-nanyang-biologics-partners-with-tech-giants-to-accelerate-ai-powered-drug-discovery-platform 2025-08-27T02:00:07+00:00 hourly 0.9 https://trial.medpath.com/news/324898609e6c24d6/santersus-receives-second-fda-breakthrough-device-designation-for-nucleocapture-in-systemic-lupus-erythematosus 2025-08-27T01:59:40+00:00 hourly 0.9 https://trial.medpath.com/news/725cc874fae0d4f2/proxygen-partners-with-epfl-to-advance-ai-driven-molecular-glue-degrader-discovery 2025-08-27T01:58:19+00:00 hourly 0.9 https://trial.medpath.com/news/3fa4e8ff68e99d5b/mount-sinai-researchers-discover-potent-monoclonal-antibodies-against-mpox-with-complete-protection-in-animal-models 2025-08-26T22:24:23+00:00 hourly 0.9 https://trial.medpath.com/news/3d9639ffd440d7be/carb-x-awards-1-1-million-to-phiogen-for-novel-bacteriophage-treatment-against-drug-resistant-e-coli-bloodstream-infections 2025-08-26T22:24:04+00:00 hourly 0.9 https://trial.medpath.com/news/59cf75737aa23c21/briacell-s-cancer-immunotherapy-mechanism-validated-in-nci-collaboration-study 2025-08-26T22:22:29+00:00 hourly 0.9 https://trial.medpath.com/news/eae7c10f64c6f99f/varian-completes-fast-02-flash-radiotherapy-trial-for-bone-metastases-at-uc-cancer-center 2025-08-26T22:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/5d4508548ffac7e1/advicenne-submits-fda-registration-application-for-sibnayal-r-in-rare-kidney-disease-treatment 2025-08-26T22:20:42+00:00 hourly 0.9 https://trial.medpath.com/news/d7bed7851c5b7be4/avita-medical-s-recell-system-demonstrates-36-reduction-in-hospital-stay-for-burn-patients 2025-08-26T22:19:18+00:00 hourly 0.9 https://trial.medpath.com/news/aa906794628ff8ef/cornell-researchers-engineer-bacteria-to-produce-therapeutic-antibodies-at-lower-cost 2025-08-26T22:19:16+00:00 hourly 0.9 https://trial.medpath.com/news/4ce80b453ff30920/amgen-secures-expanded-fda-approval-for-repatha-r-in-cardiovascular-risk-management 2025-08-26T22:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/6664b1fc24b14f4b/arctx-medical-receives-fda-ide-approval-for-pivotal-trial-of-novel-cooling-therapy-for-acute-pancreatitis 2025-08-26T22:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/69faeabd7b05a102/european-regulators-approve-first-in-class-topical-anti-androgen-therapy-for-acne-treatment 2025-08-26T22:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/9f2776aad579ed8c/novel-immunotherapy-combination-achieves-100-disease-control-in-recurrent-glioblastoma-pilot-study 2025-08-26T22:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/ebce31080e9f254a/comprehensive-clinical-trials-review-reveals-global-lennox-gastaut-syndrome-research-landscape 2025-08-26T22:16:27+00:00 hourly 0.9 https://trial.medpath.com/news/eb7e69dd2885a4e5/charles-river-laboratories-joins-eu-backed-easygen-consortium-to-accelerate-bedside-car-t-manufacturing 2025-08-26T18:04:03+00:00 hourly 0.9 https://trial.medpath.com/news/b588b7d098133913/allarity-therapeutics-receives-fda-fast-track-designation-for-stenoparib-in-advanced-ovarian-cancer 2025-08-26T18:02:29+00:00 hourly 0.9 https://trial.medpath.com/news/771db7778dd1c938/appia-bio-shuts-down-cell-therapy-operations-after-failed-partnership-with-kite-pharma 2025-08-26T18:02:20+00:00 hourly 0.9 https://trial.medpath.com/news/236d5c74957a7396/intron-bio-files-patent-applications-for-crispr-cas9-gene-editing-technology-targeting-pasteurella-bacteriophages 2025-08-26T18:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/8f2a528fd7a14391/dendritic-cell-vaccine-shows-promise-in-liver-cancer-trial-extending-progression-free-survival 2025-08-26T18:01:15+00:00 hourly 0.9 https://trial.medpath.com/news/66849c96ac787e5b/polaritybio-completes-phase-iii-enrollment-for-skinte-in-diabetic-foot-ulcers-targeting-first-bla-approval-in-chronic-wounds-since-1997 2025-08-26T18:00:24+00:00 hourly 0.9 https://trial.medpath.com/news/024cbd063430a5ad/curanex-pharmaceuticals-raises-15-million-in-ipo-to-advance-ulcerative-colitis-treatment 2025-08-26T18:00:19+00:00 hourly 0.9 https://trial.medpath.com/news/40d3a83125b38a57/ema-grants-first-ever-orphan-drug-designation-for-radiation-maculopathy-treatment 2025-08-26T17:58:39+00:00 hourly 0.9 https://trial.medpath.com/news/be6730ed39740ccb/qlaris-bio-initiates-phase-ii-trial-for-novel-glaucoma-therapy-qls-111-in-south-korea 2025-08-26T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/badf65d60fd5f165/akeso-reports-record-sales-growth-as-ivonescimab-meets-overall-survival-endpoint-in-phase-iii-trial 2025-08-26T17:57:00+00:00 hourly 0.9 https://trial.medpath.com/news/059cb87d6d3246a7/mosaic-neuroscience-partners-with-ixcells-to-pioneer-patient-specific-als-disease-models 2025-08-26T17:56:55+00:00 hourly 0.9 https://trial.medpath.com/news/3ed2813a753cc89f/sohm-achieves-major-breakthrough-with-abbie-gene-editing-platform-using-advanced-dcas12a-technology 2025-08-26T17:55:56+00:00 hourly 0.9 https://trial.medpath.com/news/ecb066d8710a8df0/correctsequence-therapeutics-achieves-first-successful-sickle-cell-disease-treatment-in-china-using-base-editing-technology-cs-101 2025-08-26T17:53:41+00:00 hourly 0.9 https://trial.medpath.com/news/7fa01116d4656201/virax-biolabs-partners-with-emory-university-for-long-covid-diagnostic-study-using-t-cell-technology 2025-08-26T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/1eeb7c8aca42628d/university-of-iowa-develops-gene-therapy-to-prevent-craniosynostosis-in-newborns 2025-08-26T17:52:50+00:00 hourly 0.9 https://trial.medpath.com/news/bb878bfe15c65c3e/dr-reddy-s-launches-first-in-class-linaclotide-for-chronic-constipation-in-india 2025-08-26T17:52:47+00:00 hourly 0.9 https://trial.medpath.com/news/1f0823d00580f0de/pd-1-pd-l1-inhibitors-show-promise-in-thyroid-cancer-treatment-through-combination-strategies 2025-08-26T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/939f654b2d8fc062/zyus-life-sciences-initiates-phase-2a-trial-for-novel-non-opioid-cancer-pain-treatment 2025-08-26T14:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/1480bdd3d241fc95/abbott-secures-first-denosumab-biosimilar-approval-in-thailand-expanding-access-to-bone-disease-treatment 2025-08-26T13:56:58+00:00 hourly 0.9 https://trial.medpath.com/news/a6237fcbd271963d/controlled-release-drug-delivery-market-expands-with-major-pharma-investment-in-precision-medicine-technologies 2025-08-26T13:56:56+00:00 hourly 0.9 https://trial.medpath.com/news/3ed5e9c35d35637c/antifibrotic-drug-development-gains-momentum-with-3b-in-deals-and-breakthrough-clinical-results 2025-08-26T13:56:20+00:00 hourly 0.9 https://trial.medpath.com/news/af29c42d047e289d/bioarctic-and-novartis-partner-on-braintransporter-technology-for-neurodegeneration-treatment-development 2025-08-26T13:56:17+00:00 hourly 0.9 https://trial.medpath.com/news/8a7498b0f358a3c5/zephyr-ai-names-watson-pharmaceuticals-founder-dr-allen-chao-as-ceo-acquires-aster-insights-to-accelerate-cancer-drug-development 2025-08-26T13:54:30+00:00 hourly 0.9 https://trial.medpath.com/news/82a51be56dd78b7f/oxcia-s-oxc-101-receives-dual-orphan-drug-designation-from-ema-and-fda-for-acute-myeloid-leukemia-treatment 2025-08-26T13:54:14+00:00 hourly 0.9 https://trial.medpath.com/news/583900387f4d30b8/new-clinical-trials-report-maps-global-landscape-for-autoimmune-hemolytic-anemia-research 2025-08-26T13:54:12+00:00 hourly 0.9 https://trial.medpath.com/news/a02bdba2f386c045/novel-panic-disorder-treatment-hb-1-enters-nationwide-clinical-trial-in-australia 2025-08-26T13:54:09+00:00 hourly 0.9 https://trial.medpath.com/news/89ecba6478dcb593/peach-bowl-donates-2-5-million-to-advance-18-pediatric-cancer-clinical-trials 2025-08-26T13:53:52+00:00 hourly 0.9 https://trial.medpath.com/news/7482e3d5b2eeca90/abdera-therapeutics-reports-promising-early-data-for-dll3-targeted-radiopharmaceutical-abd-147-in-small-cell-lung-cancer 2025-08-26T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/280a091122582635/aditxt-s-adimune-advances-dna-based-immune-reprogramming-platform-with-96-patents-eyes-2026-clinical-trials 2025-08-26T09:55:59+00:00 hourly 0.9 https://trial.medpath.com/news/033059db710556a9/panntherapi-advances-pti5803-to-phase-iia-trial-for-drug-resistant-epilepsy 2025-08-26T09:54:42+00:00 hourly 0.9 https://trial.medpath.com/news/c3c79a6e29515c70/first-ever-clinical-trial-launches-to-test-afatinib-in-fanconi-anemia-associated-head-and-neck-cancer 2025-08-26T09:54:06+00:00 hourly 0.9 https://trial.medpath.com/news/7d0339e23fb886c1/basecare-medical-s-gems-culture-medium-receives-nmpa-approval-breaking-30-year-import-monopoly-in-china-s-ivf-market 2025-08-26T09:54:01+00:00 hourly 0.9 https://trial.medpath.com/news/1210ff129a32a125/global-analysis-reveals-critical-dosing-gaps-in-msc-derived-extracellular-vesicle-clinical-trials 2025-08-26T05:56:03+00:00 hourly 0.9 https://trial.medpath.com/news/dcfb292aa128502b/mascc-fellow-advocates-for-comprehensive-supportive-oncology-integration-in-cancer-centers 2025-08-26T03:04:48+00:00 hourly 0.9 https://trial.medpath.com/news/b3770d71960263f2/covid-19-vaccine-stocks-plummet-on-reports-of-potential-market-withdrawal 2025-08-26T01:56:02+00:00 hourly 0.9 https://trial.medpath.com/news/adf68a9f60284079/memgen-initiates-phase-1-combination-trial-of-mem-288-plus-docetaxel-for-advanced-nsclc 2025-08-26T01:55:19+00:00 hourly 0.9 https://trial.medpath.com/news/287001443f4f16bd/fda-cleared-chemo-mouthpiece-reduces-oral-pain-by-46-and-opioid-use-by-68-in-pivotal-cancer-trial 2025-08-26T01:55:16+00:00 hourly 0.9 https://trial.medpath.com/news/ab1d79fcac6d1fcd/vyome-therapeutics-goes-public-through-reverse-merger-advances-phase-ii-trial-for-rare-cancer-wound-condition 2025-08-26T01:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/474f2ccbb719e21c/absci-strengthens-abs-201-hair-loss-program-with-leading-dermatology-experts 2025-08-26T01:53:42+00:00 hourly 0.9 https://trial.medpath.com/news/b712cc28d85880c6/uae-grants-world-s-first-approval-for-tolebrutinib-breakthrough-oral-treatment-for-progressive-multiple-sclerosis 2025-08-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/314eb0b7aa535626/rmtg-subsidiary-opens-advanced-cell-therapy-manufacturing-facility-in-mexico 2025-08-25T21:58:57+00:00 hourly 0.9 https://trial.medpath.com/news/db312ee6ae5f7d36/propanc-biopharma-advances-novel-cancer-drug-prp-to-phase-1b-human-trials-following-4m-nasdaq-ipo 2025-08-25T21:58:52+00:00 hourly 0.9 https://trial.medpath.com/news/8e34d54a7012ba5f/xeris-secures-additional-orange-book-patent-protection-for-recorlev-through-2040 2025-08-25T21:56:30+00:00 hourly 0.9 https://trial.medpath.com/news/953c3df43f3133f7/bridgebio-to-present-cardiovascular-mortality-data-for-acoramidis-at-esc-congress-2025 2025-08-25T21:55:24+00:00 hourly 0.9 https://trial.medpath.com/news/abb8edf2f37e4e3a/trump-administration-reportedly-considering-covid-19-vaccine-withdrawal-within-months 2025-08-25T21:54:26+00:00 hourly 0.9 https://trial.medpath.com/news/b6775114aec56268/arnatar-therapeutics-emerges-with-52m-to-develop-first-in-class-rna-therapy-for-rare-genetic-disease 2025-08-25T21:53:55+00:00 hourly 0.9 https://trial.medpath.com/news/e4d2e1e579542ce4/roche-breaks-ground-on-700m-north-carolina-manufacturing-facility-for-next-generation-obesity-treatments 2025-08-25T21:51:27+00:00 hourly 0.9 https://trial.medpath.com/news/7b65eb13e3365172/fda-issues-form-483-to-novo-nordisk-s-bloomington-plant-over-contamination-and-safety-violations 2025-08-25T21:51:13+00:00 hourly 0.9 https://trial.medpath.com/news/80c0cf959c85f008/fda-expands-repatha-indication-to-include-adults-at-high-risk-for-cardiovascular-events-without-prior-disease-diagnosis 2025-08-25T21:49:44+00:00 hourly 0.9 https://trial.medpath.com/news/b3e76954af183ef0/mannkind-acquires-scpharmaceuticals-for-up-to-360m-to-expand-cardiorenal-portfolio 2025-08-25T18:00:29+00:00 hourly 0.9 https://trial.medpath.com/news/930149af848f2540/fda-approves-forzinity-for-barth-syndrome-following-congressional-advocacy 2025-08-25T17:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/72a6715df44b617e/fda-transitions-to-daily-adverse-event-reporting-for-drugs-and-biologics 2025-08-25T17:59:18+00:00 hourly 0.9 https://trial.medpath.com/news/b72c97cc70a4fe2b/catalyst-pharmaceuticals-secures-patent-protection-for-firdapse-until-2035-through-lupin-settlement 2025-08-25T17:58:40+00:00 hourly 0.9 https://trial.medpath.com/news/a32ef2e2ba47c401/i-mab-strengthens-leadership-team-with-three-new-board-appointments-and-r-d-committee-formation 2025-08-25T17:58:22+00:00 hourly 0.9 https://trial.medpath.com/news/850ca87da19758c7/biofrontera-completes-phase-2b-trial-of-ameluz-for-moderate-to-severe-acne-treatment 2025-08-25T17:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/f08383091a360946/immuneering-partners-with-lilly-for-phase-2-nsclc-combination-trial-testing-dual-mapk-pathway-blockade 2025-08-25T17:57:02+00:00 hourly 0.9 https://trial.medpath.com/news/4bbbf4f906012cad/bristol-myers-squibb-to-present-new-cardiovascular-data-at-esc-congress-2025-including-breakthrough-non-obstructive-hcm-trial-results 2025-08-25T17:56:12+00:00 hourly 0.9 https://trial.medpath.com/news/7d0f46f6df9a44cd/genetic-testing-shows-promise-for-faster-ivf-success-in-women-over-35-pilot-study-finds 2025-08-25T17:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/f1eda26a4984dca5/fda-grants-priority-review-to-omidubicel-for-severe-aplastic-anemia-treatment 2025-08-25T17:53:38+00:00 hourly 0.9 https://trial.medpath.com/news/301226d0c4a34258/amarin-to-present-new-reduce-it-analyses-and-epa-mechanistic-data-at-esc-congress-2025 2025-08-25T17:53:33+00:00 hourly 0.9 https://trial.medpath.com/news/1aa18f9bcf4ed231/arnatar-therapeutics-emerges-from-stealth-with-fda-orphan-drug-designation-for-art4-in-alagille-syndrome 2025-08-25T17:53:25+00:00 hourly 0.9 https://trial.medpath.com/news/a87145a1281bbe4f/danforth-advisors-acquires-pharmadirections-to-create-comprehensive-drug-development-platform 2025-08-25T17:52:22+00:00 hourly 0.9 https://trial.medpath.com/news/f825d4df053901ae/briacell-receives-2-million-nci-grant-to-advance-personalized-prostate-cancer-immunotherapy 2025-08-25T17:52:09+00:00 hourly 0.9 https://trial.medpath.com/news/33aae57eba8ff956/fda-issues-not-approvable-letter-for-envveno-medical-s-venovalve-shares-plummet-76 2025-08-25T17:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/66f49122b8b96319/pcm-trials-emvenio-research-and-clinical-trial-service-consolidate-under-emvenio-clinical-research-brand 2025-08-25T17:50:09+00:00 hourly 0.9 https://trial.medpath.com/news/dfadc7a2ae66fba0/adva-biotechnology-and-autolomous-launch-digital-pioneer-program-to-transform-autologous-cell-therapy-manufacturing 2025-08-25T17:50:01+00:00 hourly 0.9 https://trial.medpath.com/news/c515d267b60cb6f3/bio-libra-study-reveals-gender-disparities-in-cardiac-device-outcomes-for-non-ischemic-cardiomyopathy 2025-08-25T17:47:58+00:00 hourly 0.9 https://trial.medpath.com/news/194a2678bd1c199b/talphera-shares-surge-20-on-nephro-crrt-trial-enrollment-milestone 2025-08-25T17:47:52+00:00 hourly 0.9 https://trial.medpath.com/news/c088fe7f4ae917d1/hereditary-angioedema-pipeline-shows-robust-growth-with-30-therapies-in-development-across-multiple-clinical-stages 2025-08-25T17:44:00+00:00 hourly 0.9 https://trial.medpath.com/news/9de4764c44f255fd/vaxxas-secures-a-90-million-to-advance-needle-free-vaccine-delivery-technology-toward-market 2025-08-25T14:03:36+00:00 hourly 0.9 https://trial.medpath.com/news/007d30ac53b7127b/oryzon-receives-ema-approval-for-first-lsd1-inhibitor-trial-in-sickle-cell-disease 2025-08-25T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c93bd5b9e74c3497/novel-stool-mrna-biomarkers-show-promise-for-non-invasive-colorectal-cancer-detection 2025-08-25T13:55:22+00:00 hourly 0.9 https://trial.medpath.com/news/629478ac249f4158/theravance-biopharma-completes-phase-3-enrollment-for-ampreloxetine-in-rare-neurological-disorder 2025-08-25T13:54:54+00:00 hourly 0.9 https://trial.medpath.com/news/405dc880fcd2ba88/incyclix-bio-raises-11-25-million-to-advance-cdk2-inhibitor-inx-315-for-treatment-resistant-breast-and-ovarian-cancers 2025-08-25T13:54:19+00:00 hourly 0.9 https://trial.medpath.com/news/31ab3b49746c5885/akiram-s-targeted-radiotherapy-akir001-advances-to-next-phase-after-completing-first-patient-cohort-without-safety-concerns 2025-08-25T13:54:05+00:00 hourly 0.9 https://trial.medpath.com/news/ebc7150718434adf/proverum-raises-80-million-series-b-to-commercialize-minimally-invasive-bph-treatment 2025-08-25T13:53:48+00:00 hourly 0.9 https://trial.medpath.com/news/1ce8a00daf73bad0/wingor-biotechnology-secures-tens-of-millions-in-funding-to-advance-stem-cell-and-gene-therapy-pipeline 2025-08-25T13:53:34+00:00 hourly 0.9 https://trial.medpath.com/news/f4938e127e883fad/organox-acquired-for-1-5-billion-in-one-of-uk-s-largest-medtech-exits 2025-08-25T13:53:25+00:00 hourly 0.9 https://trial.medpath.com/news/9448ecb6c2e2bb37/royalty-pharma-acquires-950-million-imdelltra-royalty-rights-from-beone-medicines 2025-08-25T13:52:13+00:00 hourly 0.9 https://trial.medpath.com/news/ac1ef38841a9b165/leads-biolabs-advances-first-in-china-gprc5d-t-cell-engager-lbl-034-to-phase-ii-trial 2025-08-25T13:51:43+00:00 hourly 0.9 https://trial.medpath.com/news/38ecba86e715e018/royalty-pharma-acquires-885-million-royalty-interest-in-amgen-s-imdelltra-for-small-cell-lung-cancer 2025-08-25T13:51:37+00:00 hourly 0.9 https://trial.medpath.com/news/2e933f7bacf5034f/dexa-psych-trial-investigates-dexamethasone-as-rapid-acting-depression-treatment 2025-08-25T13:51:31+00:00 hourly 0.9 https://trial.medpath.com/news/f29e2b9340bb4491/oculis-strengthens-leadership-with-appointment-of-two-world-renowned-ophthalmology-experts-as-chief-medical-advisors 2025-08-25T13:50:50+00:00 hourly 0.9 https://trial.medpath.com/news/f15d0b49a3151005/lumateperone-shows-significant-efficacy-as-adjunctive-therapy-for-treatment-resistant-major-depression 2025-08-25T13:50:39+00:00 hourly 0.9 https://trial.medpath.com/news/227a7ce2daebc286/south-african-hiv-cure-trial-achieves-breakthrough-one-woman-may-be-cured-using-novel-kick-and-kill-strategy 2025-08-25T13:50:31+00:00 hourly 0.9 https://trial.medpath.com/news/1365d148ceabc87f/gd2-targeting-car-t-cells-show-66-response-rate-in-high-risk-neuroblastoma-trial 2025-08-25T09:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/0372cb1c6cc1bfa0/lundbeck-s-bexicaserin-shows-sustained-59-seizure-reduction-in-rare-epilepsy-extension-study 2025-08-25T09:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/33194492d18fa094/neuren-pharmaceuticals-launches-first-ever-phase-3-trial-for-phelan-mcdermid-syndrome 2025-08-25T09:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/96fb81948a15ccf5/gsk-launches-first-pd-1-immunotherapy-and-parp-inhibitor-for-gynecological-cancers-in-india 2025-08-25T09:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/8e6243b2a941e926/cambrex-expands-peptide-manufacturing-capabilities-with-20-facility-growth-in-massachusetts 2025-08-25T09:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/fecf4e83780066ae/vyvgart-achieves-primary-endpoint-in-phase-3-trial-for-achr-ab-seronegative-myasthenia-gravis 2025-08-25T09:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/b24a6494546f7bcc/chinese-scientists-develop-first-human-stem-cell-derived-a10-dopamine-neurons-for-depression-treatment 2025-08-25T09:20:54+00:00 hourly 0.9 https://trial.medpath.com/news/b1b9547f8a7fc1be/expecto-health-science-partners-with-vertispro-to-deploy-ai-driven-patient-recruitment-in-asia-pacific-clinical-trials 2025-08-25T09:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/1c5764ae9a39e44d/pbac-rejects-pbs-listing-for-alzheimer-s-drug-donanemab-despite-clinical-need 2025-08-25T05:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/0639281f867b639c/harbour-biomed-appoints-yajie-li-as-chief-medical-officer-to-advance-antibody-therapeutics-pipeline 2025-08-25T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/9e4f0ba7ef2a54b3/metformin-shows-potential-survival-benefit-in-her2-positive-breast-cancer-patients 2025-08-25T01:03:45+00:00 hourly 0.9 https://trial.medpath.com/news/ff9a52bbecec6943/legend-innovation-life-science-fund-commits-50-million-to-mid-atlantic-biotherapeutics-for-anti-aging-drug-development 2025-08-24T17:50:29+00:00 hourly 0.9 https://trial.medpath.com/news/20b5dde5164c4322/savara-to-present-phase-3-impala-2-trial-data-and-host-apap-symposium-at-ers-congress-2025 2025-08-24T17:50:18+00:00 hourly 0.9 https://trial.medpath.com/news/6b2a1d1ce80d91f0/cancer-immunotherapy-strategies-repurposed-for-autoimmune-disease-treatment-show-promise-in-early-studies 2025-08-24T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/583efb47e0bfe9f8/akums-drugs-partners-with-zambian-government-to-establish-50-million-pharmaceutical-manufacturing-facility 2025-08-24T13:34:31+00:00 hourly 0.9 https://trial.medpath.com/news/7db51fb7de63e57c/stellate-ganglion-block-shows-promise-for-ptsd-treatment-with-68-78-success-rate-in-israel 2025-08-24T13:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/9a895c1e4b368a20/cancer-patients-show-strong-confidence-in-pharmacist-delivered-vaccines-despite-low-vaccination-rates 2025-08-24T03:05:13+00:00 hourly 0.9 https://trial.medpath.com/news/12f66a74a29cb1e2/real-world-data-reveals-higher-infection-risk-with-ms-treatments-particularly-ocrelizumab 2025-08-24T03:04:49+00:00 hourly 0.9 https://trial.medpath.com/news/b52a4bc6f6143a0f/rasal2-variant-identified-as-novel-biomarker-for-anti-egfr-therapy-resistance-in-colorectal-cancer 2025-08-24T01:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/83c996a80585b29f/sarepta-therapeutics-refinances-700m-convertible-notes-to-strengthen-financial-position 2025-08-23T21:52:31+00:00 hourly 0.9 https://trial.medpath.com/news/17b4a5ddaf809a72/biogen-advances-litifilimab-development-with-phase-3-extension-study-and-novel-drug-delivery-research-for-lupus-treatment 2025-08-23T21:49:32+00:00 hourly 0.9 https://trial.medpath.com/news/cd119276454dd5e8/immunitybio-s-anktiva-shows-promise-in-reversing-lymphopenia-in-advanced-lung-cancer-patients 2025-08-23T21:48:49+00:00 hourly 0.9 https://trial.medpath.com/news/0b9121d4daa047df/dynavax-technologies-z-1018-shingles-vaccine-shows-promise-in-phase-1-2-trial-with-improved-safety-profile 2025-08-23T21:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/9778f46a880d8d75/infliximab-biosimilar-ct-p13-demonstrates-safety-and-efficacy-in-real-world-rheumatoid-arthritis-treatment 2025-08-23T21:47:55+00:00 hourly 0.9 https://trial.medpath.com/news/f2e54b5df57db5e6/boston-scientific-issues-class-i-recall-of-carotid-wallstent-over-manufacturing-defect-linked-to-stroke-risk 2025-08-23T21:47:28+00:00 hourly 0.9 https://trial.medpath.com/news/a07ea5f03a0b1061/larkspur-biosciences-unveils-first-in-class-pip4k2c-degrader-lrk-4189-for-microsatellite-stable-colorectal-cancer 2025-08-23T17:53:12+00:00 hourly 0.9 https://trial.medpath.com/news/56df3b315a8282c6/fda-approves-first-myopia-treatment-for-children-and-barth-syndrome-therapy-in-september-2025 2025-08-23T17:52:30+00:00 hourly 0.9 https://trial.medpath.com/news/0e94d627a726b9c8/pbac-rejects-multi-cancer-funding-model-for-keytruda-after-eight-years-of-deliberation 2025-08-23T17:49:53+00:00 hourly 0.9 https://trial.medpath.com/news/744a259563e034e5/defence-therapeutics-raises-up-to-1-2m-through-convertible-debenture-financing-to-advance-adc-platform 2025-08-23T17:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/bc63e6fa0291dfaf/agilent-technologies-receives-fda-approval-for-first-of-its-kind-colorectal-cancer-companion-diagnostic 2025-08-23T17:48:51+00:00 hourly 0.9 https://trial.medpath.com/news/8a6b0af1f4a424df/corbion-and-kuehnle-agrosystems-partner-to-develop-natural-astaxanthin-through-algae-fermentation 2025-08-23T13:46:29+00:00 hourly 0.9 https://trial.medpath.com/news/80572bdd16c3b40e/lb-pharmaceuticals-files-for-100-million-ipo-to-advance-schizophrenia-drug-lb-102-into-phase-iii 2025-08-23T13:46:27+00:00 hourly 0.9 https://trial.medpath.com/news/52210581bf97764c/tempus-ai-acquires-paige-to-build-world-s-largest-oncology-foundation-model 2025-08-23T13:44:42+00:00 hourly 0.9 https://trial.medpath.com/news/c5a4c8cca41eb078/anlon-healthcare-sets-ipo-price-band-at-86-91-per-share-for-121-crore-public-offering 2025-08-23T09:48:01+00:00 hourly 0.9 https://trial.medpath.com/news/f79bb2b12a7e5763/fluorescent-probes-reveal-how-tirzepatide-targets-pancreas-and-brain-cells 2025-08-23T09:46:01+00:00 hourly 0.9 https://trial.medpath.com/news/7d8250fdff73e159/astrazeneca-partners-with-philippines-to-establish-first-pharmaceutical-innovation-hub-in-peza-ecozone 2025-08-23T05:46:00+00:00 hourly 0.9 https://trial.medpath.com/news/bda9ac9ce3e2c1fa/anti-pd-1-immunotherapy-shows-superior-outcomes-in-gastric-cancer-patients-with-chronic-hepatitis-b 2025-08-23T05:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/db239ce949fadd5a/fda-rejects-blu-disposable-e-cigarette-marketing-application-over-dual-use-concerns 2025-08-23T05:44:58+00:00 hourly 0.9 https://trial.medpath.com/news/7ca30730bde8307f/oncologists-explore-two-year-immunotherapy-duration-for-advanced-nsclc-to-balance-efficacy-and-financial-burden 2025-08-23T03:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/0307a1cfc632c9ba/nci-funding-cut-forces-pediatric-brain-tumor-consortium-to-halt-clinical-trial-enrollment 2025-08-23T01:49:28+00:00 hourly 0.9 https://trial.medpath.com/news/fb8589fb6f76faf7/blossomhill-therapeutics-advances-egfr-mutant-nsclc-treatment-with-first-in-class-omni-egfr-inhibitor-bh-30643 2025-08-23T01:49:21+00:00 hourly 0.9 https://trial.medpath.com/news/bc92487cfc4c34ce/novel-basket-trial-design-targets-multiple-rare-fibrotic-skin-diseases-with-single-antifibrotic-therapy 2025-08-23T01:49:14+00:00 hourly 0.9 https://trial.medpath.com/news/9c140a8b81baec1d/miami-valley-hospital-south-leads-global-bella-trial-testing-relacorilant-for-platinum-resistant-ovarian-cancer 2025-08-22T21:50:16+00:00 hourly 0.9 https://trial.medpath.com/news/305829683d40461f/aahi-partners-with-quratis-to-accelerate-global-vaccine-development-for-tuberculosis-malaria-and-hiv 2025-08-22T21:49:58+00:00 hourly 0.9 https://trial.medpath.com/news/e208e9cf822db57f/gift-card-incentives-significantly-boost-low-income-participation-in-alzheimer-s-clinical-trial-registry 2025-08-22T21:48:43+00:00 hourly 0.9 https://trial.medpath.com/news/f52805b4f68f0053/indian-parliamentary-panel-calls-for-expanded-price-controls-on-cancer-drugs-including-immunotherapy-and-vaccines 2025-08-22T17:56:57+00:00 hourly 0.9 https://trial.medpath.com/news/35ae5de10b6efe90/tirzepatide-shows-promise-for-weight-loss-and-brown-adipose-tissue-activation-in-obesity-treatment 2025-08-22T17:53:49+00:00 hourly 0.9 https://trial.medpath.com/news/c6ba8e1462be68b5/cube-biotech-and-x-chem-breakthrough-enables-dna-encoded-library-screening-of-membrane-proteins 2025-08-22T17:53:28+00:00 hourly 0.9 https://trial.medpath.com/news/7f631f73dc7ec6e6/cantargia-advances-nadunolimab-development-following-trifour-trial-results-secures-otsuka-partnership-for-can10-program 2025-08-22T17:53:26+00:00 hourly 0.9 https://trial.medpath.com/news/74b4f678ec35632c/lighthouse-pharmaceuticals-secures-49-2-million-nih-grant-for-novel-alzheimer-s-disease-treatment-targeting-bacterial-infection 2025-08-22T17:53:13+00:00 hourly 0.9 https://trial.medpath.com/news/c8ec634f158c2f14/fda-delays-gene-therapy-approval-for-sanfilippo-syndrome-until-2026-affecting-young-patients 2025-08-22T17:52:20+00:00 hourly 0.9 https://trial.medpath.com/news/3cad8f8254cc4015/yale-researchers-repurpose-cancer-drug-erlotinib-for-rare-genetic-skin-disorder 2025-08-22T17:52:07+00:00 hourly 0.9 https://trial.medpath.com/news/884e7d4f1b989a73/jyong-biotech-s-botreso-r-shows-promising-phase-iii-results-for-benign-prostatic-hyperplasia-treatment 2025-08-22T17:52:00+00:00 hourly 0.9 https://trial.medpath.com/news/5e6d3b2031d044b6/ten-year-study-confirms-long-term-safety-of-biosimilar-filgrastim-in-healthy-stem-cell-donors 2025-08-22T17:51:57+00:00 hourly 0.9 https://trial.medpath.com/news/6670d4b73d03ed3b/optimized-drug-treatment-reduces-mortality-in-acute-type-a-aortic-dissection-patients 2025-08-22T17:51:55+00:00 hourly 0.9 https://trial.medpath.com/news/25af7db8a6d5d7c3/fda-cancels-advisory-committee-meeting-for-biohaven-s-troriluzole-signaling-potential-regulatory-clarity 2025-08-22T17:49:41+00:00 hourly 0.9 https://trial.medpath.com/news/9e4e732c02770dd4/scientists-identify-protective-antibodies-against-strep-a-paving-way-for-life-saving-vaccine 2025-08-22T13:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/7ef0fa9a06c314bd/invivyd-raises-57-5-million-to-advance-monoclonal-antibody-pipeline-targeting-rsv-measles-and-long-covid 2025-08-22T13:23:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a77f3ca779fa369/australian-researchers-launch-human-challenge-trial-to-accelerate-strep-a-vaccine-development 2025-08-22T13:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/1cd129ced1dbcd88/esaote-s-mylab-a50-and-a70-ultrasound-systems-receive-fda-approval-for-us-market 2025-08-22T13:18:18+00:00 hourly 0.9 https://trial.medpath.com/news/a0092aa52b8eb279/valitor-s-vltr-559-shows-favorable-safety-profile-in-preclinical-studies-for-twice-yearly-wet-amd-treatment 2025-08-22T10:00:47+00:00 hourly 0.9 https://trial.medpath.com/news/8d320b4e4a39c2c2/lupus-nephritis-pipeline-shows-strong-activity-with-35-companies-developing-40-investigational-therapies 2025-08-22T09:55:12+00:00 hourly 0.9 https://trial.medpath.com/news/3e3b9278159ab017/nugen-medical-devices-develops-next-generation-needle-free-injection-system-with-internal-cartridge-technology 2025-08-22T09:53:10+00:00 hourly 0.9 https://trial.medpath.com/news/bd0c97cef574a014/biotech-companies-develop-glp-1-implant-for-pet-obesity-targeting-2028-market-launch 2025-08-22T07:02:00+00:00 hourly 0.9 https://trial.medpath.com/news/84a40ef671a22da7/vaginal-estrogen-tablets-show-no-increased-stroke-risk-for-postmenopausal-women-with-prior-stroke-history 2025-08-22T02:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/2c83b901bf13d28b/artrya-receives-fda-clearance-for-ai-powered-coronary-plaque-detection-module-expands-us-revenue-opportunity 2025-08-22T02:04:57+00:00 hourly 0.9 https://trial.medpath.com/news/ffdd1281f47fc0b4/cyclophilin-inhibitor-shows-promise-for-reversing-alcohol-related-liver-fibrosis-in-human-tissue-models 2025-08-22T02:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/cdb9251be9e863cb/adalimumab-increases-infection-risk-53-in-hidradenitis-suppurativa-patients-compared-to-psoriasis 2025-08-22T02:04:09+00:00 hourly 0.9 https://trial.medpath.com/news/3cc47893c9b0a385/oral-testosterone-undecanoate-shows-superior-sexual-function-improvements-in-phase-3-trial 2025-08-22T02:03:21+00:00 hourly 0.9 https://trial.medpath.com/news/d6a35acb79e4b3fb/xoma-royalty-acquires-mural-oncology-for-36-2-million-in-strategic-biotech-consolidation 2025-08-22T02:02:46+00:00 hourly 0.9 https://trial.medpath.com/news/f0e31ce3a24998c1/rambam-hospital-pioneers-crispr-gene-therapy-trial-for-cardiac-amyloidosis 2025-08-22T02:02:41+00:00 hourly 0.9 https://trial.medpath.com/news/15b41f2fecafd8e1/fda-inspection-reveals-contamination-issues-at-novo-nordisk-s-indiana-manufacturing-plant 2025-08-22T02:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/d4c4658042810f42/vanda-pharmaceuticals-appeals-to-fda-commissioner-makary-over-generic-hetlioz-approvals-following-court-victory 2025-08-22T02:00:22+00:00 hourly 0.9 https://trial.medpath.com/news/37017970a84b4a96/biontech-s-bnt113-mrna-cancer-vaccine-advances-in-phase-2-trial-for-hpv-head-and-neck-cancer 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/40c713f9b9c401ef/thryv-therapeutics-unveils-breakthrough-sgk1-inhibitor-data-for-heart-failure-and-long-qt-syndrome-at-esc-congress-2025 2025-08-22T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d61609fb0634ef38/thermo-fisher-scientific-opens-192-5m-manufacturing-facility-to-boost-us-laboratory-supply-chain 2025-08-21T21:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/c5ac4ad212a33de7/ibt-s-ibp-9414-shows-27-reduction-in-death-risk-for-premature-infants-with-nec-in-phase-iii-trial 2025-08-21T20:55:46+00:00 hourly 0.9 https://trial.medpath.com/news/aaf3871390095446/pneumococcal-disease-pipeline-shows-strong-growth-with-20-therapies-in-development 2025-08-21T20:46:54+00:00 hourly 0.9 https://trial.medpath.com/news/a918131aa4c2b12e/krystal-biotech-prioritizes-inhaled-kb707-for-nsclc-treatment-secures-fda-end-of-phase-2-meeting 2025-08-21T20:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/8553b22467531bba/robotic-manufacturing-achieves-74-cost-reduction-in-cell-therapy-production 2025-08-21T20:41:53+00:00 hourly 0.9 https://trial.medpath.com/news/29aeab2df75f6776/smsbiotech-launches-first-in-human-phase-1-trial-of-novel-stem-cell-therapy-for-copd 2025-08-21T20:41:38+00:00 hourly 0.9 https://trial.medpath.com/news/e0006be64dd47f78/bispecific-innate-cell-engager-afm28-shows-promise-against-leukemic-stem-cells-in-aml-and-mds 2025-08-21T20:40:07+00:00 hourly 0.9 https://trial.medpath.com/news/a8255ce0985ad0e7/european-scientists-propose-alliance-to-advance-proximity-induced-drug-development-for-undruggable-targets 2025-08-21T20:26:10+00:00 hourly 0.9 https://trial.medpath.com/news/2fbc4de619cb216c/johnson-johnson-commits-2-billion-to-north-carolina-manufacturing-facility-in-major-us-investment-push 2025-08-21T20:23:22+00:00 hourly 0.9 https://trial.medpath.com/news/9fe2ec5b671f2677/realta-life-sciences-receives-european-orphan-drug-designation-for-graft-versus-host-disease-treatment 2025-08-21T20:22:07+00:00 hourly 0.9 https://trial.medpath.com/news/7016a696ea1916d8/protagenic-therapeutics-advances-novel-tcap-based-therapy-pt00114-into-multiple-dose-phase-1-trial-for-stress-related-disorders 2025-08-21T20:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/d7afe151a34b14f2/septerna-initiates-first-in-human-trial-of-sep-631-for-chronic-spontaneous-urticaria 2025-08-21T20:18:07+00:00 hourly 0.9 https://trial.medpath.com/news/ebd7c6f177eea31f/dynavax-s-z-1018-shingles-vaccine-matches-gsk-s-shingrix-efficacy-with-superior-tolerability-in-phase-i-ii-trial 2025-08-21T20:17:51+00:00 hourly 0.9 https://trial.medpath.com/news/4db29baade87178b/kite-acquires-interius-biotherapeutics-for-350m-to-advance-in-vivo-car-t-platform 2025-08-21T20:17:42+00:00 hourly 0.9 https://trial.medpath.com/news/afcc3dc71df70307/novartis-secures-pan-canadian-agreement-for-leqvio-access-in-familial-hypercholesterolemia 2025-08-21T20:10:23+00:00 hourly 0.9 https://trial.medpath.com/news/72ee552883d07d69/fda-grants-orphan-drug-designation-to-crinetics-atumelnant-for-congenital-adrenal-hyperplasia-treatment 2025-08-21T20:09:21+00:00 hourly 0.9 https://trial.medpath.com/news/42a179293e315d38/zeiss-receives-ce-mark-approval-for-ai-powered-cirrus-pathfinder-oct-assessment-tool 2025-08-21T20:08:35+00:00 hourly 0.9 https://trial.medpath.com/news/a9c190b6c1cb2c8a/andelyn-biosciences-partners-with-amplo-biotechnology-to-advance-aav-gene-therapies-for-neuromuscular-junction-disorders 2025-08-21T20:05:03+00:00 hourly 0.9 https://trial.medpath.com/news/eb45bfa4c38eb4a5/scilex-subsidiary-semnur-secures-20-million-funding-for-sp-102-phase-3-trial-in-sciatica-treatment 2025-08-21T20:04:37+00:00 hourly 0.9 https://trial.medpath.com/news/6ab5c3d3a8b295b2/catheter-precision-initiates-locket-compare-study-to-evaluate-safety-of-external-suture-retention-device 2025-08-21T20:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/e9d92d7a6ca64b61/remote-weight-loss-intervention-shows-significant-success-in-breast-cancer-survivors-at-one-year-mark 2025-08-21T20:02:11+00:00 hourly 0.9 https://trial.medpath.com/news/8ec6353dfe4f186d/researchers-identify-anti-mouse-pd-1-agonist-antibodies-that-inhibit-t-cell-activation 2025-08-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/870bf56c4bb72cdd/johnson-johnson-commits-55-billion-to-u-s-manufacturing-expansion-in-strategic-reshoring-initiative 2025-08-21T15:02:12+00:00 hourly 0.9 https://trial.medpath.com/news/1fd582069e0119c4/mendus-expands-vididencel-clinical-strategy-across-aml-risk-categories-and-into-chronic-myeloid-leukemia 2025-08-21T15:00:34+00:00 hourly 0.9 https://trial.medpath.com/news/96c0eee304ab0fb9/takeda-pharmaceutical-explores-india-for-global-clinical-trials-to-accelerate-drug-launches 2025-08-21T14:59:57+00:00 hourly 0.9 https://trial.medpath.com/news/c85561464d0a173b/strand-therapeutics-appoints-cancer-immunotherapy-pioneer-dr-jason-luke-as-chief-medical-officer 2025-08-21T14:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/1c39185f890bd826/gist-treatment-pipeline-shows-robust-activity-with-28-therapies-in-development-across-multiple-clinical-phases 2025-08-21T14:58:30+00:00 hourly 0.9 https://trial.medpath.com/news/96ba88e9352dc453/oncozenge-secures-funding-for-european-phase-iii-cancer-trial-as-alzinova-advances-alzheimer-s-program 2025-08-21T14:57:12+00:00 hourly 0.9 https://trial.medpath.com/news/b9f36251b4b01300/boehringer-ingelheim-partners-with-anges-for-hgf-gene-therapy-manufacturing-ahead-of-fda-filing 2025-08-21T14:56:32+00:00 hourly 0.9 https://trial.medpath.com/news/09bc8429fe527b98/krystal-biotech-halts-melanoma-study-of-kb707-following-fda-rejection-of-similar-viral-immunotherapy 2025-08-21T14:55:53+00:00 hourly 0.9 https://trial.medpath.com/news/abdc2be0fa06bf9b/nuwellis-receives-fda-510-k-clearance-for-extended-length-catheter-to-enhance-fluid-management-platform 2025-08-21T12:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/d73d17f38212c1ea/fat-trapping-microbeads-show-promise-for-drug-free-weight-loss-in-preclinical-study 2025-08-21T10:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/1c4657feab44cf43/world-s-first-gene-therapy-for-p47-chronic-granulomatous-disease-shows-success-in-teenage-patient 2025-08-21T09:50:13+00:00 hourly 0.9 https://trial.medpath.com/news/cc16a32342f01774/molecular-partners-appoints-martin-steegmaier-as-chief-scientific-officer-to-advance-darpin-therapeutics-pipeline 2025-08-21T09:50:08+00:00 hourly 0.9 https://trial.medpath.com/news/5beaf3cf3e8ffb06/jak-inhibitor-pipeline-shows-robust-growth-with-55-therapies-in-development-across-multiple-therapeutic-areas 2025-08-21T08:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/5415639508f1e7ea/cvs-health-declines-coverage-for-gilead-s-hiv-prevention-drug-yeztugo-despite-99-9-efficacy 2025-08-21T04:48:59+00:00 hourly 0.9 https://trial.medpath.com/news/6a5d54faf5d82fb1/trethera-secures-5-3-million-in-nih-funding-to-advance-first-in-class-dck-inhibitor-tre-515-across-cancer-and-autoimmune-indications 2025-08-21T04:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/7c22a5ba839f75c7/paroxysmal-nocturnal-hemoglobinuria-pipeline-shows-robust-development-with-25-therapies-from-leading-pharmaceutical-companies 2025-08-21T04:44:53+00:00 hourly 0.9 https://trial.medpath.com/news/74adbff53223392e/esophageal-cancer-pipeline-shows-promise-with-100-therapies-in-development-across-80-companies 2025-08-21T04:44:39+00:00 hourly 0.9 https://trial.medpath.com/news/99bbe280f9564aec/tryptamine-therapeutics-partners-with-imperial-college-to-develop-eeg-based-biomarker-for-precision-psychedelic-therapy 2025-08-21T04:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/1df938725f876c21/ascentage-pharma-reports-strong-growth-with-93-increase-in-olverembatinib-sales-and-historic-lisaftoclax-approval 2025-08-21T04:43:37+00:00 hourly 0.9 https://trial.medpath.com/news/2610cc1f35e2108f/equitable-access-to-biomarker-testing-and-perioperative-treatment-critical-for-nsclc-outcomes 2025-08-21T04:39:46+00:00 hourly 0.9 https://trial.medpath.com/news/311749fa421074f2/xoma-royalty-acquires-mural-oncology-for-35-2-38-8m-in-latest-biotech-liquidation-deal 2025-08-21T03:07:42+00:00 hourly 0.9 https://trial.medpath.com/news/07c8a5cf276cafb5/steel-therapeutics-advances-fizurex-topical-wipe-for-anal-fissures-with-2m-funding-and-pivotal-toxicology-study 2025-08-21T03:07:39+00:00 hourly 0.9 https://trial.medpath.com/news/c22d95e4b80d5996/kromatid-secures-8-million-series-c-to-advance-genomic-analysis-platform-for-gene-and-cell-therapy 2025-08-21T03:07:30+00:00 hourly 0.9 https://trial.medpath.com/news/c951eecccd8c7c8b/savara-s-inhaled-molgramostim-shows-9-8-lung-function-improvement-in-phase-3-autoimmune-pap-trial 2025-08-21T03:06:10+00:00 hourly 0.9 https://trial.medpath.com/news/066a977d31aec279/chempartner-establishes-boston-r-d-center-to-strengthen-u-s-biopharma-partnerships 2025-08-21T03:06:05+00:00 hourly 0.9 https://trial.medpath.com/news/418d059c4e90328d/primary-hyperoxaluria-pipeline-shows-promise-with-6-therapies-in-development-as-gene-editing-advances 2025-08-21T03:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/9af1bb929e5bba43/experimental-epilepsy-drug-z944-reverses-autism-like-behaviors-in-preclinical-study 2025-08-21T03:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/8ea7802ab1e5a4a6/hdac-inhibitors-market-projected-to-surge-through-2034-as-next-generation-cancer-therapies-advance-in-clinical-trials 2025-08-21T03:05:46+00:00 hourly 0.9 https://trial.medpath.com/news/4f052375f94d53d4/greenwich-lifesciences-advances-phase-iii-flamingo-01-trial-for-her2-positive-breast-cancer-immunotherapy 2025-08-21T03:05:40+00:00 hourly 0.9 https://trial.medpath.com/news/df69ebcba7e64122/healthcare-coalition-urges-cms-to-accelerate-medicare-coverage-for-breakthrough-medical-devices 2025-08-21T03:04:58+00:00 hourly 0.9 https://trial.medpath.com/news/b86a45663af56bea/nhs-approves-breakthrough-bladder-cancer-treatment-that-doubles-survival-rates 2025-08-21T03:04:51+00:00 hourly 0.9 https://trial.medpath.com/news/4b467dd94120e7fa/crispr-screen-identifies-gator1-complex-as-key-suppressor-of-myc-driven-lymphomas-with-therapeutic-implications 2025-08-21T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/502c7335c54d98c7/accelerated-manufacturing-platform-enables-rapid-hiv-vaccine-production-for-clinical-trials 2025-08-20T21:14:46+00:00 hourly 0.9 https://trial.medpath.com/news/af045b5fd770cbe3/trehalose-loaded-lipid-nanoparticles-enhance-mrna-vaccine-stability-and-bridge-in-vitro-in-vivo-efficacy-gap 2025-08-20T21:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/9a2b5f44cfb0277e/novo-nordisk-completes-phase-i-trial-for-investigational-oral-drug-nnc0560-0004 2025-08-20T21:12:58+00:00 hourly 0.9 https://trial.medpath.com/news/33900f3eb81ce812/elysium-therapeutics-advances-novel-fentanyl-overdose-rescue-therapy-following-fda-pre-ind-meeting 2025-08-20T21:12:45+00:00 hourly 0.9 https://trial.medpath.com/news/a9f3b1386e446106/fda-upholds-rejection-of-envveno-s-venovalve-for-chronic-venous-insufficiency-treatment 2025-08-20T21:09:47+00:00 hourly 0.9 https://trial.medpath.com/news/a69b9b05a5263989/stanford-research-demonstrates-ultra-high-concentration-biologic-delivery-via-subcutaneous-injection 2025-08-20T21:09:05+00:00 hourly 0.9 https://trial.medpath.com/news/46fc316986a98286/evolus-submits-fda-application-for-evolysse-sculpt-mid-face-dermal-filler 2025-08-20T21:08:59+00:00 hourly 0.9 https://trial.medpath.com/news/887389c7402b635d/rituximab-outperforms-cladribine-in-real-world-multiple-sclerosis-study 2025-08-20T21:04:46+00:00 hourly 0.9 https://trial.medpath.com/news/49b3ef086967c44a/enanta-pharmaceuticals-challenges-pfizer-s-paxlovid-in-european-patent-court-seeking-damages-for-antiviral-ip-infringement 2025-08-20T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/6317d21cce097241/sun-pharma-receives-mixed-cdsco-decisions-on-dermatology-drug-trials 2025-08-20T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/5824113ea63c2cb2/tivic-health-advances-entolimod-development-with-two-fda-investigational-new-drug-applications 2025-08-20T17:17:52+00:00 hourly 0.9 https://trial.medpath.com/news/99d04cf7aee0eccb/former-fda-commissioner-stephen-hahn-named-ceo-of-radiopharmaceuticals-cdmo-nucleus-radiopharma 2025-08-20T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/b6db4ef3fc0f46d2/u-s-senate-backs-expanded-clinical-trial-endpoints-for-alcohol-use-disorder-boosting-adial-s-ad04-development-strategy 2025-08-20T17:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/d8a7f7615ea139c4/jazz-pharmaceuticals-acquires-exclusive-rights-to-epilepsy-drug-san2355-in-42-5m-deal 2025-08-20T17:15:29+00:00 hourly 0.9 https://trial.medpath.com/news/6e9e854a9db2edfe/cdsco-digital-transformation-slashes-cell-and-gene-therapy-approval-times-by-82 2025-08-20T17:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b7cf8be5e9136b8/keros-therapeutics-receives-fda-orphan-drug-designation-for-ker-065-in-duchenne-muscular-dystrophy 2025-08-20T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/867dc86c7c5e9c36/ginkgo-bioworks-partners-with-inductive-bio-and-tangible-scientific-to-launch-ai-driven-drug-discovery-platform 2025-08-20T17:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/837343bc15efb3cb/molecular-you-raises-5m-series-a-to-scale-multi-omic-predictive-health-platform 2025-08-20T17:13:28+00:00 hourly 0.9 https://trial.medpath.com/news/f5b602180d08e201/bioskryb-genomics-secures-exclusive-license-for-single-cell-dna-methylation-and-variant-analysis-technology 2025-08-20T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/a672f007ec84b6ee/scipher-medicine-launches-ai-platform-to-predict-clinical-trial-failures-with-near-perfect-accuracy 2025-08-20T17:13:08+00:00 hourly 0.9 https://trial.medpath.com/news/43314630c7a69b9e/tharimmune-stock-surges-60-following-fda-fast-track-designation-and-5-47m-equity-raise 2025-08-20T17:13:06+00:00 hourly 0.9 https://trial.medpath.com/news/aa807b3c2102ed26/agilent-s-mmr-ihc-panel-pharmdx-receives-fda-approval-as-companion-diagnostic-for-colorectal-cancer-immunotherapy 2025-08-20T17:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/1bb124fc91ef9988/dana-farber-researchers-launch-phase-1-trial-of-novel-cyclin-inhibitor-for-small-cell-lung-cancer 2025-08-20T17:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/ca13a7ea1918551a/eli-lilly-neuroscience-chief-anne-white-to-retire-after-leading-alzheimer-s-drug-launch 2025-08-20T17:11:41+00:00 hourly 0.9 https://trial.medpath.com/news/87778c870a42d31f/first-nations-launch-comparative-drug-trial-to-combat-psoroptic-mange-in-declining-bighorn-sheep-population 2025-08-20T17:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/6b44822e0279c81c/illuminated-extractors-secures-patent-for-revolutionary-cryogenic-refrigeration-system-with-pharmaceutical-applications 2025-08-20T13:53:32+00:00 hourly 0.9 https://trial.medpath.com/news/44aa5e585d9507e9/alzecure-pharma-strengthens-clinical-development-team-with-appointment-of-cecilia-wadell-as-head-of-development 2025-08-20T13:06:35+00:00 hourly 0.9 https://trial.medpath.com/news/404ff939cf42c61c/brazilian-researchers-develop-novel-zika-vaccine-using-virus-like-particles-preventing-brain-and-testicular-damage 2025-08-20T13:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/4e8aa2761629f2ba/neurovalens-secures-ps6m-to-expand-fda-approved-neurostimulation-devices-for-mental-health 2025-08-20T13:05:23+00:00 hourly 0.9 https://trial.medpath.com/news/f5bfdb7e7060c5f9/india-advances-rare-disease-treatment-pipeline-with-nine-new-medications 2025-08-20T13:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/163437471da2ee4a/natco-pharma-launches-generic-bosentan-for-pediatric-pulmonary-arterial-hypertension-with-180-day-us-market-exclusivity 2025-08-20T13:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/8a2672318936eebb/envoy-medical-secures-three-new-patents-for-fully-implantable-cochlear-implant-technology 2025-08-20T12:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/0579f937b92d087a/fda-approves-first-continuous-glucose-monitor-for-weight-management-beyond-diabetes 2025-08-20T09:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/835ebc53a564db32/circle-pharma-s-novel-cyclin-inhibitor-shows-promise-against-e2f-driven-cancers-in-nature-study 2025-08-20T08:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f142ad1442257ea1/nice-recommends-major-shift-in-type-2-diabetes-treatment-with-earlier-access-to-sglt-2-inhibitors-and-weight-loss-drugs 2025-08-20T05:37:19+00:00 hourly 0.9 https://trial.medpath.com/news/5f7515b2d755fc55/invion-s-inv043-receives-fda-orphan-drug-designation-for-anal-cancer-treatment 2025-08-20T05:36:05+00:00 hourly 0.9 https://trial.medpath.com/news/9db68bdbd153eec8/ruxolitinib-maintains-long-term-efficacy-in-polycythemia-vera-and-myelofibrosis-despite-emergence-of-novel-jak-inhibitors 2025-08-20T03:38:31+00:00 hourly 0.9 https://trial.medpath.com/news/b52615ceaddd9f32/wistar-institute-launches-17-million-personalized-hiv-cure-initiative-with-six-component-therapy-approach 2025-08-20T01:45:36+00:00 hourly 0.9 https://trial.medpath.com/news/259d24255f5fae2b/celldex-s-barzolvolimab-phase-2-trial-provides-key-insights-into-mast-cell-role-in-eosinophilic-esophagitis 2025-08-20T01:43:39+00:00 hourly 0.9 https://trial.medpath.com/news/39e981f532838523/federal-circuit-upholds-patent-cancellation-for-dexcom-glucose-monitor-sensor-technology 2025-08-20T01:43:34+00:00 hourly 0.9 https://trial.medpath.com/news/8d844b782208c591/arc-therapies-advances-yb328-gut-microbe-research-toward-cancer-immunotherapy-clinical-trials 2025-08-20T01:42:39+00:00 hourly 0.9 https://trial.medpath.com/news/23f0b76e3b64a580/radioparp-phase-1-trial-demonstrates-safety-of-olaparib-combined-with-radiotherapy-in-triple-negative-breast-cancer 2025-08-20T01:42:36+00:00 hourly 0.9 https://trial.medpath.com/news/e9d817a23110e534/friends-of-cancer-research-partners-with-mms-to-develop-framework-for-interpreting-interim-overall-survival-data-in-oncology-trials 2025-08-20T01:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/4b5c310c47803fed/merit-medical-enrolls-first-patient-in-wrapsody-registry-for-hemodialysis-vascular-access 2025-08-20T01:39:24+00:00 hourly 0.9 https://trial.medpath.com/news/994294d526160609/fda-uncertainties-about-cancer-drugs-largely-missing-from-medical-literature-and-guidelines 2025-08-20T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/03ab84ac0897891f/viking-therapeutics-phase-2-oral-obesity-trial-results-generate-mixed-market-response 2025-08-19T21:48:36+00:00 hourly 0.9 https://trial.medpath.com/news/ced022349536d64c/health-canada-approves-iovance-s-amtagvi-as-first-t-cell-therapy-for-solid-tumors-in-canada 2025-08-19T21:48:26+00:00 hourly 0.9 https://trial.medpath.com/news/e79a3647d2a43629/belhaven-biopharma-secures-oversubscribed-series-a-funding-to-advance-first-dry-powder-nasal-epinephrine-therapy 2025-08-19T21:44:05+00:00 hourly 0.9 https://trial.medpath.com/news/a9f7f15c9d40617a/fda-approves-nipocalimab-for-myasthenia-gravis-as-pipeline-advances-with-20-novel-therapies 2025-08-19T21:43:52+00:00 hourly 0.9 https://trial.medpath.com/news/f58cf68404358915/pcv21-pneumococcal-vaccine-demonstrates-favorable-immunogenicity-in-pediatric-phase-2-trial 2025-08-19T21:43:43+00:00 hourly 0.9 https://trial.medpath.com/news/8775813defba5676/greenwich-lifesciences-builds-internal-clinical-team-to-reduce-costs-and-enhance-flamingo-01-breast-cancer-trial-operations 2025-08-19T21:42:33+00:00 hourly 0.9 https://trial.medpath.com/news/fdde2c3d1a337aed/fda-issues-new-draft-guidance-for-optimizing-radiopharmaceutical-dosing-in-cancer-clinical-trials 2025-08-19T21:42:11+00:00 hourly 0.9 https://trial.medpath.com/news/56159af8787c78fc/australian-researchers-launch-world-s-first-long-covid-diagnostic-test-trial 2025-08-19T21:41:44+00:00 hourly 0.9 https://trial.medpath.com/news/8e20e35e619dbf52/biosimilar-laronidase-shows-comparable-efficacy-to-reference-drug-in-mps-i-patients 2025-08-19T21:40:15+00:00 hourly 0.9 https://trial.medpath.com/news/2a26ff2f9b231644/nutraland-usa-and-youthorin-biotechnology-partner-to-develop-next-generation-probiotic-and-anti-aging-ingredients 2025-08-19T21:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/9efcde084e45937b/beginngs-newborn-genome-screening-program-expands-to-qatar-in-first-international-collaboration 2025-08-19T21:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/df5868f99f2e101a/eight-sleep-secures-100m-series-d-to-advance-ai-powered-sleep-technology-and-medical-applications 2025-08-19T21:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/2dfb8bc22d2aa050/fda-issues-complete-response-letter-for-darzalex-faspro-in-newly-diagnosed-multiple-myeloma 2025-08-19T21:37:29+00:00 hourly 0.9 https://trial.medpath.com/news/84ab9da835a56d06/university-of-oklahoma-researchers-unlock-amylin-receptor-mechanisms-for-next-generation-obesity-drugs 2025-08-19T21:37:21+00:00 hourly 0.9 https://trial.medpath.com/news/99f659570212edf5/fsgs-treatment-landscape-approaches-critical-inflection-point-as-multiple-novel-therapies-near-approval 2025-08-19T21:37:09+00:00 hourly 0.9 https://trial.medpath.com/news/888e232181768feb/psoriasis-care-evolves-beyond-skin-deep-new-therapies-and-patient-centered-approaches-transform-treatment-landscape 2025-08-19T20:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/af602930026c906d/cour-pharma-initiates-first-in-class-type-1-diabetes-trial-with-cnp-103-nanoparticle-therapy 2025-08-19T17:55:44+00:00 hourly 0.9 https://trial.medpath.com/news/fdd9c8bd7b4543df/health-canada-approves-ozempic-for-kidney-protection-in-type-2-diabetes-patients 2025-08-19T17:47:22+00:00 hourly 0.9 https://trial.medpath.com/news/899eab05594c838d/xspray-pharma-submits-improved-nilotinib-formulation-xs003-to-fda-for-chronic-myeloid-leukemia-treatment 2025-08-19T17:47:06+00:00 hourly 0.9 https://trial.medpath.com/news/134ee687cc8a1972/kelonia-therapeutics-doses-first-patient-in-groundbreaking-in-vivo-car-t-trial-for-multiple-myeloma 2025-08-19T17:45:31+00:00 hourly 0.9 https://trial.medpath.com/news/791e93873101a565/evofem-biosciences-secures-patent-protection-for-solosec-through-2041-strengthening-market-position-for-single-dose-sti-treatment 2025-08-19T17:45:23+00:00 hourly 0.9 https://trial.medpath.com/news/d0629b0d7298e06e/delcath-systems-initiates-phase-2-trial-of-hepzato-for-liver-dominant-metastatic-colorectal-cancer 2025-08-19T17:44:45+00:00 hourly 0.9 https://trial.medpath.com/news/ef24ae5dafec7624/ashibio-licenses-vantictumab-for-rare-bone-disease-ado2-in-strategic-pipeline-expansion 2025-08-19T17:44:38+00:00 hourly 0.9 https://trial.medpath.com/news/8c03251d7186f3e8/corrixr-therapeutics-secures-1m-delaware-investment-to-advance-crispr-based-cancer-gene-therapy 2025-08-19T17:44:07+00:00 hourly 0.9 https://trial.medpath.com/news/8ed0c90a9da1a9eb/axelyf-closes-2-6m-seed-round-to-advance-superior-rna-lnp-gene-editing-technology 2025-08-19T17:43:40+00:00 hourly 0.9 https://trial.medpath.com/news/86157effe9da9254/tenofovir-amibufenamide-shows-significant-efficacy-in-chronic-hepatitis-b-patients-with-normal-alt-levels 2025-08-19T17:43:02+00:00 hourly 0.9 https://trial.medpath.com/news/cd3943e93be76524/conflicting-evidence-emerges-on-ketamine-s-effectiveness-for-chronic-pain-management 2025-08-19T17:42:24+00:00 hourly 0.9 https://trial.medpath.com/news/3813dba00f9f3e66/novel-kappa-opioid-receptor-agonist-anrikefon-shows-superior-efficacy-in-treating-chronic-kidney-disease-associated-pruritus 2025-08-19T17:42:15+00:00 hourly 0.9 https://trial.medpath.com/news/ef6de82015a1711d/neuroone-secures-fda-clearance-for-onerf-trigeminal-nerve-ablation-system-to-treat-chronic-facial-pain 2025-08-19T17:41:42+00:00 hourly 0.9 https://trial.medpath.com/news/9feba520d73d4c4c/biogen-stock-surges-6-following-fda-approval-boost-amid-pipeline-developments 2025-08-19T17:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/b638c1934fde84c9/transcelerate-and-fda-release-framework-to-scale-pragmatic-clinical-trials-in-routine-care-settings 2025-08-19T17:41:03+00:00 hourly 0.9 https://trial.medpath.com/news/10530a386378420f/immunitybio-launches-phase-2-trial-of-anktiva-for-long-covid-treatment 2025-08-19T17:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/4e614f2ad437d35a/scripps-research-launches-fully-remote-clinical-trial-for-long-covid-treatment-using-repurposed-drug 2025-08-19T17:40:44+00:00 hourly 0.9 https://trial.medpath.com/news/d5fcaa800a0027a4/vasthera-receives-fda-clearance-for-phase-1-trial-of-novel-pah-drug-vtb-10 2025-08-19T13:39:07+00:00 hourly 0.9 https://trial.medpath.com/news/2e617f9c9602e940/knightsbridge-and-camelot-biocapital-partner-to-transform-biotech-funding-through-blockchain-technology 2025-08-19T13:38:56+00:00 hourly 0.9 https://trial.medpath.com/news/40c5158c8b7442e6/pcsk9-inhibitors-demonstrate-efficacy-and-safety-in-chronic-kidney-disease-patients-including-advanced-stages 2025-08-19T13:38:52+00:00 hourly 0.9 https://trial.medpath.com/news/7421c4f594da89eb/aprogen-s-pmc-309-shows-early-anticancer-activity-in-phase-1-trial-advances-to-higher-dose-testing 2025-08-19T13:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/706c56de2b871511/china-medical-system-s-mg-k10-advances-to-phase-iii-trials-for-chronic-spontaneous-urticaria-treatment 2025-08-19T13:38:28+00:00 hourly 0.9 https://trial.medpath.com/news/138336389cc91b8e/teleflex-launches-barrigel-rectal-spacer-in-japan-following-pmda-approval-for-prostate-cancer-radiation-protection 2025-08-19T13:37:56+00:00 hourly 0.9 https://trial.medpath.com/news/b4cf340fd0488c2d/luzhu-biotechnology-s-lz901-herpes-zoster-vaccine-advances-through-clinical-development-with-strong-safety-profile 2025-08-19T09:45:04+00:00 hourly 0.9 https://trial.medpath.com/news/4989065ac27d5ce3/csl-to-spin-off-seqirus-vaccine-unit-and-launch-487m-share-buyback-in-major-restructuring 2025-08-19T09:43:11+00:00 hourly 0.9 https://trial.medpath.com/news/a24ca066367dd7d7/jcyte-initiates-phase-2-trial-of-famzeretcel-cell-therapy-for-retinitis-pigmentosa 2025-08-19T09:35:39+00:00 hourly 0.9 https://trial.medpath.com/news/6819e0b6d9fe6853/biomed-x-and-novo-nordisk-partner-to-advance-oral-peptide-drug-delivery-technology 2025-08-19T09:34:40+00:00 hourly 0.9 https://trial.medpath.com/news/1ce2c53d616ba4a7/tenon-medical-launches-catamaran-se-si-joint-fusion-system-with-reduced-profile-design 2025-08-19T08:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5563edb5680c37d/oric-pharmaceuticals-appoints-kevin-brodbeck-as-chief-technical-officer-ahead-of-phase-3-trials 2025-08-19T05:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/ea2de20fb185fdcb/remegen-and-santen-strike-1-3-billion-licensing-deal-for-dual-target-ophthalmic-drug-rc28-e 2025-08-19T05:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/f822be9b8d60f9c5/multimodal-ai-model-predicts-egfr-tki-treatment-outcomes-in-advanced-nsclc-patients 2025-08-19T05:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/635eb39e52b2c596/molecular-testing-and-targeted-therapies-transform-treatment-landscape-for-pediatric-low-grade-gliomas 2025-08-19T03:05:31+00:00 hourly 0.9 https://trial.medpath.com/news/e5ef868ff717e201/ozempic-faces-2-billion-in-lawsuits-over-severe-side-effects-including-stomach-paralysis-and-vision-loss 2025-08-19T01:44:04+00:00 hourly 0.9 https://trial.medpath.com/news/c85f475507a1e532/iranian-company-launches-spartina-domestic-tirzepatide-for-type-2-diabetes-and-obesity-treatment 2025-08-19T01:39:50+00:00 hourly 0.9 https://trial.medpath.com/news/0d7d1962d3f5c350/invivyd-s-pemgarda-maintains-neutralizing-activity-against-dominant-xfg-covid-19-variant 2025-08-19T01:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/a92578c306d68f55/self-powered-microneedle-patch-enables-painless-biomarker-monitoring-without-blood-draws 2025-08-19T01:38:39+00:00 hourly 0.9 https://trial.medpath.com/news/1dfcf8a8310db26e/roche-canada-secures-public-funding-for-vabysmo-in-quebec-for-retinal-vein-occlusion-treatment 2025-08-19T01:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/4c36d5f90b153462/over-the-counter-birth-control-pill-dramatically-increases-contraceptive-access-among-underserved-populations 2025-08-19T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/0a2609350af7a767/fda-issues-draft-guidance-prioritizing-overall-survival-as-primary-endpoint-for-cancer-drug-approvals 2025-08-19T01:36:40+00:00 hourly 0.9 https://trial.medpath.com/news/790bcc84c5b62f72/roche-s-vabysmo-shows-sustained-efficacy-over-four-years-in-neovascular-amd-and-delivers-vision-gains-in-difficult-to-treat-asian-subtype 2025-08-19T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/1dfbfcf658a2d9c5/vcu-massey-becomes-first-virginia-center-to-offer-fda-approved-til-therapy-for-advanced-melanoma 2025-08-18T21:44:23+00:00 hourly 0.9 https://trial.medpath.com/news/3ad5829d5ef471df/wuxi-biologics-receives-ema-approval-for-ireland-manufacturing-facility-advancing-global-dual-sourcing-strategy 2025-08-18T21:44:15+00:00 hourly 0.9 https://trial.medpath.com/news/22af3e14a13531af/first-in-class-monoclonal-antibody-shows-promise-against-sepsis-induced-immune-dysregulation 2025-08-18T21:43:34+00:00 hourly 0.9 https://trial.medpath.com/news/dcc7e970e234f17c/university-of-houston-develops-first-spleen-targeted-nanoparticle-system-for-lupus-treatment 2025-08-18T21:43:32+00:00 hourly 0.9 https://trial.medpath.com/news/7fd6e5431184922c/novel-monoclonal-antibody-stapokibart-demonstrates-significant-efficacy-in-severe-chronic-rhinosinusitis-with-nasal-polyps 2025-08-18T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/d42ebb46a04db061/dnl343-shows-promise-as-first-in-class-eif2b-activator-for-als-treatment-in-phase-1-clinical-trial 2025-08-18T21:41:19+00:00 hourly 0.9 https://trial.medpath.com/news/f6f42ce70d621692/genentech-initiates-first-patent-litigation-against-pertuzumab-biosimilar-hlx11 2025-08-18T21:40:31+00:00 hourly 0.9 https://trial.medpath.com/news/1caf8e13439b07f1/propanc-biopharma-surges-150-following-nasdaq-uplisting-and-fda-orphan-drug-designations 2025-08-18T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/da0b4520b26abff6/qihan-biotech-receives-fda-clearance-for-qt-019b-first-universal-dual-target-car-t-therapy-for-refractory-lupus 2025-08-18T21:40:08+00:00 hourly 0.9 https://trial.medpath.com/news/cc13785a20c84967/livanova-launches-essenz-perfusion-system-in-china-following-nmpa-approval 2025-08-18T21:40:06+00:00 hourly 0.9 https://trial.medpath.com/news/554d4341f2526f5e/natera-s-signatera-assay-shows-promise-in-phase-iii-bladder-cancer-trial-seeks-fda-approval 2025-08-18T21:39:26+00:00 hourly 0.9 https://trial.medpath.com/news/81930ac87ead6eb3/cantargia-appoints-biotech-veteran-dr-hilde-steineger-as-ceo-to-lead-il1rap-targeted-therapy-development 2025-08-18T21:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/4caa0d839514e7e7/atropos-health-and-novartis-partner-to-deploy-ai-for-faster-rare-disease-diagnosis-in-pnh-patients 2025-08-18T21:38:25+00:00 hourly 0.9 https://trial.medpath.com/news/90ed17a837c2ca12/novel-buprenorphine-protocol-eliminates-withdrawal-requirement-for-opioid-use-disorder-treatment 2025-08-18T17:51:17+00:00 hourly 0.9 https://trial.medpath.com/news/72413ead6b1cc22f/impact-biomedical-secures-patent-for-plant-based-antimicrobial-technology-targeting-infectious-diseases 2025-08-18T17:48:40+00:00 hourly 0.9 https://trial.medpath.com/news/ece016a332cc1b51/oman-achieves-medical-milestone-with-first-successful-car-t-cell-therapy-implementation 2025-08-18T17:46:36+00:00 hourly 0.9 https://trial.medpath.com/news/dd6b5218d5cd90fc/pharmaceutical-industry-accelerates-glp-1-injectable-manufacturing-and-delivery-innovation-to-meet-surging-global-demand 2025-08-18T17:46:21+00:00 hourly 0.9 https://trial.medpath.com/news/af18f9a232f67a5c/sino-biopharm-reports-strong-h1-2025-results-with-27-growth-in-innovative-drug-sales-and-strategic-lanova-acquisition 2025-08-18T17:46:16+00:00 hourly 0.9 https://trial.medpath.com/news/04d81b18727cbe3f/upperton-pharma-and-oxford-university-secure-funding-to-develop-needle-free-oral-adenovirus-vaccine-platform 2025-08-18T17:45:57+00:00 hourly 0.9 https://trial.medpath.com/news/aa449c1cc194e5b2/ravicti-receives-regulatory-approval-in-saudi-arabia-qatar-and-kuwait-for-urea-cycle-disorders 2025-08-18T17:45:32+00:00 hourly 0.9 https://trial.medpath.com/news/5e543e6d314c94f0/viewsml-and-iprocess-form-strategic-partnership-to-accelerate-ai-powered-virtual-biomarker-testing 2025-08-18T17:45:06+00:00 hourly 0.9 https://trial.medpath.com/news/a71884e473f1bbbe/capricor-therapeutics-initiates-first-in-human-trial-of-stealthx-exosome-based-vaccine-platform 2025-08-18T17:43:45+00:00 hourly 0.9 https://trial.medpath.com/news/87ce5bd79b7226c8/genprex-secures-key-patents-for-reqorsa-gene-therapy-combinations-with-checkpoint-inhibitors 2025-08-18T17:43:35+00:00 hourly 0.9 https://trial.medpath.com/news/d40be16b95bed549/opus-genetics-receives-fda-clearance-for-best1-gene-therapy-trial-in-rare-inherited-retinal-disease 2025-08-18T17:43:09+00:00 hourly 0.9 https://trial.medpath.com/news/9925f7a7f5681781/accord-biopharma-launches-imuldosa-biosimilar-at-92-discount-to-stelara 2025-08-18T17:43:07+00:00 hourly 0.9 https://trial.medpath.com/news/1df44b264040813d/influenza-pipeline-surges-with-120-therapies-as-moderna-astrazeneca-lead-innovation-wave 2025-08-18T17:42:27+00:00 hourly 0.9 https://trial.medpath.com/news/59af9368fda2d28c/quoin-pharmaceuticals-appoints-sally-lawlor-as-cfo-to-navigate-qrx003-commercialization 2025-08-18T17:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/af3f9fb0cd576e4d/merck-kgaa-partners-with-skyhawk-therapeutics-in-2-billion-rna-splicing-collaboration-for-neurological-disorders 2025-08-18T17:41:05+00:00 hourly 0.9 https://trial.medpath.com/news/d72f647c191f0d76/redhill-biopharma-receives-1-1-million-in-talicia-licensing-payments-following-first-international-launch 2025-08-18T17:41:01+00:00 hourly 0.9 https://trial.medpath.com/news/3910bc42c69210e2/newamsterdam-s-obicetrapib-receives-ema-validation-for-european-review-following-positive-phase-3-results 2025-08-18T17:38:59+00:00 hourly 0.9 https://trial.medpath.com/news/73f7fd3179710d59/nanoviricides-nv-387-antiviral-drug-shows-potential-to-prevent-cancer-metastasis-resurgence-through-anti-inflammatory-effects 2025-08-18T17:37:42+00:00 hourly 0.9 https://trial.medpath.com/news/a8ea2afdfde9007c/iqvia-and-veeva-systems-form-strategic-partnership-to-accelerate-clinical-development-and-commercial-operations 2025-08-18T17:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/b05afc31dd3733ec/multi-omics-reveals-tumor-draining-lymph-nodes-as-critical-hubs-for-cancer-immunotherapy 2025-08-18T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d95764419818ab37/crispr-therapies-advance-against-infectious-diseases-as-ebt-101-becomes-first-hiv-gene-editing-treatment-in-human-trials 2025-08-18T13:41:36+00:00 hourly 0.9 https://trial.medpath.com/news/529ba8a43918edd9/unicycive-therapeutics-secures-patent-protection-for-uni-494-kidney-disease-treatment-through-2040 2025-08-18T13:41:11+00:00 hourly 0.9 https://trial.medpath.com/news/c0df0b255d81a1ed/luna-health-secures-23-6m-series-a-to-advance-nighttime-insulin-patch-pump-for-pen-users 2025-08-18T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/ee54aafba8904767/jnk-pathway-suppression-identified-as-key-driver-of-treatment-resistance-in-er-breast-cancer 2025-08-18T13:40:02+00:00 hourly 0.9 https://trial.medpath.com/news/9cccf9b7d2825ef4/aster-70-trial-shows-no-survival-benefit-from-adjuvant-chemotherapy-in-elderly-breast-cancer-patients 2025-08-18T13:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/3737fcb2489202f9/phase-iii-imvigor011-trial-demonstrates-significant-survival-benefits-for-ctdna-guided-bladder-cancer-treatment 2025-08-18T13:39:55+00:00 hourly 0.9 https://trial.medpath.com/news/2ea11062b65229da/fda-reinstates-sarepta-s-elevidys-gene-therapy-following-parent-advocacy-despite-failed-trial 2025-08-18T13:39:34+00:00 hourly 0.9 https://trial.medpath.com/news/326c0dc7e46c7fe7/outlook-therapeutics-awaits-critical-fda-decision-for-wet-amd-treatment-ons-5010 2025-08-18T13:38:45+00:00 hourly 0.9 https://trial.medpath.com/news/8c88a01eb1936de9/fda-grants-breakthrough-therapy-designation-to-bristol-myers-squibb-and-systimmune-s-iza-bren-for-advanced-egfr-mutant-lung-cancer 2025-08-18T13:37:04+00:00 hourly 0.9 https://trial.medpath.com/news/e3ce8bcd27d70ad7/fda-commissioner-launches-controversial-expert-panels-with-financial-conflicts-raising-transparency-concerns 2025-08-18T13:09:00+00:00 hourly 0.9 https://trial.medpath.com/news/a6cc579490161863/smartalpha-s-nerveblox-ai-software-receives-fda-510-k-clearance-for-ultrasound-guided-regional-anesthesia 2025-08-18T11:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/f63dbfb295ac6b31/anocca-secures-46m-to-advance-europe-s-first-non-viral-gene-edited-tcr-t-therapy-for-pancreatic-cancer 2025-08-18T09:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/54d069c6925ee85d/gc-biopharma-expands-asian-presence-with-thai-red-cross-partnership-for-plasma-derived-therapeutics 2025-08-18T05:40:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb1d051aac7f4f94/fda-releases-white-paper-on-selective-safety-data-collection-framework-for-late-stage-clinical-trials 2025-08-18T05:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/c0f6770f6559d9fa/alembic-pharmaceuticals-receives-fda-approval-for-generic-tretinoin-cream-to-treat-acne-vulgaris 2025-08-18T04:29:00+00:00 hourly 0.9 https://trial.medpath.com/news/0d496283cf70b3be/musc-researchers-engineer-char-tregs-to-target-organ-rejection-with-precision-immunosuppression 2025-08-17T21:02:37+00:00 hourly 0.9 https://trial.medpath.com/news/4e20268d0c756d68/novo-nordisk-gains-fda-approval-for-wegovy-in-liver-disease-treatment 2025-08-17T21:02:15+00:00 hourly 0.9 https://trial.medpath.com/news/aa2b8e499c977505/enable-injections-secures-regulatory-approvals-for-enfuse-drug-delivery-system-in-brazil-and-uk 2025-08-17T21:02:05+00:00 hourly 0.9 https://trial.medpath.com/news/4b0c6dfcfc2e5b3c/sihuan-pharmaceutical-s-semaglutide-injection-advances-through-chinese-regulatory-pipeline-with-marketing-application-acceptance 2025-08-17T17:34:09+00:00 hourly 0.9 https://trial.medpath.com/news/9688abd0e3178bb7/columbia-university-develops-mrna-based-universal-antiviral-therapy-inspired-by-rare-genetic-mutation 2025-08-17T17:31:57+00:00 hourly 0.9 https://trial.medpath.com/news/1e4d4b5fdff10c7b/mscs-show-promise-for-rotator-cuff-repair-through-immune-modulation-and-tissue-engineering 2025-08-17T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7b2bac78dd0cf8ca/aurobindo-pharma-s-china-manufacturing-facility-expected-to-reach-break-even-by-q3-fy26 2025-08-17T09:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/284de9334d71705e/palisade-bio-registers-8-9m-shares-for-resale-amid-financial-challenges-and-pali-2108-development 2025-08-17T05:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/2a553842d138fde2/clinical-trials-show-mango-consumption-improves-blood-sugar-control-in-type-2-diabetes-patients 2025-08-17T01:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/b3a18c543f9959a9/regulatory-t-cell-therapy-unexpectedly-promotes-pathogenic-th17-cell-generation-through-il-2-suppression 2025-08-16T21:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/f57c9ff436c8c8db/kriya-therapeutics-raises-313m-to-advance-gene-therapy-pipeline-for-chronic-diseases 2025-08-16T21:35:44+00:00 hourly 0.9 https://trial.medpath.com/news/946652587d162b2e/childhood-eoe-inflammation-control-reduces-esophageal-stiffening-and-complications-first-longitudinal-study-shows 2025-08-16T17:30:13+00:00 hourly 0.9 https://trial.medpath.com/news/f843a5793ac40540/talphera-accelerates-nafamostat-trial-enrollment-with-strategic-site-optimization 2025-08-16T13:36:48+00:00 hourly 0.9 https://trial.medpath.com/news/91d948365274134f/pfizer-s-oxbryta-withdrawal-highlights-sickle-cell-disease-treatment-challenges-as-ema-extends-marketing-suspension 2025-08-16T13:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/02ac3d1c3983e9bc/nationwide-study-reveals-critical-gaps-in-hpv-cancer-awareness-particularly-in-midwest-and-south 2025-08-16T13:32:51+00:00 hourly 0.9 https://trial.medpath.com/news/93979652dba61cd9/hemorrhoids-treatment-pipeline-shows-promise-with-three-key-therapies-in-late-stage-development 2025-08-16T09:02:35+00:00 hourly 0.9 https://trial.medpath.com/news/62c78b0bb4d8bbd5/fiocruz-and-ems-sign-historic-technology-transfer-agreement-for-glp-1-diabetes-and-obesity-drugs 2025-08-16T09:02:32+00:00 hourly 0.9 https://trial.medpath.com/news/f9fc1863fa027f4f/oregon-study-demonstrates-psilocybin-therapy-efficacy-for-low-income-adults-with-major-depression 2025-08-16T09:01:22+00:00 hourly 0.9 https://trial.medpath.com/news/8fca6585b0856c75/hippocampal-avoidance-during-brain-radiation-reduces-cognitive-toxicity-in-small-cell-lung-cancer-patients 2025-08-16T05:02:08+00:00 hourly 0.9 https://trial.medpath.com/news/084da0d4246fd73e/trump-orders-strategic-stockpiling-of-essential-medicine-ingredients-to-reduce-foreign-dependence 2025-08-16T03:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/471076c122b164b4/sonoma-pharmaceuticals-expands-hocl-technology-reach-with-major-us-retail-and-hospital-launches 2025-08-16T03:01:26+00:00 hourly 0.9 https://trial.medpath.com/news/20decf4a2889d2e4/vcare-partners-with-huadong-medicine-for-vc005-jak1-inhibitor-commercialization-in-china 2025-08-16T01:36:55+00:00 hourly 0.9 https://trial.medpath.com/news/c40eea76ee63400b/major-pharmaceutical-companies-face-surge-in-generic-drug-patent-challenges-in-early-2025 2025-08-16T01:36:10+00:00 hourly 0.9 https://trial.medpath.com/news/0f52572f3ca9ca75/psma-pet-ct-before-salvage-radiotherapy-improves-survival-in-recurrent-prostate-cancer 2025-08-16T01:34:55+00:00 hourly 0.9 https://trial.medpath.com/news/ad9f0b882183a569/engineered-bacteria-virus-system-cappsid-shows-promise-for-targeted-cancer-therapy 2025-08-16T01:34:15+00:00 hourly 0.9 https://trial.medpath.com/news/866e3903cf0f5940/bristol-myers-squibb-exelixis-and-novartis-advance-pan-tumor-rollover-study-for-long-term-nivolumab-safety-assessment 2025-08-16T01:33:14+00:00 hourly 0.9 https://trial.medpath.com/news/64a0e077df1c7215/novo-nordisk-s-wegovy-becomes-first-glp-1-therapy-approved-for-liver-disease-mash 2025-08-16T01:31:26+00:00 hourly 0.9 https://trial.medpath.com/news/56a09cc1685f1065/tivic-health-advances-military-discussions-for-entolimod-as-radiation-countermeasure 2025-08-15T21:48:44+00:00 hourly 0.9 https://trial.medpath.com/news/24061ef2d2307eb4/australian-court-ruling-opens-entresto-to-generic-competition-invalidates-novartis-patent-extension 2025-08-15T21:45:13+00:00 hourly 0.9 https://trial.medpath.com/news/8ac398cf6bc28952/federal-court-orders-fda-to-reconsider-vanda-s-hetlioz-application-for-jet-lag-disorder 2025-08-15T21:43:30+00:00 hourly 0.9 https://trial.medpath.com/news/4e0a849aafab5c12/chop-researchers-discover-novel-rna-fragments-as-immunotherapy-targets-for-pediatric-brain-tumors 2025-08-15T21:43:18+00:00 hourly 0.9 https://trial.medpath.com/news/0d286130b65328da/sam-altman-s-merge-labs-explores-gene-therapy-approach-for-brain-computer-interface-technology 2025-08-15T21:41:40+00:00 hourly 0.9 https://trial.medpath.com/news/78124b9b1c4438e9/ascelia-pharma-nears-orviglance-nda-submission-for-orphan-liver-imaging-agent 2025-08-15T21:39:22+00:00 hourly 0.9 https://trial.medpath.com/news/7ea3fc4db3c0335a/pfizer-s-inclacumab-fails-phase-iii-trial-for-sickle-cell-disease-marking-second-setback-from-global-blood-therapeutics-acquisition 2025-08-15T21:38:48+00:00 hourly 0.9 https://trial.medpath.com/news/92ba2924e12598a5/lumenis-dynamic-muscle-stimulation-technology-shows-promise-for-treating-dry-eye-disease-through-lower-lid-laxity-correction 2025-08-15T21:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/47ce2a1e1cf87cfd/nemvaleukin-alfa-shows-durable-antitumor-activity-in-advanced-melanoma-and-renal-cell-carcinoma 2025-08-15T18:27:53+00:00 hourly 0.9 https://trial.medpath.com/news/074d40efeafda8b1/fda-approves-precigen-s-papzimeos-as-first-gene-therapy-for-recurrent-respiratory-papillomatosis 2025-08-15T18:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/61c14678b25fe7a6/russian-supreme-court-upholds-compulsory-licensing-for-ozempic-generics-as-domestic-manufacturers-capture-semaglutide-market 2025-08-15T18:11:44+00:00 hourly 0.9 https://trial.medpath.com/news/bd256431ba9e97fe/rift-valley-fever-vaccine-enters-phase-ii-trials-in-kenya-using-oxford-s-chadox1-platform 2025-08-15T18:10:56+00:00 hourly 0.9 https://trial.medpath.com/news/2712675df9b282f1/novel-pi3kd-inhibitor-roginolisib-shows-promise-in-phase-2-trial-for-metastatic-uveal-melanoma 2025-08-15T18:08:53+00:00 hourly 0.9 https://trial.medpath.com/news/701ead20ca1d71f7/astrazeneca-s-flumist-home-becomes-first-self-administered-flu-vaccine-available-for-home-delivery-in-us 2025-08-15T18:00:30+00:00 hourly 0.9 https://trial.medpath.com/news/5d0b674382bb36f2/aha-acc-release-updated-2025-hypertension-guidelines-with-new-treatment-recommendations 2025-08-15T17:59:46+00:00 hourly 0.9 https://trial.medpath.com/news/79e72d1a43d0c4c9/ai-model-comet-accelerates-rna-medicine-development-cutting-timelines-from-months-to-weeks 2025-08-15T13:48:45+00:00 hourly 0.9 https://trial.medpath.com/news/280ca3aebbc8c9d9/sol-gel-completes-phase-3-enrollment-for-gorlin-syndrome-treatment-sgt-610-targets-300m-peak-revenue 2025-08-15T13:48:38+00:00 hourly 0.9 https://trial.medpath.com/news/40d149bf1897e5f6/umass-chan-gene-therapy-shows-biochemical-correction-in-gm2-gangliosidosis-phase-i-ii-trial 2025-08-15T13:48:21+00:00 hourly 0.9 https://trial.medpath.com/news/fc80958abc644aaf/glp-1-receptor-agonists-show-promise-as-novel-treatment-for-hidradenitis-suppurativa 2025-08-15T13:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/77b342af911a3c30/istios-health-expands-infectious-disease-research-network-through-strategic-partnerships-in-georgia-and-virginia 2025-08-15T09:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/fd2f0de906fa26ae/novel-alk-targeted-antibody-drug-conjugate-demonstrates-complete-tumor-regression-in-preclinical-cancer-models 2025-08-15T09:36:51+00:00 hourly 0.9 https://trial.medpath.com/news/d70b38c508fe2f95/innogen-pharmaceutical-soars-296-in-hong-kong-debut-following-glp-1-diabetes-drug-approval 2025-08-15T09:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/fb114f3e00d57c42/restem-receives-fda-orphan-drug-designation-for-stem-cell-therapy-in-polymyositis-treatment 2025-08-15T08:56:00+00:00 hourly 0.9 https://trial.medpath.com/news/d8f568890ba611c8/ai-designed-antibiotics-show-promise-against-drug-resistant-gonorrhea-and-mrsa-in-laboratory-studies 2025-08-15T05:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/3eaa0219a2a27ca2/fda-requires-confirmatory-study-for-minerva-s-roluperidone-in-schizophrenia-as-company-explores-strategic-alternatives 2025-08-15T05:36:16+00:00 hourly 0.9 https://trial.medpath.com/news/f4b28745f21d4682/delaware-court-rules-pfizer-covid-19-vaccine-does-not-infringe-alnylam-s-nanoparticle-patents 2025-08-15T05:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/eb286972f8c3af66/archer-trial-opens-enrollment-to-test-shortened-radiation-therapy-for-muscle-invasive-bladder-cancer 2025-08-15T05:35:51+00:00 hourly 0.9 https://trial.medpath.com/news/307d3e7e78a98293/citizen-health-raises-30m-series-a-to-develop-ai-advocate-for-rare-disease-patients 2025-08-15T05:35:38+00:00 hourly 0.9 https://trial.medpath.com/news/45a24b0fa473ceec/mink-therapeutics-reports-clinical-progress-with-inkt-cell-therapy-targets-phase-ii-gastric-cancer-data-by-end-of-2025 2025-08-15T05:34:44+00:00 hourly 0.9 https://trial.medpath.com/news/9db69c49dff36418/patient-perspectives-reveal-gaps-in-ckd-education-despite-support-for-collaborative-care 2025-08-15T03:02:18+00:00 hourly 0.9 https://trial.medpath.com/news/ebef5eea30832278/international-expert-panel-issues-new-guidelines-for-sglt-2-and-glp-1-use-in-type-2-diabetes-based-on-cardiovascular-risk 2025-08-15T03:01:51+00:00 hourly 0.9 https://trial.medpath.com/news/ef7d777dfa52c1c0/rubicon-research-secures-250-crore-pre-ipo-investment-from-amansa-reduces-fresh-issue-size-ahead-of-year-end-public-listing 2025-08-15T01:38:42+00:00 hourly 0.9 https://trial.medpath.com/news/47d2c3690f6dfc53/repare-therapeutics-reports-52-reduction-in-q2-loss-amid-strategic-pivot-to-licensing-model 2025-08-15T01:38:04+00:00 hourly 0.9 https://trial.medpath.com/news/9c9e584bce4a856a/cue-biopharma-initiates-phase-1b-trial-of-cue-102-for-recurrent-glioblastoma-at-dana-farber 2025-08-15T01:37:00+00:00 hourly 0.9 https://trial.medpath.com/news/dc3b6be1d9bd224c/paldara-and-mayo-clinic-advance-bacteriophage-hydrogel-platform-toward-first-human-trials 2025-08-15T01:32:40+00:00 hourly 0.9 https://trial.medpath.com/news/1e7210b67a1b7ea4/spruce-biosciences-reports-breakthrough-long-term-data-for-ta-ert-in-rare-sanfilippo-syndrome-type-b 2025-08-15T01:32:28+00:00 hourly 0.9 https://trial.medpath.com/news/e4253c7f4cdead43/smart-t-smoking-cessation-app-shows-nearly-double-quit-rates-in-low-income-adults 2025-08-15T01:30:57+00:00 hourly 0.9 https://trial.medpath.com/news/6fe126876bacbee9/fda-approves-first-immunotherapy-for-recurrent-respiratory-papillomatosis 2025-08-15T01:30:16+00:00 hourly 0.9 https://trial.medpath.com/news/9ba370da51b6f61a/major-pharma-m-a-surge-and-landmark-antitrust-rulings-shape-2025-life-sciences-landscape 2025-08-14T21:41:41+00:00 hourly 0.9 https://trial.medpath.com/news/00e2baade91f6401/saniona-secures-1-billion-licensing-deal-with-jazz-pharmaceuticals-in-major-biotech-partnership 2025-08-14T21:39:27+00:00 hourly 0.9 https://trial.medpath.com/news/79c3fa2da11446c4/acelink-therapeutics-al01211-shows-promising-safety-and-biomarker-reduction-in-phase-2-fabry-disease-trial 2025-08-14T21:39:09+00:00 hourly 0.9 https://trial.medpath.com/news/5586d73968175587/novel-oral-polio-vaccines-demonstrate-safety-and-efficacy-in-first-in-human-phase-1-trial 2025-08-14T21:39:04+00:00 hourly 0.9 https://trial.medpath.com/news/66f2c39f7ce99b99/crispr-based-casgevy-emerges-as-preferred-gene-therapy-for-beta-thalassemia-survey-shows 2025-08-14T21:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/9ad654e284440707/swri-develops-games-ai-model-to-accelerate-drug-discovery-through-smiles-generation 2025-08-14T21:36:45+00:00 hourly 0.9 https://trial.medpath.com/news/6d1dbf1892026877/kiffik-biomedical-strengthens-leadership-with-strategic-appointments-to-advance-interstitial-fluid-diagnostics 2025-08-14T17:11:34+00:00 hourly 0.9 https://trial.medpath.com/news/5e8513c3c4f85d0f/macrogenics-names-eric-risser-as-new-ceo-succeeding-24-year-leader-scott-koenig 2025-08-14T17:10:41+00:00 hourly 0.9 https://trial.medpath.com/news/3851a5c7cad41d4e/boehringer-ingelheim-secures-upc-court-victory-protecting-nintedanib-patent-against-generic-competition 2025-08-14T17:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/33e5c75114827985/scpharmaceuticals-secures-five-new-patents-for-heart-failure-drug-scp-111 2025-08-14T17:10:01+00:00 hourly 0.9 https://trial.medpath.com/news/b1acae1136a76ffe/peak-car-t-cell-expansion-linked-to-improved-outcomes-in-b-all-patients-receiving-brexu-cel 2025-08-14T17:09:42+00:00 hourly 0.9 https://trial.medpath.com/news/d100166e56b595e1/schrodinger-discontinues-blood-cancer-drug-sgr-2921-after-two-patient-deaths-in-phase-i-trial 2025-08-14T17:09:27+00:00 hourly 0.9 https://trial.medpath.com/news/b327008eb97d95b8/lantern-pharma-reports-complete-responses-in-two-cancer-trials-advances-ai-driven-pipeline 2025-08-14T17:08:36+00:00 hourly 0.9 https://trial.medpath.com/news/92b103c13bb42ebc/engineered-cd40-antibody-achieves-complete-cancer-remission-in-phase-1-trial 2025-08-14T17:07:38+00:00 hourly 0.9 https://trial.medpath.com/news/81c05aabba0466d2/pds-biotechnology-s-versamune-hpv-shows-30-month-median-survival-in-phase-2-head-and-neck-cancer-trial 2025-08-14T17:05:58+00:00 hourly 0.9 https://trial.medpath.com/news/1bf717dcbfeec81e/on-demand-pharmaceuticals-demonstrates-point-of-care-manufacturing-platform-to-hhs-officials 2025-08-14T17:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/59c45485d8c0d559/denosumab-biosimilar-ly01011-demonstrates-therapeutic-equivalence-in-phase-3-bone-metastases-trial 2025-08-14T17:04:16+00:00 hourly 0.9 https://trial.medpath.com/news/e6f89ece9b5154a8/basilea-pharmaceutica-acquires-global-rights-to-phase-3-ready-oral-antibiotic-for-drug-resistant-utis 2025-08-14T17:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/973f883a8accfa1c/herantis-pharma-completes-phase-1b-trial-of-her-096-for-parkinson-s-disease-topline-results-expected-within-nine-weeks 2025-08-14T17:02:01+00:00 hourly 0.9 https://trial.medpath.com/news/062daf93cb5baf4a/ignitedata-secures-series-a-funding-to-expand-clinical-trial-data-automation-platform-globally 2025-08-14T17:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/dfbb1d15a42d1e25/vedanta-biosciences-cuts-20-of-workforce-after-microbiome-therapy-ve202-fails-phase-2-ulcerative-colitis-trial 2025-08-14T17:01:52+00:00 hourly 0.9 https://trial.medpath.com/news/209e328b7171c629/breakthrough-t1d-publishes-clinical-trial-roadmap-for-next-generation-beta-cell-replacement-therapies 2025-08-14T16:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/d96830406bdffcd3/dual-checkpoint-inhibitor-therapy-fails-to-improve-outcomes-in-mgmt-unmethylated-glioblastoma 2025-08-14T13:39:16+00:00 hourly 0.9 https://trial.medpath.com/news/35d8d2d7722535b3/aquestive-therapeutics-secures-75m-strategic-funding-from-rtw-for-anaphylm-commercial-launch 2025-08-14T13:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/46bde65574589dd2/evolveimmune-receives-fda-clearance-for-novel-trispecific-t-cell-engager-evolve104-targeting-solid-tumors 2025-08-14T13:33:18+00:00 hourly 0.9 https://trial.medpath.com/news/b274d4642f32d04e/goa-becomes-india-s-first-state-to-implement-pricing-policy-for-high-cost-cancer-and-rare-disease-therapies 2025-08-14T13:33:11+00:00 hourly 0.9 https://trial.medpath.com/news/6f73ce86e0e97da9/trinity-biotech-s-15-day-cgm-eliminates-fingerstick-calibration-in-clinical-trial 2025-08-14T09:06:45+00:00 hourly 0.9 https://trial.medpath.com/news/04fa8fe08c8d06a5/taiwan-accepts-everest-medicines-velsipity-application-for-ulcerative-colitis-treatment 2025-08-14T09:05:27+00:00 hourly 0.9 https://trial.medpath.com/news/a59759538ebc10a3/reprieve-cardiovascular-secures-61-million-series-b-funding-initiates-pivotal-heart-failure-trial 2025-08-14T09:04:32+00:00 hourly 0.9 https://trial.medpath.com/news/03b4d9d683986edd/daewoong-s-microneedle-patch-achieves-80-bioavailability-for-semaglutide-setting-new-standard-for-needle-free-obesity-treatment 2025-08-14T05:05:59+00:00 hourly 0.9 https://trial.medpath.com/news/4120913617f82f78/liquidia-s-yutrepia-achieves-rapid-market-uptake-with-900-prescriptions-in-11-weeks-post-approval 2025-08-14T05:05:06+00:00 hourly 0.9 https://trial.medpath.com/news/8858509d9905e407/gilead-sciences-settles-patent-dispute-with-laurus-labs-over-hiv-drug-tenofovir 2025-08-14T05:04:24+00:00 hourly 0.9 https://trial.medpath.com/news/b326945ede7e8974/ebus-guided-lung-biopsies-demonstrate-superior-safety-profile-for-comprehensive-biomarker-testing 2025-08-14T03:02:09+00:00 hourly 0.9 https://trial.medpath.com/news/f2dff724c93045f3/oncology-experts-address-operational-challenges-in-value-based-cancer-care-implementation 2025-08-14T03:02:06+00:00 hourly 0.9 https://trial.medpath.com/news/e226f64ec64a816d/aligos-therapeutics-initiates-phase-2-trial-of-alg-000184-for-chronic-hepatitis-b-treatment 2025-08-14T01:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/e8a9c17fd2e6ddfd/dermata-therapeutics-reports-positive-phase-3-xyngari-trial-results-for-moderate-to-severe-acne-treatment 2025-08-14T01:13:55+00:00 hourly 0.9 https://trial.medpath.com/news/892090e3a91b0a93/alvotech-reports-record-first-half-2025-results-with-over-200-product-revenue-growth 2025-08-14T01:11:01+00:00 hourly 0.9 https://trial.medpath.com/news/5c85ad9b8c91da77/allogene-therapeutics-reports-narrowed-q2-loss-despite-clinical-trial-delays-for-car-t-programs 2025-08-14T01:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/f8afb7cc2accb0ec/anlotinib-plus-epirubicin-receives-world-s-first-approval-in-china-for-advanced-soft-tissue-sarcoma 2025-08-14T01:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/df2f51861af115c5/mediwound-s-escharex-phase-ii-data-reveals-strong-correlation-between-wound-bed-preparation-and-healing-in-venous-leg-ulcers 2025-08-14T01:10:17+00:00 hourly 0.9 https://trial.medpath.com/news/3a38b7d479825991/baptist-health-hardin-launches-world-s-first-4d-mammography-clinical-trial-using-x-ray-diffraction-technology 2025-08-14T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5ee44a53ea930747/vyome-therapeutics-secures-nasdaq-approval-for-merger-with-reshape-lifesciences-targeting-100b-inflammatory-disease-market 2025-08-13T21:45:03+00:00 hourly 0.9 https://trial.medpath.com/news/9453e48f2a2bf89f/helix-biopharma-s-l-dos47-shows-promising-survival-extension-in-advanced-nsclc-phase-i-ii-study 2025-08-13T21:40:10+00:00 hourly 0.9 https://trial.medpath.com/news/0c0358515874ea82/vedanta-biosciences-ve202-fails-phase-2-trial-for-ulcerative-colitis-company-refocuses-on-c-difficile-program 2025-08-13T21:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/2a738127b517166f/biocardia-and-cart-tech-form-exclusive-partnership-for-heart3d-fusion-imaging-technology-in-cardiac-biotherapeutic-delivery 2025-08-13T21:39:21+00:00 hourly 0.9 https://trial.medpath.com/news/109afc4a34dcb4af/australian-biotech-mirugen-raises-a-4-5m-to-advance-cell-reprogramming-therapy-for-retinal-diseases 2025-08-13T21:38:09+00:00 hourly 0.9 https://trial.medpath.com/news/8d015e9bdc73236c/major-pharmaceutical-patent-settlements-reshape-generic-drug-market-in-q2-q3-2025 2025-08-13T21:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/ffb31ffe3baeee84/fda-issues-warning-letters-to-sunscreen-companies-over-unapproved-mousse-formulations 2025-08-13T21:34:59+00:00 hourly 0.9 https://trial.medpath.com/news/8a96db56c7f1ac65/cit-therapeutics-secures-2-5m-partnership-with-ifli-to-advance-novel-sumoylation-targeted-cancer-therapy 2025-08-13T21:34:51+00:00 hourly 0.9 https://trial.medpath.com/news/ff8e75bfeaa95c63/duke-nus-receives-1-5m-to-advance-ai-powered-antifibrotic-drug-discovery-platform 2025-08-13T17:42:49+00:00 hourly 0.9 https://trial.medpath.com/news/e04b246d527bc24f/dallas-cowboys-owner-jerry-jones-credits-pd-1-immunotherapy-for-stage-4-melanoma-survival 2025-08-13T17:42:42+00:00 hourly 0.9 https://trial.medpath.com/news/db5641b4ec85d5e5/fda-issues-urgent-correction-for-tandem-t-slim-x2-insulin-pump-following-700-adverse-events 2025-08-13T17:41:24+00:00 hourly 0.9 https://trial.medpath.com/news/f77f0bcba3080a02/curacell-receives-german-approval-for-phase-i-iia-trial-of-cc-38-til-therapy-in-metastatic-cancers 2025-08-13T17:40:18+00:00 hourly 0.9 https://trial.medpath.com/news/394ead2978e36fe4/st-jude-develops-ai-powered-tool-to-accelerate-dual-target-car-t-cell-therapy-design 2025-08-13T17:39:12+00:00 hourly 0.9 https://trial.medpath.com/news/7c22af77a39e3e8f/neuronascent-s-nni-362-shows-promise-in-phase-1a-trial-for-alzheimer-s-disease-with-novel-neuron-regeneration-approach 2025-08-13T17:39:10+00:00 hourly 0.9 https://trial.medpath.com/news/00fa92d7af07770a/apertura-gene-therapy-licenses-blood-brain-barrier-penetrant-aav-capsid-to-multiple-partners-for-cns-treatments 2025-08-13T17:38:12+00:00 hourly 0.9 https://trial.medpath.com/news/301fe8568d999f35/nine-year-old-becomes-third-patient-worldwide-to-receive-experimental-gene-therapy-for-rare-batten-disease 2025-08-13T17:38:01+00:00 hourly 0.9 https://trial.medpath.com/news/a7c8c1e8e04485ed/elevatebio-basecamp-becomes-first-genetic-medicine-manufacturer-to-achieve-comprehensive-icmc-certification-across-multiple-modalities 2025-08-13T17:37:40+00:00 hourly 0.9 https://trial.medpath.com/news/0c39ab7c1ae68dfb/avista-therapeutics-partners-with-forge-biologics-to-advance-avst-101-gene-therapy-for-x-linked-retinoschisis 2025-08-13T17:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/086d2a073ea4d95d/x4-pharmaceuticals-secures-85-million-private-placement-to-advance-mavorixafor-development 2025-08-13T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/news/323e8005b7a2d88f/pilatus-biosciences-partners-with-roche-for-first-in-human-trial-of-plt012-in-hepatocellular-carcinoma 2025-08-13T17:36:56+00:00 hourly 0.9 https://trial.medpath.com/news/c4ba910452673387/caris-life-sciences-study-reveals-optimal-sequencing-strategy-for-antibody-drug-conjugates-in-her2-negative-breast-cancer 2025-08-13T17:34:41+00:00 hourly 0.9 https://trial.medpath.com/news/fdf8a6382c484e88/oxford-biodynamics-partners-with-google-cloud-to-scale-ai-powered-3d-genomic-analytics-platform 2025-08-13T17:34:39+00:00 hourly 0.9 https://trial.medpath.com/news/7eac1e9bc1981a4c/creative-medical-technology-secures-fda-fast-track-designation-for-celz-201-ddt-back-pain-therapy 2025-08-13T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/b04a6eed5251b9dc/pulse-biosciences-advances-nspfa-technology-with-fda-breakthrough-designation-and-clinical-expansion 2025-08-13T17:34:35+00:00 hourly 0.9 https://trial.medpath.com/news/dea0d1ad7555b936/uc-cancer-center-launches-phase-3-trial-testing-high-dose-radiation-for-locally-advanced-pancreatic-cancer 2025-08-13T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/6f5fcb47be2f80e2/ars-pharmaceuticals-reports-strong-q3-2025-growth-for-needle-free-epinephrine-nasal-spray-neffy 2025-08-13T17:32:54+00:00 hourly 0.9 https://trial.medpath.com/news/7fc0ce714b52fdbf/immunitybio-s-cd19-car-nk-therapy-achieves-complete-responses-in-late-stage-waldenstrom-macroglobulinemia 2025-08-13T17:32:09+00:00 hourly 0.9 https://trial.medpath.com/news/7fabce674a1f0e53/two-dose-dalbavancin-matches-standard-therapy-for-complicated-staphylococcus-aureus-bloodstream-infections 2025-08-13T17:32:01+00:00 hourly 0.9 https://trial.medpath.com/news/f2f7943902a4cb6d/high-volume-cancer-centers-with-greater-neoadjuvant-chemotherapy-use-show-reduced-mortality-in-advanced-ovarian-cancer 2025-08-13T13:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/25d467098324c12c/uk-government-and-eli-lilly-launch-ps85-million-partnership-to-transform-obesity-care-access 2025-08-13T13:37:57+00:00 hourly 0.9 https://trial.medpath.com/news/410e979ed308060e/iptacopan-shows-promise-in-treating-life-threatening-transplant-associated-thrombotic-microangiopathy 2025-08-13T13:35:50+00:00 hourly 0.9 https://trial.medpath.com/news/c0be8db251309c28/hku-researchers-discover-atorvastatin-s-potential-as-novel-liver-cancer-treatment 2025-08-13T13:34:46+00:00 hourly 0.9 https://trial.medpath.com/news/2972dd2587998b9a/canbridge-pharmaceuticals-secures-12-7m-strategic-investment-from-baheal-medical-to-accelerate-rare-disease-drug-commercialization 2025-08-13T13:34:43+00:00 hourly 0.9 https://trial.medpath.com/news/9e297207db473ce8/china-approves-first-miniature-spinal-surgical-robot-with-sub-millimeter-precision 2025-08-13T13:33:02+00:00 hourly 0.9 https://trial.medpath.com/news/4e1d99f297713078/variable-long-covid-definitions-hamper-clinical-care-and-research-progress 2025-08-13T13:32:22+00:00 hourly 0.9 https://trial.medpath.com/news/4dd362db6e687832/tumor-infiltrating-lymphocyte-therapy-market-poised-for-explosive-growth-following-first-fda-approval 2025-08-13T09:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/261507f47dfe8b97/btl-industries-receives-fda-clearance-to-expand-emface-platform-for-tmj-dysfunction-treatment 2025-08-13T09:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/bcde36534b162ff1/polypid-appoints-dr-nurit-tweezer-zaks-as-chief-medical-officer-following-positive-phase-3-results 2025-08-13T05:34:22+00:00 hourly 0.9 https://trial.medpath.com/news/df2e61e1a1be84e9/avendus-fund-and-sbi-life-invest-300-crore-in-indian-crdmo-aragen-life-sciences 2025-08-13T05:32:02+00:00 hourly 0.9 https://trial.medpath.com/news/e2e9a14f54ae01de/ulcerative-colitis-treatment-market-reaches-8-4-billion-as-pipeline-expands-with-75-novel-therapies 2025-08-13T05:30:17+00:00 hourly 0.9 https://trial.medpath.com/news/744e9dea945688e7/zevra-therapeutics-reports-strong-q2-2025-results-seeks-european-approval-for-miplyffa 2025-08-13T05:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/240123dafeb60d72/snmmi-launches-ai-powered-platform-to-connect-patients-with-radiopharmaceutical-clinical-trials 2025-08-13T05:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/773ecd0cbef9e56b/imf-s-m-power-initiative-tackles-multiple-myeloma-disparities-in-black-communities-through-trust-building-and-clinical-trial-access 2025-08-13T03:02:25+00:00 hourly 0.9 https://trial.medpath.com/news/e5a12667afd9558e/ucla-develops-off-the-shelf-car-nkt-cell-therapy-for-ovarian-cancer-treatment 2025-08-13T01:39:05+00:00 hourly 0.9 https://trial.medpath.com/news/509b188ff8eb4867/coya-therapeutics-awaits-fda-decision-on-als-treatment-as-q2-results-show-mixed-performance 2025-08-13T01:35:02+00:00 hourly 0.9 https://trial.medpath.com/news/10f1eeb9d1228bb4/southern-research-opens-98-million-biotechnology-center-in-birmingham-to-accelerate-drug-discovery 2025-08-13T01:31:55+00:00 hourly 0.9 https://trial.medpath.com/news/d3a6aca0f620acfc/meta-analysis-confirms-safety-and-efficacy-of-biologic-switching-in-psoriasis-treatment 2025-08-13T01:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/c3587387f85ce05e/who-endorses-first-new-malaria-vector-control-tool-in-four-decades-as-spatial-repellents-show-56-protection-rate 2025-08-13T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb7746623a937f69/uc-davis-researchers-discover-gut-bacteria-molecule-that-reverses-liver-damage-and-repairs-intestinal-barrier 2025-08-12T21:38:07+00:00 hourly 0.9 https://trial.medpath.com/news/e4da8a0b4c5cff5f/met-inhibitor-shows-promise-in-enhancing-small-cell-lung-cancer-treatment-response 2025-08-12T21:36:49+00:00 hourly 0.9 https://trial.medpath.com/news/0d607b1d22503a65/atossa-therapeutics-streamlines-phase-ii-breast-cancer-trial-design-while-advancing-z-endoxifen-development 2025-08-12T21:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/6c430e66eb85d3ea/abbvie-invests-195-million-to-expand-u-s-api-manufacturing-capacity-in-north-chicago 2025-08-12T21:35:09+00:00 hourly 0.9 https://trial.medpath.com/news/939626434d3db362/mabwell-initiates-first-us-clinical-trial-of-nectin-4-adc-in-previously-treated-triple-negative-breast-cancer 2025-08-12T21:34:13+00:00 hourly 0.9 https://trial.medpath.com/news/b1eade6b06d96c8f/bostongene-validates-multimodal-rna-dna-tumor-assay-in-landmark-study-across-2200-cancer-samples 2025-08-12T21:34:01+00:00 hourly 0.9 https://trial.medpath.com/news/07c9db5c7bc80d0f/sareum-partners-with-receptor-ai-to-accelerate-ai-driven-discovery-of-brain-penetrating-tyk2-jak1-inhibitors-for-neuroinflammatory-diseases 2025-08-12T21:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/ff2f505d2ed92f7a/south-korea-emerges-as-major-drug-licensing-hub-with-7-68-billion-in-deals-driven-by-eli-lilly-and-gsk 2025-08-12T21:33:54+00:00 hourly 0.9 https://trial.medpath.com/news/12fe2c4ae83fa37f/ph-d-feminine-health-initiates-first-fda-cleared-phase-3-trial-for-boric-acid-suppositories-in-yeast-infections 2025-08-12T21:33:07+00:00 hourly 0.9 https://trial.medpath.com/news/a33071fac8ac3f5e/acumen-pharmaceuticals-advances-alzheimer-s-pipeline-with-jcr-partnership-and-altitude-ad-phase-2-trial 2025-08-12T21:33:03+00:00 hourly 0.9 https://trial.medpath.com/news/b1cd087389c029de/lung-fibrosis-drug-pirfenidone-shows-promise-as-copd-treatment-alternative-to-steroids 2025-08-12T21:32:03+00:00 hourly 0.9 https://trial.medpath.com/news/24fc9eec5d1e1daa/early-long-covid-trials-of-paxlovid-and-monoclonal-antibodies-show-no-significant-benefits-but-research-continues 2025-08-12T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/c503b4a1102de7c8/mail-order-and-digital-pharmacies-surge-ahead-as-chain-drugstores-face-customer-satisfaction-crisis 2025-08-12T20:41:00+00:00 hourly 0.9 https://trial.medpath.com/news/c7cb903c05531df5/hope-trial-extends-alteplase-treatment-window-to-24-hours-for-acute-ischemic-stroke-patients 2025-08-12T17:43:56+00:00 hourly 0.9 https://trial.medpath.com/news/88179c1d4ff5dc2b/gameto-secures-44m-series-c-funding-as-stem-cell-ivf-therapy-fertilo-advances-to-phase-3-trial 2025-08-12T17:43:03+00:00 hourly 0.9 https://trial.medpath.com/news/0ebe17579f40c827/v116-pneumococcal-vaccine-demonstrates-superior-immunogenicity-in-japanese-adults-65-and-older 2025-08-12T17:42:45+00:00 hourly 0.9 https://trial.medpath.com/news/99fc3025268fd7e4/hhs-halts-vaxart-s-460-million-oral-covid-19-vaccine-trial-amid-federal-mrna-program-rollback 2025-08-12T17:42:20+00:00 hourly 0.9 https://trial.medpath.com/news/ab93848dfecb842f/combination-therapies-enhance-oncolytic-virus-cancer-treatment-through-immune-system-reprogramming 2025-08-12T17:42:18+00:00 hourly 0.9 https://trial.medpath.com/news/316a2539d6b2fb2c/x4-pharmaceuticals-secures-60-million-financing-and-installs-new-leadership-team 2025-08-12T17:39:19+00:00 hourly 0.9 https://trial.medpath.com/news/9031b548f238d7aa/imdx-enrolls-first-patient-in-graftassuredx-transplant-rejection-monitoring-trial 2025-08-12T17:39:00+00:00 hourly 0.9 https://trial.medpath.com/news/b663218b9e2edfe6/expedition-therapeutics-secures-645m-deal-for-chinese-dpp-1-inhibitor-in-growing-cross-border-biotech-trend 2025-08-12T17:38:33+00:00 hourly 0.9 https://trial.medpath.com/news/717f2c823652c922/biotree-s-natural-metabolic-syndrome-drug-ph-100-advances-through-clinical-trials-with-global-partnership 2025-08-12T17:38:27+00:00 hourly 0.9 https://trial.medpath.com/news/6bef717ff257e602/heartflow-raises-364m-in-oversubscribed-ipo-stock-surges-58-on-strong-investor-confidence 2025-08-12T17:38:15+00:00 hourly 0.9 https://trial.medpath.com/news/03a43b55f2e3b15f/airway-therapeutics-secures-ema-pediatric-approval-for-first-in-class-bpd-prevention-therapy 2025-08-12T17:37:20+00:00 hourly 0.9 https://trial.medpath.com/news/cbdc8467702122cf/abcentra-initiates-phase-2b-fortify-trial-for-novel-anti-inflammatory-cardiovascular-therapy-orticumab 2025-08-12T17:37:07+00:00 hourly 0.9 https://trial.medpath.com/news/72b835c0ff67094a/fda-approves-expansion-of-aquedeon-s-duett-vascular-graft-system-trial-to-90-patients 2025-08-12T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/8e52de2634b8711f/fda-clears-sonic-incytes-ai-guided-velacur-one-ultrasound-device-for-chronic-liver-disease-management 2025-08-12T16:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/01470b1e7291a562/machine-learning-transforms-drug-drug-interaction-prediction-with-85-accuracy-improvement 2025-08-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0e9a5ac5812e53f8/black-swan-graphene-partners-with-ferro-south-africa-to-expand-graphene-technology-distribution 2025-08-12T14:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/00b8cda5dbc45d48/avicanna-secures-us-patent-for-cannabinoid-based-topical-formulation-targeting-skin-conditions 2025-08-12T13:49:42+00:00 hourly 0.9 https://trial.medpath.com/news/74567cf2cbb11a2f/vicentra-secures-85m-series-d-to-scale-kaleido-insulin-patch-pump-manufacturing-and-us-market-entry 2025-08-12T13:46:59+00:00 hourly 0.9 https://trial.medpath.com/news/439614fe200e37ad/xspray-pharma-secures-first-patent-license-deal-with-handa-therapeutics-for-dasatinib-commercialization 2025-08-12T13:44:15+00:00 hourly 0.9 https://trial.medpath.com/news/70c875b5fc3c777e/rakovina-therapeutics-and-nanopalm-form-joint-venture-to-advance-ai-discovered-cancer-drug-kt-3283 2025-08-12T13:42:43+00:00 hourly 0.9 https://trial.medpath.com/news/29d906ddd3b313c4/bayer-partners-with-kumquat-biosciences-in-1-3-billion-deal-to-develop-kras-g12d-inhibitor-for-hard-to-treat-cancers 2025-08-12T13:42:29+00:00 hourly 0.9 https://trial.medpath.com/news/b2b0ceae754179a9/mabylon-raises-chf-30-million-to-advance-tri-specific-peanut-allergy-antibody-my006-through-phase-i-trials 2025-08-12T13:42:06+00:00 hourly 0.9 https://trial.medpath.com/news/1c37c99f52866a76/fda-allowed-over-150-drugs-from-banned-foreign-factories-to-enter-u-s-market-despite-safety-violations 2025-08-12T13:41:57+00:00 hourly 0.9 https://trial.medpath.com/news/ac9a8e09565126c5/lupin-partners-with-sandoz-to-commercialize-ranibizumab-biosimilar-across-multiple-global-markets 2025-08-12T13:40:37+00:00 hourly 0.9 https://trial.medpath.com/news/4fa468ac52fc9ede/pfizer-s-padcev-keytruda-combination-shows-significant-survival-benefit-in-muscle-invasive-bladder-cancer-trial 2025-08-12T13:40:35+00:00 hourly 0.9 https://trial.medpath.com/news/e39d598747d8ade5/amphastar-pharmaceuticals-expands-pipeline-with-453-million-licensing-deal-for-three-novel-peptide-therapeutics 2025-08-12T13:39:18+00:00 hourly 0.9 https://trial.medpath.com/news/9d4084d7cd017af2/puretech-health-launches-celea-therapeutics-to-advance-phase-3-ready-ipf-treatment 2025-08-12T13:38:23+00:00 hourly 0.9 https://trial.medpath.com/news/d233007703d0aa63/panthera-biopartners-secures-major-investment-from-ldc-to-expand-uk-s-largest-clinical-trial-smo-network 2025-08-12T13:38:20+00:00 hourly 0.9 https://trial.medpath.com/news/acdc5b868fc18530/mmj-biopharma-files-emergency-motion-to-dea-as-trump-signals-openness-to-medical-cannabis 2025-08-12T09:40:22+00:00 hourly 0.9 https://trial.medpath.com/news/d73ae37514048c0c/adze-biotechnology-receives-ethics-approval-for-phase-i-oncolytic-immunotherapy-trial-in-metastatic-melanoma 2025-08-12T09:39:48+00:00 hourly 0.9 https://trial.medpath.com/news/3bde08a8d5546360/fosun-pharma-secures-645-million-global-licensing-deal-for-novel-dpp-1-inhibitor-xh-s004 2025-08-12T05:03:35+00:00 hourly 0.9 https://trial.medpath.com/news/50b0e13218ceda67/study-reveals-significant-treatment-disparities-in-high-risk-myelodysplastic-syndrome-patients 2025-08-12T03:01:54+00:00 hourly 0.9 https://trial.medpath.com/news/99e10d420c483140/mirum-pharmaceuticals-raises-2025-revenue-guidance-to-490-510-million-following-strong-q2-performance 2025-08-12T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/63e4e604c4d47d90/sana-biotechnology-reports-breakthrough-in-type-1-diabetes-cell-therapy-with-6-month-clinical-data 2025-08-12T01:31:15+00:00 hourly 0.9 https://trial.medpath.com/news/88ffbb0c1ff185f1/researchers-identify-first-potential-biomarker-for-long-covid-diagnosis 2025-08-11T21:05:30+00:00 hourly 0.9 https://trial.medpath.com/news/ac21314b07b4c669/india-approves-roche-s-7-minute-subcutaneous-cancer-injection-tecentriq-cutting-treatment-time-by-85 2025-08-11T21:05:18+00:00 hourly 0.9 https://trial.medpath.com/news/0057024bc7301fef/garden-launches-bloom-ai-engine-to-accelerate-ip-aware-drug-discovery 2025-08-11T21:04:25+00:00 hourly 0.9 https://trial.medpath.com/news/f048a07b16943967/early-rhythm-control-therapy-remains-effective-for-atrial-fibrillation-patients-with-obesity-and-diabetes 2025-08-11T21:03:30+00:00 hourly 0.9 https://trial.medpath.com/news/af14306dea980df2/tahoe-therapeutics-secures-30m-to-create-world-s-largest-single-cell-dataset-for-ai-driven-drug-discovery 2025-08-11T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/6637bdd5f2798881/veru-selects-novel-modified-release-enobosarm-formulation-for-weight-loss-management-using-advanced-3d-printing-technology 2025-08-11T17:14:53+00:00 hourly 0.9 https://trial.medpath.com/news/45f64add48081e32/avicanna-secures-u-s-patent-for-topical-cannabinoid-compositions 2025-08-11T17:13:48+00:00 hourly 0.9 https://trial.medpath.com/news/68383b9274c3d88a/io-biotech-phase-3-trial-fails-to-meet-primary-endpoints 2025-08-11T17:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/3634c60cfd0bcc26/intermittent-fasting-enhances-anti-androgen-therapy-efficacy-in-prostate-cancer-preclinical-study-shows 2025-08-11T17:11:10+00:00 hourly 0.9 https://trial.medpath.com/news/02de1a6608687cce/inovio-s-ino-3107-dna-medicine-shows-sustained-long-term-benefits-in-recurrent-respiratory-papillomatosis-treatment 2025-08-11T17:10:24+00:00 hourly 0.9 https://trial.medpath.com/news/5090189f45b12a12/ankylosing-spondylitis-pipeline-shows-robust-growth-with-20-therapies-in-development 2025-08-11T17:10:21+00:00 hourly 0.9 https://trial.medpath.com/news/6875e7525f37bb62/io-biotech-s-cylembio-plus-pembrolizumab-demonstrates-clinical-improvement-in-advanced-melanoma-phase-3-trial 2025-08-11T17:09:39+00:00 hourly 0.9 https://trial.medpath.com/news/fe67dc9a5b6328cc/subcutaneous-eeg-device-demonstrates-superior-seizure-detection-in-treatment-resistant-epilepsy-study 2025-08-11T17:08:51+00:00 hourly 0.9 https://trial.medpath.com/news/bf2d153df6f006c0/io-biotech-s-melanoma-vaccine-narrowly-misses-primary-endpoint-in-phase-3-trial-despite-promising-subgroup-results 2025-08-11T17:08:48+00:00 hourly 0.9 https://trial.medpath.com/news/d1ced17ab24ab90e/sartorius-stedim-biotech-partners-with-nanotein-technologies-to-enhance-cell-therapy-manufacturing-with-nanospark-r-platform 2025-08-11T17:08:39+00:00 hourly 0.9 https://trial.medpath.com/news/06f19256a516c9f9/viatris-secures-fda-approval-for-first-generic-iron-sucrose-injection-with-180-day-market-exclusivity 2025-08-11T17:06:12+00:00 hourly 0.9 https://trial.medpath.com/news/3beedd45404c5bf4/inflammation-and-oxidative-stress-drive-osteoporosis-through-disrupted-bone-remodeling 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/90d4d63dbf7bef2b/protac-technology-emerges-as-next-generation-approach-for-ido1-targeted-cancer-immunotherapy 2025-08-11T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c975460c674002b4/compass-therapeutics-reports-promising-clinical-data-across-bispecific-antibody-pipeline 2025-08-11T13:08:19+00:00 hourly 0.9 https://trial.medpath.com/news/b68110c46a532dae/forx-therapeutics-doses-first-patient-with-novel-parg-inhibitor-forx-428-in-phase-1-cancer-trial 2025-08-11T13:08:17+00:00 hourly 0.9 https://trial.medpath.com/news/42e370b190a98dfe/tango-therapeutics-secures-225-million-in-financing-to-advance-precision-cancer-medicine-pipeline 2025-08-11T12:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/3838acfa95627edc/algeria-approves-sino-biopharmaceutical-s-adalimumab-biosimilar-for-autoimmune-disease-treatment 2025-08-11T12:07:51+00:00 hourly 0.9 https://trial.medpath.com/news/48a759f7d17fa2c1/seed-therapeutics-receives-fda-clearance-for-first-in-human-trial-of-rbm39-degrader-st-01156 2025-08-11T12:06:26+00:00 hourly 0.9 https://trial.medpath.com/news/26d6352d4bd38fc1/89bio-reports-q2-2025-results-with-111-5m-net-loss-as-phase-3-mash-and-shtg-trials-advance 2025-08-11T12:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/856f277698cfa073/wuxi-biologics-launches-wuxia293stable-platform-to-address-manufacturing-challenges-for-complex-biologics 2025-08-11T12:05:48+00:00 hourly 0.9 https://trial.medpath.com/news/abb3ac6b7a32d6ed/kexing-biopharm-partners-with-iqvia-to-accelerate-global-drug-development-and-market-access 2025-08-11T12:05:43+00:00 hourly 0.9 https://trial.medpath.com/news/74644e380b19990d/zydus-lifesciences-secures-fda-approval-for-generic-diltiazem-tablets-to-treat-angina-and-hypertension 2025-08-11T12:05:36+00:00 hourly 0.9 https://trial.medpath.com/news/640689b4f296a7c8/amphastar-receives-fda-approval-for-generic-iron-sucrose-injection-to-treat-anemia-in-chronic-kidney-disease-patients 2025-08-11T12:04:55+00:00 hourly 0.9 https://trial.medpath.com/news/8014fad340c3a163/kamada-receives-fda-approval-for-houston-plasma-collection-center-expanding-specialty-plasma-operations 2025-08-11T12:04:53+00:00 hourly 0.9 https://trial.medpath.com/news/1584425e877433c7/major-medical-organizations-excluded-from-cdc-vaccine-advisory-workgroups 2025-08-11T12:04:18+00:00 hourly 0.9 https://trial.medpath.com/news/9e9095f34344bf87/cpap-therapy-shows-differential-cardiovascular-effects-based-on-sleep-apnea-risk-profile 2025-08-11T12:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/4e25bc4e7e8cf4c0/heart-failure-drug-ivabradine-shows-promise-for-pots-treatment-in-pilot-study 2025-08-11T12:02:13+00:00 hourly 0.9 https://trial.medpath.com/news/7a69c5edf5f66397/china-s-star-market-reforms-boost-biotech-financing-as-healthgen-becomes-first-company-to-benefit-from-resumed-rules 2025-08-11T09:26:21+00:00 hourly 0.9 https://trial.medpath.com/news/766702e038676187/ami-pharm-s-ayp-101-enters-phase-3-trial-for-non-inflammatory-fat-reduction 2025-08-11T09:25:51+00:00 hourly 0.9 https://trial.medpath.com/news/2294c2c7fa5fb797/surrozen-reports-strong-q2-2025-turnaround-with-39-7m-net-income-advances-retinal-disease-pipeline 2025-08-11T09:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/e62aa038655ea57d/maxwell-biosciences-secures-20m-to-advance-immune-inspired-antimicrobial-platform-through-fda-trials 2025-08-11T09:23:25+00:00 hourly 0.9 https://trial.medpath.com/news/0da20f3c3aa15e32/bionxt-solutions-completes-1-25m-oversubscribed-funding-round-to-advance-drug-delivery-platform-development 2025-08-11T05:02:28+00:00 hourly 0.9 https://trial.medpath.com/news/37ab6c3f42870bb8/truemeds-raises-85m-to-expand-generic-drug-platform-serving-india-s-400-million-chronic-patients 2025-08-11T05:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/3226b4ce6a98ac42/histoindex-launches-ai-powered-fibrosight-plus-for-enhanced-mash-fibrosis-assessment 2025-08-11T05:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/e8308f17bb9ee235/syntara-receives-fda-guidance-for-amsulostat-phase-2-trial-in-myelofibrosis 2025-08-11T05:00:32+00:00 hourly 0.9 https://trial.medpath.com/news/799ebd01fc55f2ba/king-s-college-london-develops-kcl-ho-1i-novel-oral-drug-to-overcome-chemotherapy-resistance 2025-08-11T01:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/7132dc93f9a32e79/lean-body-mass-based-oxaliplatin-dosing-reduces-neuropathy-without-compromising-efficacy-in-stage-iii-colon-cancer 2025-08-10T21:08:45+00:00 hourly 0.9 https://trial.medpath.com/news/b540a06815455a7c/io-biotech-s-cylembio-narrowly-misses-primary-endpoint-in-phase-3-melanoma-trial-despite-progression-free-survival-benefit 2025-08-10T21:08:30+00:00 hourly 0.9 https://trial.medpath.com/news/cc9ab7b78e4801dd/modular-medical-advances-tubeless-pivot-insulin-pump-with-october-fda-filing-and-gamified-training-platform 2025-08-10T17:10:27+00:00 hourly 0.9 https://trial.medpath.com/news/b66b4370462d3ceb/real-world-study-confirms-high-volume-intravitreal-injections-do-not-increase-glaucoma-risk 2025-08-10T17:05:39+00:00 hourly 0.9 https://trial.medpath.com/news/827bb041bce09acc/ube2n-emerges-as-novel-prognostic-biomarker-and-therapeutic-target-in-lung-adenocarcinoma 2025-08-10T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/53925bf0b19fc35b/abiogenesis-clinpharm-receives-regulatory-approval-for-phase-iii-trial-of-phenazopyridine-in-urinary-tract-infections 2025-08-10T09:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/75d68943aa887502/biomarker-analysis-reveals-predictive-factors-for-adjuvant-nivolumab-success-in-muscle-invasive-urothelial-carcinoma 2025-08-10T09:29:22+00:00 hourly 0.9 https://trial.medpath.com/news/f301f84b103eedca/belite-bio-raises-275-million-in-upsized-private-placement-to-advance-retinal-disease-therapies 2025-08-10T09:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/acea745d808b95f7/avidity-biosciences-reports-strong-q2-results-advances-three-rna-therapeutics-toward-bla-submissions 2025-08-10T05:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/5f6846a792ecc447/geron-appoints-harout-semerjian-as-ceo-to-drive-rytelo-expansion-and-late-stage-pipeline 2025-08-10T05:32:18+00:00 hourly 0.9 https://trial.medpath.com/news/8492fa01988f0b81/us-oncology-enterprise-faces-unprecedented-financial-crisis-as-nci-budget-cuts-threaten-cancer-research-infrastructure 2025-08-10T03:01:16+00:00 hourly 0.9 https://trial.medpath.com/news/5ff01feec9393f33/novel-multivalent-mrna-vaccines-show-promise-against-mpxv-and-sars-cov-2-in-preclinical-studies 2025-08-10T01:30:52+00:00 hourly 0.9 https://trial.medpath.com/news/312efa46dd99dd58/shilpa-medicare-receives-world-s-first-approval-for-norudca-novel-nafld-treatment 2025-08-10T01:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/c6ab2c7489965d5c/researchers-develop-wireless-soft-neural-interface-with-integrated-micropump-for-targeted-brain-drug-delivery 2025-08-10T01:29:18+00:00 hourly 0.9 https://trial.medpath.com/news/947297fc64c1014f/remimazolam-demonstrates-superior-safety-profile-over-propofol-in-icu-bronchoscopy-procedures 2025-08-09T21:27:21+00:00 hourly 0.9 https://trial.medpath.com/news/31db8fe5e987f97e/janux-therapeutics-receives-10-million-milestone-payment-from-merck-as-first-patient-dosed-in-tractr-cancer-immunotherapy-trial 2025-08-09T21:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/f7787bb4d1618bdb/heartflow-s-316-7m-ipo-signals-ai-revolution-in-cardiovascular-diagnostics 2025-08-09T21:26:16+00:00 hourly 0.9 https://trial.medpath.com/news/1b6a00a4a0524124/cosmo-pharmaceuticals-and-takeda-renew-multi-year-manufacturing-agreement-for-ulcerative-colitis-treatment 2025-08-09T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/8b97de02287d43e9/india-s-first-indigenous-car-t-therapy-achieves-two-year-remission-milestone-in-aggressive-blood-cancer 2025-08-09T17:29:42+00:00 hourly 0.9 https://trial.medpath.com/news/62e01ec814a2ea44/fda-approves-boehringer-ingelheim-s-hernexeos-as-first-in-class-her2-tki-for-rare-lung-cancer-subset 2025-08-09T17:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/6e688815941c59f8/mobile-app-otx-202-reduces-suicide-attempts-by-58-in-high-risk-psychiatric-patients 2025-08-09T13:29:36+00:00 hourly 0.9 https://trial.medpath.com/news/762d4eaad6a3e529/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-children-under-5 2025-08-09T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/2bc941250e39be4a/fda-restricts-bluebird-bio-s-skysona-gene-therapy-following-tripled-cancer-risk 2025-08-09T09:31:09+00:00 hourly 0.9 https://trial.medpath.com/news/7673b122491793b8/sitryx-regains-rights-to-first-in-class-itaconate-mimetic-syx-1042-from-lilly-after-successful-phase-1-trial 2025-08-09T09:30:44+00:00 hourly 0.9 https://trial.medpath.com/news/2f8f683b1342b867/eli-lilly-divests-troubled-new-jersey-plant-while-expanding-global-manufacturing-network 2025-08-09T09:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/dc53dfd4a689b411/gsk-advances-phase-3-trial-of-tafenoquine-for-plasmodium-vivax-malaria-treatment-in-india 2025-08-09T09:28:53+00:00 hourly 0.9 https://trial.medpath.com/news/4a6638a67dbc656b/ascendis-pharma-gains-fda-approval-for-skytrofa-in-adult-growth-hormone-deficiency 2025-08-09T09:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/147a049a0c94e076/oncolytics-biotech-voluntarily-delists-from-toronto-stock-exchange-to-focus-on-u-s-operations 2025-08-09T05:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/fcfd5ac0bce447a5/dermarite-industries-recalls-four-otc-products-due-to-life-threatening-burkholderia-cepacia-contamination 2025-08-09T05:30:28+00:00 hourly 0.9 https://trial.medpath.com/news/b105c18fdc4aa077/atyr-pharma-completes-phase-3-enrollment-for-pulmonary-sarcoidosis-treatment-results-expected-q3-2025 2025-08-09T05:30:21+00:00 hourly 0.9 https://trial.medpath.com/news/0bc070e29d50c3d8/fda-issues-safety-alerts-for-boston-scientific-heart-devices-linked-to-33-deaths 2025-08-09T05:29:58+00:00 hourly 0.9 https://trial.medpath.com/news/cb6f3e17736dfcfb/cormedix-acquires-melinta-therapeutics-for-300-million-to-expand-anti-infective-portfolio 2025-08-09T05:25:35+00:00 hourly 0.9 https://trial.medpath.com/news/5fcea36cf11fd042/latvian-biotech-cellbox-labs-raises-eur3-3m-to-advance-organ-on-chip-drug-discovery-platform 2025-08-09T05:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/e888499bca0f7913/anbio-biotechnology-launches-15-minute-ultra-fast-pcr-system-and-chikungunya-rapid-test-to-combat-global-disease-outbreaks 2025-08-09T05:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/a2fada18bfaf4a43/regenxbio-initiates-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy-gene-therapy 2025-08-09T01:39:35+00:00 hourly 0.9 https://trial.medpath.com/news/0654a53b7c1e3268/real-world-safety-analysis-reveals-complex-toxicity-profile-of-tremelimumab-durvalumab-combination-in-hepatocellular-carcinoma 2025-08-09T01:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/c7aa44d7766e05f4/epipen-patent-expiration-on-september-11-2025-set-to-transform-epinephrine-auto-injector-market 2025-08-09T01:34:48+00:00 hourly 0.9 https://trial.medpath.com/news/04b65c4af41d43fc/iovance-biotherapeutics-stock-plunges-14-amid-legal-challenges-and-leadership-changes 2025-08-09T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/55b1134ee9a10b4c/yale-developed-canine-cancer-vaccine-doubles-survival-rates-in-clinical-trials 2025-08-09T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/d297a00f179cc421/poxel-enters-reorganization-proceedings-as-clinical-stage-biotech-faces-financial-restructuring 2025-08-08T21:37:02+00:00 hourly 0.9 https://trial.medpath.com/news/2b04b177ef50c295/radella-pharmaceuticals-md-18-demonstrates-2-7-weight-loss-and-cardiometabolic-benefits-in-phase-1b-trial 2025-08-08T21:36:22+00:00 hourly 0.9 https://trial.medpath.com/news/4c53ad089ff8261f/rbl-secures-investment-from-modi-ventures-to-accelerate-biotech-venture-creation 2025-08-08T21:35:12+00:00 hourly 0.9 https://trial.medpath.com/news/2450280fbd48e2e5/zai-lab-s-dll3-adc-shows-68-response-rate-in-small-cell-lung-cancer-advances-to-global-registrational-study 2025-08-08T21:35:06+00:00 hourly 0.9 https://trial.medpath.com/news/7120530160a9575b/bicycle-therapeutics-delays-zelenectide-pevedotin-regulatory-update-to-q1-2026-amid-multi-agency-consultations 2025-08-08T21:34:03+00:00 hourly 0.9 https://trial.medpath.com/news/1c3e7eaff69624d8/alector-s-phase-3-ftd-trial-misses-primary-endpoint-despite-fda-endorsed-statistical-plan-amendment 2025-08-08T21:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/8805ab0640a69543/novel-pde4-inhibitor-me3183-demonstrates-significant-efficacy-in-phase-2-plaque-psoriasis-trial 2025-08-08T21:32:05+00:00 hourly 0.9 https://trial.medpath.com/news/a980db2e25d05d20/dana-farber-researchers-develop-swift-seq-blood-test-to-replace-bone-marrow-biopsies-in-multiple-myeloma 2025-08-08T21:30:26+00:00 hourly 0.9 https://trial.medpath.com/news/8b9acb68b87921c9/iovance-biotherapeutics-withdraws-amtagvi-eu-filing-stock-plunges-29-despite-strong-q2-sales 2025-08-08T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/b8389e9b0a46c593/gilead-s-hiv-prevention-drug-yeztugo-exceeds-launch-expectations-projected-to-reach-5-billion-by-2031 2025-08-08T21:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/f52add6235804c74/neonc-technologies-receives-fda-authorization-for-phase-ii-brain-cancer-trial-of-neo212 2025-08-08T17:43:00+00:00 hourly 0.9 https://trial.medpath.com/news/94df1ee8a120d2f8/faron-secures-extended-patent-protection-for-bexmarilimab-cancer-immunotherapy-through-2040 2025-08-08T17:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/976322af3abf2746/lisata-therapeutics-extends-cash-runway-to-q4-2026-advances-certepetide-development-through-catalent-partnership 2025-08-08T17:38:26+00:00 hourly 0.9 https://trial.medpath.com/news/7b806cc3dd96f2ce/fosun-s-hlx43-cancer-drug-rights-deal-with-j-j-and-roche-could-generate-hundreds-of-millions-in-strategic-ip-monetization 2025-08-08T17:37:48+00:00 hourly 0.9 https://trial.medpath.com/news/60cb8c8586dc74cc/eli-lilly-reports-positive-phase-iii-results-for-oral-glp-1-therapy-orforglipron-in-type-2-diabetes-and-obesity 2025-08-08T17:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/0979729d9ee363ba/kiora-pharmaceuticals-advances-two-phase-2-retinal-disease-trials-secures-110m-asian-partnership 2025-08-08T17:36:13+00:00 hourly 0.9 https://trial.medpath.com/news/06939932ccd649be/car-t-therapy-shows-unprecedented-promise-as-potential-cure-for-lupus-in-early-clinical-trials 2025-08-08T17:34:47+00:00 hourly 0.9 https://trial.medpath.com/news/6e06cc3c55b9d5b7/hope-therapeutics-receives-florida-regulatory-approval-for-dura-medical-acquisition-to-expand-precision-psychiatry-network 2025-08-08T17:33:53+00:00 hourly 0.9 https://trial.medpath.com/news/672396d5df029718/iovance-biotherapeutics-implements-major-restructuring-amid-regulatory-setbacks-and-commercial-challenges 2025-08-08T17:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/3484c527c9a0d6d6/wcc-biomedical-advances-microneedle-drug-delivery-platform-with-winmap-technology-at-nacds-expo 2025-08-08T17:33:16+00:00 hourly 0.9 https://trial.medpath.com/news/8fa538cf12023cac/genmab-s-epkinly-achieves-79-reduction-in-disease-progression-risk-in-phase-iii-follicular-lymphoma-trial 2025-08-08T17:32:44+00:00 hourly 0.9 https://trial.medpath.com/news/02ff59c017c5ba0e/capivasertib-causes-distinctive-glucose-spikes-in-breast-cancer-patient-prompting-japanese-safety-warning 2025-08-08T13:25:49+00:00 hourly 0.9 https://trial.medpath.com/news/c5919f42e17d83ad/roswell-park-researchers-develop-first-genomic-tool-to-guide-kidney-cancer-immunotherapy-decisions 2025-08-08T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/f035bf06b4ecd650/codex-genetics-partners-with-pacific-edge-to-bring-non-invasive-bladder-cancer-testing-to-hong-kong 2025-08-08T13:23:50+00:00 hourly 0.9 https://trial.medpath.com/news/9fadd4b29df340f7/remegen-receives-fda-clearance-for-phase-ii-trial-of-bispecific-antibody-rc148-in-advanced-solid-tumors 2025-08-08T13:23:27+00:00 hourly 0.9 https://trial.medpath.com/news/f4eedc24b2ef0a1a/orchestra-biomed-expands-backbeat-hypertension-trial-eligibility-24-fold-following-fda-protocol-approval 2025-08-08T13:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/827fe98b765e60b0/10x-genomics-acquires-scale-biosciences-to-expand-single-cell-analysis-capabilities 2025-08-08T09:37:38+00:00 hourly 0.9 https://trial.medpath.com/news/900eb84494c4bf5a/skye-bioscience-reports-promising-preclinical-data-for-nimacimab-as-obesity-treatment-ahead-of-phase-2a-results 2025-08-08T09:34:08+00:00 hourly 0.9 https://trial.medpath.com/news/6e77698116ffd5d5/trinity-biotech-launches-fda-cleared-preeclampsia-testing-service-with-potential-10-million-cost-savings 2025-08-08T09:31:13+00:00 hourly 0.9 https://trial.medpath.com/news/dcc7773af0b767c2/gsk-secures-370-million-settlement-and-future-royalties-in-curevac-biontech-mrna-patent-dispute 2025-08-08T09:30:25+00:00 hourly 0.9 https://trial.medpath.com/news/df987756f133c369/smart-hydrogel-achieves-90-diabetic-wound-closure-in-12-days-through-novel-mirna-therapy 2025-08-08T09:29:20+00:00 hourly 0.9 https://trial.medpath.com/news/807fe7c38fabf9db/89bio-advances-phase-3-trials-for-pegozafermin-in-mash-and-severe-hypertriglyceridemia-with-561m-cash-position 2025-08-08T09:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/976e5e185be6a5a5/dewpoint-therapeutics-cuts-70-of-workforce-refocuses-on-lead-cancer-drug-dptx3186 2025-08-08T09:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/5e0315b071ae0b90/kura-oncology-s-ziftomenib-receives-fda-priority-review-for-npm1-mutant-aml-pdufa-date-set-for-november-2025 2025-08-08T05:37:39+00:00 hourly 0.9 https://trial.medpath.com/news/1fb27558e3d580db/progressive-supranuclear-palsy-market-poised-for-growth-as-emerging-therapies-advance-through-clinical-trials 2025-08-08T05:36:18+00:00 hourly 0.9 https://trial.medpath.com/news/7bcf22aac59a5546/newcastle-study-shows-safe-withdrawal-of-eculizumab-in-rare-kidney-disease-saving-nhs-ps4-2-million-per-patient 2025-08-08T05:33:31+00:00 hourly 0.9 https://trial.medpath.com/news/2975f8ea17ac72fa/retension-pharmaceuticals-secures-15m-series-b-to-advance-novel-hypertension-drug-rtn-001-into-phase-2b-trial 2025-08-08T05:33:17+00:00 hourly 0.9 https://trial.medpath.com/news/523bc56329433ca9/insulin-access-disparities-persist-despite-cost-stabilization-study-reveals-long-term-health-system-burden 2025-08-08T03:32:27+00:00 hourly 0.9 https://trial.medpath.com/news/7f8bdb9ea69fed2a/infectious-disease-screening-in-substance-use-treatment-programs-shows-dramatic-increases-in-detection-and-prevention 2025-08-08T03:31:52+00:00 hourly 0.9 https://trial.medpath.com/news/e28443c48319949e/clinical-trial-supply-chains-face-new-challenges-from-tariffs-and-ai-disruption 2025-08-08T03:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/025bed9cf9e5d4d9/myriad-genetics-reports-strong-q2-2025-results-pivots-strategy-to-focus-on-cancer-care-continuum 2025-08-08T03:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/10620d9da49fa6da/genetic-testing-reduces-severe-chemotherapy-side-effects-by-42-in-gastrointestinal-cancer-patients 2025-08-08T01:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/9841de369c5cd066/relay-therapeutics-advances-rly-2608-to-phase-3-trial-with-promising-breast-cancer-data 2025-08-08T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/2648957b71e02b7a/biomendics-launches-tames-02-trial-for-first-in-class-eb-simplex-therapy-tolasure 2025-08-08T01:36:36+00:00 hourly 0.9 https://trial.medpath.com/news/c32c1c78dcb0d399/cassava-sciences-appoints-joseph-hulihan-as-chief-medical-officer-to-lead-simufilam-development-for-tsc-related-epilepsy 2025-08-08T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/76b4d1b913c71159/arcellx-reports-strong-car-t-clinical-data-despite-72-revenue-drop-in-q2-2025 2025-08-08T01:32:38+00:00 hourly 0.9 https://trial.medpath.com/news/6553da1ecd555962/real-world-evidence-validates-bispecific-antibodies-as-effective-treatment-option-in-relapsed-refractory-multiple-myeloma 2025-08-08T01:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/2b55f47e9a2429ee/pattern-computer-secures-global-patent-protection-for-ai-discovered-triple-negative-breast-cancer-therapy-pci020302 2025-08-08T01:32:21+00:00 hourly 0.9 https://trial.medpath.com/news/a9478ea88d842c58/ignite-proteomics-partners-with-vanderbilt-to-advance-breast-cancer-immunotherapy-biomarker-discovery 2025-08-08T01:31:03+00:00 hourly 0.9 https://trial.medpath.com/news/3a149be483f7d09a/fibrogen-receives-fda-approval-for-phase-3-trial-of-roxadustat-in-lower-risk-mds-patients-with-high-transfusion-burden 2025-08-08T01:29:52+00:00 hourly 0.9 https://trial.medpath.com/news/75ca936743ec427a/iovance-reports-strong-q2-2025-results-with-60m-revenue-as-amtagvi-adoption-accelerates 2025-08-08T01:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/15a9480f50a2b072/daxor-receives-fda-clearance-for-next-generation-blood-volume-analyzer-with-3x-faster-analysis 2025-08-08T01:29:23+00:00 hourly 0.9 https://trial.medpath.com/news/1ce706488bb0ca6a/annexon-s-vonaprument-selected-for-ema-s-product-development-coordinator-pilot-program-for-dry-amd-treatment 2025-08-08T01:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/b48c9fe08bc5a8bf/fda-approves-first-liquid-embolic-system-for-hypervascular-tumor-treatment 2025-08-08T01:28:22+00:00 hourly 0.9 https://trial.medpath.com/news/26c918bd23326a39/sequence-lifescience-receives-irb-approval-for-novel-matched-controls-trial-in-diabetic-foot-ulcers 2025-08-08T01:27:12+00:00 hourly 0.9 https://trial.medpath.com/news/4d55b37ed487605d/viiv-healthcare-s-n6ls-broadly-neutralizing-antibody-shows-promise-in-phase-2b-hiv-trial 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fca4e53cccbe1c02/triple-combination-therapy-shows-promise-for-ruxolitinib-resistant-myelofibrosis-patient 2025-08-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/47cf5811ce6a7039/sellas-life-sciences-receives-positive-idmc-recommendation-to-continue-phase-3-regal-trial-of-galinpepimut-s-in-aml 2025-08-07T21:42:14+00:00 hourly 0.9 https://trial.medpath.com/news/deff109d3d00b670/landmark-pkids-trial-challenges-standard-pediatric-kidney-stone-treatment-approaches 2025-08-07T21:41:43+00:00 hourly 0.9 https://trial.medpath.com/news/6caa4f46f52be7cc/faers-database-analysis-reveals-safety-profile-of-imiglucerase-in-gaucher-disease-treatment 2025-08-07T21:39:40+00:00 hourly 0.9 https://trial.medpath.com/news/bcfc4c4c41f53a9d/quince-therapeutics-partners-with-option-care-health-to-streamline-edsp-commercialization-for-rare-disease-treatment 2025-08-07T21:39:03+00:00 hourly 0.9 https://trial.medpath.com/news/6258eefc8fbd5c11/fda-issues-complete-response-letter-for-replimune-s-rp1-oncolytic-immunotherapy-delaying-melanoma-launch 2025-08-07T21:37:44+00:00 hourly 0.9 https://trial.medpath.com/news/693ca87003b9f42e/strand-therapeutics-raises-153m-series-b-to-advance-programmable-mrna-cancer-therapies 2025-08-07T21:37:13+00:00 hourly 0.9 https://trial.medpath.com/news/6c6a5f91cc3c7648/cancer-cachexia-pipeline-shows-promise-with-20-therapies-in-development-across-multiple-companies 2025-08-07T21:35:40+00:00 hourly 0.9 https://trial.medpath.com/news/fa38847d485d7fec/dulaglutide-biosimilar-ly05008-demonstrates-therapeutic-equivalence-in-phase-3-trial-for-type-2-diabetes 2025-08-07T21:35:35+00:00 hourly 0.9 https://trial.medpath.com/news/6c60cd50f05fd260/cardiol-therapeutics-stock-plunges-20-as-cbd-based-cardiolrx-misses-primary-endpoints-in-myocarditis-trial 2025-08-07T21:33:38+00:00 hourly 0.9 https://trial.medpath.com/news/d20e12b060020346/avobis-bio-seeks-fda-fast-track-status-for-implantable-cell-therapy-following-positive-crohn-s-fistula-trial 2025-08-07T21:33:26+00:00 hourly 0.9 https://trial.medpath.com/news/7dcc624d8efda91c/fda-approved-asthma-drug-zileuton-shows-promise-in-preventing-food-allergy-reactions 2025-08-07T21:33:08+00:00 hourly 0.9 https://trial.medpath.com/news/397c8eb1feff6b3b/sanome-s-ai-platform-memori-receives-class-iib-ce-certification-for-early-healthcare-associated-infection-detection 2025-08-07T21:32:35+00:00 hourly 0.9 https://trial.medpath.com/news/0b501364c38371b3/brightwater-research-prepares-clinical-trials-for-anti-metastatic-lung-cancer-drug-valoxydin 2025-08-07T21:32:33+00:00 hourly 0.9 https://trial.medpath.com/news/dc8a02a675a835dd/nccn-updates-small-cell-lung-cancer-guidelines-to-include-lambert-eaton-myasthenic-syndrome-testing-and-treatment 2025-08-07T17:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/0a49d0356d63ad30/annovis-bio-secures-comprehensive-patent-protection-for-crystal-buntanetap-through-2046 2025-08-07T17:39:47+00:00 hourly 0.9 https://trial.medpath.com/news/27622834a16209c1/tegoprazan-demonstrates-superior-long-term-gerd-management-in-phase-3-triumph-study 2025-08-07T17:38:46+00:00 hourly 0.9 https://trial.medpath.com/news/4e8fe8b8e8303e56/fda-approves-ajovy-as-first-cgrp-antagonist-for-pediatric-migraine-prevention 2025-08-07T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/b470bfb34fdc8a34/federal-circuit-rules-optional-storage-instructions-don-t-induce-patent-infringement-in-generic-drug-case 2025-08-07T17:38:08+00:00 hourly 0.9 https://trial.medpath.com/news/cded4ae131cb86a5/iovance-biotherapeutics-cuts-workforce-by-nearly-20-following-slow-amtagvi-cell-therapy-launch 2025-08-07T17:37:51+00:00 hourly 0.9 https://trial.medpath.com/news/8ec319ca379fdc8c/maxona-pharmaceuticals-submits-ind-application-for-max-001-novel-non-opioid-pain-treatment 2025-08-07T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/e4921ca3d139c945/nice-recommends-first-nhs-treatment-for-rare-eye-disease-lhon-ending-access-disparity-in-england 2025-08-07T17:37:15+00:00 hourly 0.9 https://trial.medpath.com/news/e9311452a85d23da/alexion-secures-canadian-access-agreement-for-ultomiris-in-two-rare-autoimmune-diseases 2025-08-07T17:37:11+00:00 hourly 0.9 https://trial.medpath.com/news/01cf7d0b670c26b0/intas-pharmaceuticals-and-accord-biopharma-acquire-udenyca-biosimilar-expanding-global-pegfilgrastim-market-presence 2025-08-07T17:36:35+00:00 hourly 0.9 https://trial.medpath.com/news/08a3a54aba83381c/large-scale-study-confirms-tamiflu-safety-in-children-debunks-neuropsychiatric-risk-concerns 2025-08-07T17:35:07+00:00 hourly 0.9 https://trial.medpath.com/news/ea1ccac986df1f27/apreo-health-raises-130-million-to-advance-pivotal-trial-for-novel-emphysema-device 2025-08-07T17:34:37+00:00 hourly 0.9 https://trial.medpath.com/news/b276210d928f3a1e/ph-responsive-graphene-nanomaterials-achieve-enhanced-tumor-targeting-in-breakthrough-cancer-drug-delivery-study 2025-08-07T17:34:23+00:00 hourly 0.9 https://trial.medpath.com/news/0addded14f1f571b/mass-general-brigham-launches-clinical-trials-for-haystack-mrd-ctdna-test-in-head-and-neck-and-skin-cancers 2025-08-07T17:32:43+00:00 hourly 0.9 https://trial.medpath.com/news/efe5af8542b9e63f/meta-analysis-confirms-epimedium-s-efficacy-in-primary-osteoporosis-treatment 2025-08-07T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/eacff7c148989d04/faron-pharmaceuticals-reports-43-complete-remission-rate-in-high-risk-myelodysplastic-syndrome-trial 2025-08-07T13:29:17+00:00 hourly 0.9 https://trial.medpath.com/news/4c0b7142ec3cacb4/minghui-pharmaceutical-secures-131-million-pre-ipo-funding-to-advance-oncology-pipeline-and-commercial-launch 2025-08-07T13:29:06+00:00 hourly 0.9 https://trial.medpath.com/news/8d5a0ed000e81c08/chinese-gene-therapy-ga001-shows-promise-in-restoring-vision-for-retinitis-pigmentosa-patients 2025-08-07T13:28:13+00:00 hourly 0.9 https://trial.medpath.com/news/b177818ca743a9f7/regenxbio-advances-gene-therapy-to-pivotal-phase-iib-iii-trial-for-diabetic-retinopathy 2025-08-07T13:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/b4a96cd22b26288a/valneva-overcomes-fda-safety-pause-for-ixchiq-chikungunya-vaccine-strengthens-market-position 2025-08-07T13:27:29+00:00 hourly 0.9 https://trial.medpath.com/news/86b9dfc1aa7aa008/sinomed-s-cometiu-stent-system-faces-regulatory-setback-in-china-despite-fda-breakthrough-designation 2025-08-07T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/48ea0b599c900f2d/fujifilm-and-horiba-develop-revolutionary-gene-delivery-system-with-100x-productivity-boost-for-gene-therapy-manufacturing 2025-08-07T09:25:58+00:00 hourly 0.9 https://trial.medpath.com/news/e1cca065ccea47bd/almirall-and-absci-expand-ai-drug-discovery-partnership-with-second-dermatology-target 2025-08-07T09:24:57+00:00 hourly 0.9 https://trial.medpath.com/news/c61f520008fa0327/expert-highlights-optimal-positioning-of-bispecific-t-cell-engagers-in-multiple-myeloma-treatment 2025-08-07T09:24:50+00:00 hourly 0.9 https://trial.medpath.com/news/dbc1b5ee16e81fca/modular-medical-completes-clinical-study-of-modd1-insulin-pump-prepares-for-next-generation-pivot-launch 2025-08-07T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/5cb932a6e2a94c64/cartherics-opens-advanced-cell-therapy-manufacturing-facility-to-support-cth-401-clinical-development 2025-08-07T05:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/f6cd63becc829cb5/voyager-therapeutics-advances-single-dose-aav-gene-therapy-vy-1706-for-alzheimer-s-disease-targeting-ind-filing-in-2026 2025-08-07T05:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/67bf3312eb079331/blood-based-protein-analysis-achieves-85-8-accuracy-in-predicting-triple-negative-breast-cancer-immunotherapy-response 2025-08-07T01:33:10+00:00 hourly 0.9 https://trial.medpath.com/news/5bd9fb08052986c6/day-one-biopharmaceuticals-reports-310-revenue-surge-for-pediatric-cancer-drug-ojemda 2025-08-07T01:32:41+00:00 hourly 0.9 https://trial.medpath.com/news/974e0b950f1d03ec/precision-biosciences-reports-first-clinical-evidence-of-hepatitis-b-gene-editing-therapy-pbgene-hbv 2025-08-07T01:31:36+00:00 hourly 0.9 https://trial.medpath.com/news/670662e5727d1663/lonza-excellos-and-akadeum-form-strategic-alliance-to-transform-cell-therapy-manufacturing-quality 2025-08-07T01:29:49+00:00 hourly 0.9 https://trial.medpath.com/news/9d104747ec853a11/protagonist-therapeutics-files-first-nda-for-icotrokinra-in-psoriasis-advances-rusfertide-for-polycythemia-vera 2025-08-07T01:29:19+00:00 hourly 0.9 https://trial.medpath.com/news/12880e3c0f8503cf/chai-discovery-raises-70m-series-a-to-revolutionize-antibody-design-with-ai-platform-achieving-20-hit-rate 2025-08-07T01:29:12+00:00 hourly 0.9 https://trial.medpath.com/news/2f07b6a12037f7f6/phase-ii-trial-shows-nestacell-r-dental-pulp-stem-cell-therapy-significantly-improves-motor-function-in-huntington-s-disease-patients 2025-08-07T01:29:05+00:00 hourly 0.9 https://trial.medpath.com/news/24e0a7ce0fd6ed2b/henlius-initiates-phase-2-trial-of-first-in-class-sialidase-therapy-hlx79-combined-with-rituximab-for-glomerulonephritis 2025-08-07T01:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/d7ddb5b1bdaaf592/ftc-blocks-edwards-lifesciences-945m-jenavalve-acquisition-over-tavr-ar-device-competition-concerns 2025-08-07T01:27:52+00:00 hourly 0.9 https://trial.medpath.com/news/fc8de4eeb1859fd7/novel-nanoparticle-therapy-agg-clnp-shows-promise-for-preventing-rheumatoid-arthritis-and-reducing-flares 2025-08-06T21:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/19ce8bcebe6ccc90/cardurion-completes-enrollment-in-phase-2-trials-for-novel-heart-failure-drug-crd-750 2025-08-06T21:37:27+00:00 hourly 0.9 https://trial.medpath.com/news/f22b4365f95ca152/renovorx-reports-strong-q2-2025-commercial-growth-and-positive-phase-iii-trial-continuation 2025-08-06T21:35:54+00:00 hourly 0.9 https://trial.medpath.com/news/494d6ec59a4f762d/therabene-appoints-dr-oscar-kashala-as-cmo-to-advance-protein-degrader-pipeline-for-hard-to-treat-cancers 2025-08-06T21:35:49+00:00 hourly 0.9 https://trial.medpath.com/news/3a59b38a19200943/phase-i-trial-establishes-maximum-tolerated-dose-for-pegylated-liposomal-doxorubicin-plus-ifosfamide-in-advanced-soft-tissue-sarcoma 2025-08-06T21:33:49+00:00 hourly 0.9 https://trial.medpath.com/news/06f192a08b51aa0b/novo-nordisk-advances-coramitug-to-phase-3-for-attr-cardiomyopathy-following-successful-phase-2-trial 2025-08-06T21:33:44+00:00 hourly 0.9 https://trial.medpath.com/news/3463893b6bddd66b/dual-clinical-trials-advance-mesothelioma-treatment-with-novel-immunotherapy-combinations 2025-08-06T21:33:33+00:00 hourly 0.9 https://trial.medpath.com/news/7f9a29a394a475ca/fda-grants-first-accelerated-approval-for-h3-k27m-mutated-diffuse-midline-glioma-with-dordaviprone 2025-08-06T21:31:54+00:00 hourly 0.9 https://trial.medpath.com/news/d179ab68521188bc/harvard-study-reveals-lithium-deficiency-as-potential-driver-of-alzheimer-s-disease 2025-08-06T17:46:07+00:00 hourly 0.9 https://trial.medpath.com/news/6b4928c5eab2ac15/astria-therapeutics-secures-16-million-japan-partnership-for-hereditary-angioedema-treatment-navenibart 2025-08-06T17:41:54+00:00 hourly 0.9 https://trial.medpath.com/news/4aa81b8ed482ca12/mark-cuban-s-cost-plus-drugs-expands-pharmacy-network-through-giant-eagle-partnership 2025-08-06T17:41:52+00:00 hourly 0.9 https://trial.medpath.com/news/5b6cf0af0997e14d/percheron-s-hmbd-002-shows-promise-against-triple-negative-breast-cancer-in-preclinical-studies 2025-08-06T17:40:51+00:00 hourly 0.9 https://trial.medpath.com/news/d91c037c4a504fad/polyactiva-initiates-us-phase-2b-trial-for-six-month-biodegradable-glaucoma-implant-pa5108 2025-08-06T17:40:21+00:00 hourly 0.9 https://trial.medpath.com/news/a658624adad56a8c/insmed-reports-strong-q2-2025-results-with-arikayce-growth-and-brensocatib-approval-pending 2025-08-06T17:39:52+00:00 hourly 0.9 https://trial.medpath.com/news/2e117ea233680158/experimental-dendritic-cell-therapy-shows-promise-for-glioblastoma-in-phase-1-trial 2025-08-06T17:39:49+00:00 hourly 0.9 https://trial.medpath.com/news/c709a52d2441fb95/diamedica-therapeutics-appoints-julie-krop-as-chief-medical-officer-to-advance-dm199-development 2025-08-06T17:39:13+00:00 hourly 0.9 https://trial.medpath.com/news/2266940ce2314009/standard-biotools-somascan-platform-selected-for-singapore-s-landmark-100000-sample-precision-medicine-study 2025-08-06T17:38:18+00:00 hourly 0.9 https://trial.medpath.com/news/a4ec668a37f4312d/samson-clinical-initiates-phase-iii-trial-of-sublingual-minoxidil-for-male-pattern-hair-loss 2025-08-06T17:38:13+00:00 hourly 0.9 https://trial.medpath.com/news/3bc010062c82959c/fda-grants-fast-track-designation-to-birelentinib-for-relapsed-refractory-cll-sll 2025-08-06T17:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/cc40b22907b964b4/revvity-launches-phsense-reagents-to-accelerate-gpcr-and-adc-drug-development 2025-08-06T17:35:59+00:00 hourly 0.9 https://trial.medpath.com/news/9e75fd4c63fd520b/dana-farber-boston-children-s-hospital-and-broad-clinical-labs-launch-brightseq-initiative-for-pediatric-cancer-genomics 2025-08-06T17:35:37+00:00 hourly 0.9 https://trial.medpath.com/news/e9a47512bf67aed6/fda-approves-tocilizumab-anoh-biosimilar-for-cytokine-release-syndrome-treatment 2025-08-06T17:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/ca4350a5c288ca4f/oxaliplatin-shows-survival-benefit-only-in-stage-iii-colorectal-cancer-patients-under-70-years 2025-08-06T15:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/97c07a190e4dfbd5/jama-surgery-study-validates-dex-g2-blood-test-for-early-gastric-cancer-detection-with-95-sensitivity 2025-08-06T13:28:25+00:00 hourly 0.9 https://trial.medpath.com/news/f6eaf7fda32af675/lantheus-secures-fda-acceptance-for-enhanced-psma-pet-imaging-agent-with-50-increased-batch-size 2025-08-06T13:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/d414baeb2ff6d0d3/mannkind-secures-500-million-strategic-financing-from-blackstone-to-advance-inhaled-therapeutics-pipeline 2025-08-06T13:25:38+00:00 hourly 0.9 https://trial.medpath.com/news/7ecb0c9c927b4fc9/novel-nmda-receptor-modulator-onfasprodil-shows-rapid-antidepressant-effects-with-reduced-side-effects-in-phase-2-trial 2025-08-06T13:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/8488e91a992e839c/two-versus-three-cycles-of-induction-chemotherapy-show-similar-survival-outcomes-in-advanced-nasopharyngeal-carcinoma 2025-08-06T13:25:16+00:00 hourly 0.9 https://trial.medpath.com/news/68c57fef45b18bca/two-major-trials-show-egfr-inhibitors-fail-to-improve-outcomes-in-head-and-neck-cancer 2025-08-06T13:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/66ff65cc6dc79e00/cognitive-functional-therapy-shows-sustained-benefits-for-chronic-low-back-pain-after-three-years 2025-08-06T13:24:28+00:00 hourly 0.9 https://trial.medpath.com/news/bc2cdc7154cc0128/biontech-establishes-clinical-trial-platform-in-victoria-to-accelerate-cancer-treatment-access 2025-08-06T13:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/2165a1db243b32f9/immunoprecise-antibodies-divests-netherlands-operations-for-12m-to-focus-on-ai-driven-drug-discovery-platform 2025-08-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/f9c2fc18b3dc1309/novel-regulation-of-cues-therapy-shows-20-greater-efficacy-than-standard-treatment-for-binge-eating-disorder-in-veterans 2025-08-06T09:32:14+00:00 hourly 0.9 https://trial.medpath.com/news/1abb61549d9809f5/galapagos-receives-fda-rmat-designation-for-car-t-therapy-glpg5101-in-relapsed-refractory-mantle-cell-lymphoma 2025-08-06T09:28:45+00:00 hourly 0.9 https://trial.medpath.com/news/8a2453e6bbf94b41/ainnova-tech-revises-clinical-trial-protocol-for-ai-based-diabetic-retinopathy-detection-following-fda-feedback 2025-08-06T09:28:10+00:00 hourly 0.9 https://trial.medpath.com/news/4fef2a720d37ae57/new-zealand-s-fast-track-approvals-act-faces-early-implementation-challenges-as-rejection-rates-rise 2025-08-06T09:28:01+00:00 hourly 0.9 https://trial.medpath.com/news/29ec14ae4c078d70/chinese-medical-technology-companies-launch-clinical-trials-for-revolutionary-ct-imaging-systems-in-shanghai 2025-08-06T09:27:51+00:00 hourly 0.9 https://trial.medpath.com/news/6d04d694ff565e8a/membrane-tethered-slp-76-engineering-overcomes-car-t-cell-limitations-against-low-antigen-tumors 2025-08-06T05:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/569af689603db246/bracco-imaging-receives-nmpa-approval-for-sonovue-in-female-infertility-assessment-in-china 2025-08-06T05:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/ec90f40ddb70ee50/esmo-2025-delivers-breakthrough-bladder-cancer-results-with-perioperative-immunotherapy-combinations 2025-08-06T05:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/ecc65cf973eea8a6/nxera-pharma-launches-comprehensive-obesity-pipeline-with-novel-oral-glp-1-agonist 2025-08-06T05:21:07+00:00 hourly 0.9 https://trial.medpath.com/news/e8933ddc79752488/bluerock-therapeutics-advances-bemdaneprocel-to-phase-iii-for-parkinson-s-disease-as-market-projected-to-reach-7-0-billion-by-2033 2025-08-06T03:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/80d4e2cbd65082c1/high-discontinuation-rates-plague-pediatric-clinical-trials-as-researchers-push-for-child-centric-design 2025-08-06T02:59:04+00:00 hourly 0.9 https://trial.medpath.com/news/718b0002ad7249ad/casi-pharmaceuticals-surges-57-following-fda-clearance-for-cid-103-kidney-transplant-rejection-therapy 2025-08-06T01:33:05+00:00 hourly 0.9 https://trial.medpath.com/news/741e8fc9f2f01996/idmc-recommends-continuation-of-eli-002-7p-phase-2-trial-in-pancreatic-cancer-following-positive-interim-analysis 2025-08-06T01:28:44+00:00 hourly 0.9 https://trial.medpath.com/news/802f77d0bd8cad95/hmnc-brain-health-s-bh-200-shows-promising-results-in-phase-2-depression-trial-with-genetic-selection-tool 2025-08-06T01:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/067cb23ec960a019/nalu-medical-s-comfort-2-trial-establishes-first-level-1-evidence-for-permanent-peripheral-nerve-stimulation-in-chronic-pain 2025-08-06T01:28:14+00:00 hourly 0.9 https://trial.medpath.com/news/ac24fb6ddd886644/forcast-orthopedics-secures-series-a-funding-to-advance-novel-periprosthetic-joint-infection-therapies 2025-08-06T01:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/2f9d1a6f718526fb/fda-adopts-intact-nmr-spectroscopy-for-enhanced-quality-assessment-of-nanoemulsion-drug-formulations 2025-08-06T01:27:33+00:00 hourly 0.9 https://trial.medpath.com/news/a0f071af68cf69fc/democratic-senators-challenge-fda-s-approval-of-juul-e-cigarettes-amid-conflict-of-interest-concerns 2025-08-06T01:26:14+00:00 hourly 0.9 https://trial.medpath.com/news/fcccf45fff3d53c0/fda-approves-first-cgrp-antagonist-for-pediatric-migraine-prevention-as-ajovy-expands-to-children 2025-08-06T01:26:12+00:00 hourly 0.9 https://trial.medpath.com/news/1e39aa2a5e543476/aurobindo-pharma-acquires-lannett-for-250m-to-expand-us-adhd-therapeutics-portfolio 2025-08-06T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/af99a4cf2bb0b03b/cho-plus-secures-10-4m-barda-contract-to-develop-cell-lines-for-filovirus-monoclonal-antibody-production 2025-08-05T21:28:15+00:00 hourly 0.9 https://trial.medpath.com/news/0c6ae351fcdd1437/promega-secures-patent-victory-against-aobious-in-luciferase-technology-dispute 2025-08-05T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/3676492cbcf53bb2/ategenos-secures-foundational-patent-for-smartpatch-platform-addressing-1t-medication-non-adherence-crisis 2025-08-05T21:26:31+00:00 hourly 0.9 https://trial.medpath.com/news/4292b4b841b13431/flare-therapeutics-initiates-phase-1b-trial-of-first-in-class-pparg-inhibitor-fx-909-for-advanced-urothelial-cancer 2025-08-05T21:25:56+00:00 hourly 0.9 https://trial.medpath.com/news/6c63093deb2b589f/kashiv-biosciences-partners-with-ms-pharma-for-mena-launch-of-omalizumab-biosimilar-adl-018 2025-08-05T21:25:14+00:00 hourly 0.9 https://trial.medpath.com/news/16358365a39474b1/civicascript-announces-low-cost-ustekinumab-biosimilar-distribution-to-expand-access-to-inflammatory-disease-treatment 2025-08-05T21:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/08e83373e1b30ab3/sanofi-discontinues-praluent-supply-to-china-amid-global-demand-surge-and-local-competition 2025-08-05T21:25:10+00:00 hourly 0.9 https://trial.medpath.com/news/e36386afaf2765ca/akyso-therapeutics-advances-long-acting-opioid-use-disorder-treatment-with-successful-phase-1a-trial-and-15m-nih-grant 2025-08-05T21:24:46+00:00 hourly 0.9 https://trial.medpath.com/news/20059616becd4c7e/vitiligo-treatment-pipeline-shows-promise-with-jak-inhibitors-and-novel-immunotherapies-in-phase-3-trials 2025-08-05T21:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/5b6d0dcb745dd08b/porosome-therapeutics-reports-breakthrough-alzheimer-s-platform-with-fda-validated-organoid-studies-and-ai-designed-therapeutics 2025-08-05T21:23:49+00:00 hourly 0.9 https://trial.medpath.com/news/850aa4b9398ba502/imperial-college-s-react-study-partners-with-dementia-trials-accelerator-to-transform-clinical-trial-recruitment 2025-08-05T21:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/d19ca46bd25221aa/biomark-diagnostics-doubles-laboratory-capacity-to-accelerate-lung-cancer-assay-commercialization 2025-08-05T17:54:45+00:00 hourly 0.9 https://trial.medpath.com/news/47b6e588840a8344/merck-s-ifinatamab-deruxtecan-receives-fda-breakthrough-designation-for-small-cell-lung-cancer 2025-08-05T17:50:53+00:00 hourly 0.9 https://trial.medpath.com/news/640c00b88766df05/epicrispr-biotechnologies-doses-first-patient-with-epi-321-novel-epigenetic-therapy-for-facioscapulohumeral-muscular-dystrophy 2025-08-05T17:50:05+00:00 hourly 0.9 https://trial.medpath.com/news/76f7eab71c140095/ac-immune-reports-strong-immunogenicity-data-for-parkinson-s-disease-vaccine-in-phase-2-trial 2025-08-05T17:45:35+00:00 hourly 0.9 https://trial.medpath.com/news/3eb2c4313d14090f/synox-therapeutics-completes-enrollment-in-phase-3-trial-of-emactuzumab-for-rare-joint-tumor 2025-08-05T17:45:30+00:00 hourly 0.9 https://trial.medpath.com/news/3d20eb0f1abbfbd8/kyoto-university-develops-non-addictive-painkiller-adriana-as-morphine-alternative 2025-08-05T17:45:09+00:00 hourly 0.9 https://trial.medpath.com/news/899b14f3450b58bc/corbus-pharmaceuticals-receives-fda-fast-track-designation-for-investigational-therapy 2025-08-05T17:44:36+00:00 hourly 0.9 https://trial.medpath.com/news/7d502077cf77932c/novel-bacterial-consortium-aun-achieves-tumor-eradication-without-immune-system-dependence 2025-08-05T17:44:28+00:00 hourly 0.9 https://trial.medpath.com/news/4e7dd3eea31ef45f/shattuck-labs-secures-103-million-to-advance-first-in-class-dr3-antibody-sl-325-through-phase-2-trials 2025-08-05T17:43:14+00:00 hourly 0.9 https://trial.medpath.com/news/531148ded87d0bda/serb-pharmaceuticals-to-acquire-y-mabs-therapeutics-for-412-million-expanding-rare-oncology-portfolio 2025-08-05T17:42:47+00:00 hourly 0.9 https://trial.medpath.com/news/cdfb7fedc35ff719/ripk1-inhibitor-pipeline-shows-promise-despite-sanofi-setback-in-multiple-sclerosis 2025-08-05T17:42:44+00:00 hourly 0.9 https://trial.medpath.com/news/ebd838e4018001b2/fda-provides-positive-feedback-on-immutep-s-eftilagimod-alfa-for-head-and-neck-cancer-treatment 2025-08-05T17:42:07+00:00 hourly 0.9 https://trial.medpath.com/news/5f98b0beb375b298/gensight-s-gene-therapy-shows-better-outcomes-when-administered-during-dynamic-phase-of-lhon-disease 2025-08-05T17:41:48+00:00 hourly 0.9 https://trial.medpath.com/news/221e6315228886c9/sophia-genetics-and-astrazeneca-expand-ai-partnership-to-optimize-breast-cancer-treatment-outcomes 2025-08-05T17:41:20+00:00 hourly 0.9 https://trial.medpath.com/news/cd32875ec85bd3f1/yatiri-bio-acquires-ngenebioai-to-strengthen-ai-powered-proteomics-platform-for-precision-medicine 2025-08-05T17:38:49+00:00 hourly 0.9 https://trial.medpath.com/news/8fd79689617ef257/gut-metabolite-imidazole-propionate-identified-as-novel-atherosclerosis-driver-and-therapeutic-target 2025-08-05T17:38:47+00:00 hourly 0.9 https://trial.medpath.com/news/e6bac1f02418c346/israeli-researchers-achieve-first-long-term-growth-of-human-kidney-organoids-opening-path-to-regenerative-therapies 2025-08-05T17:38:44+00:00 hourly 0.9 https://trial.medpath.com/news/086b09f9f473696b/contract-manufacturing-industry-report-reveals-impact-of-global-conflicts-and-inflation-on-pharmaceutical-production 2025-08-05T17:38:29+00:00 hourly 0.9 https://trial.medpath.com/news/ad0eb2010fc63143/health-canada-generic-drug-approval-delays-threaten-patient-access-and-healthcare-cost-savings 2025-08-05T17:37:41+00:00 hourly 0.9 https://trial.medpath.com/news/ad35d14e6c516e8e/nih-launches-escape-trial-to-test-maternal-diet-s-role-in-preventing-early-food-allergies-in-infants 2025-08-05T17:37:31+00:00 hourly 0.9 https://trial.medpath.com/news/4865e68655818c87/gedeon-richter-reintroduces-dydrogesterone-only-hrt-option-to-uk-market-after-17-year-absence 2025-08-05T17:36:38+00:00 hourly 0.9 https://trial.medpath.com/news/c87c03239f46dc1c/mdxhealth-acquires-bio-techne-s-exodx-prostate-test-platform-in-15-million-strategic-deal 2025-08-05T16:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/a7ca805dc7fe8c78/global-study-reveals-chronic-spontaneous-urticaria-patients-face-greater-disease-burden-than-other-inflammatory-skin-conditions 2025-08-05T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/b092b415fc0e882b/180-life-sciences-pivots-from-biotech-to-ethereum-treasury-strategy-with-581-million-in-funding 2025-08-05T13:36:02+00:00 hourly 0.9 https://trial.medpath.com/news/f971fe8adfca5a82/biomarin-sets-ambitious-900m-935m-voxzogo-revenue-target-for-2025-amid-strategic-portfolio-restructuring 2025-08-05T13:35:33+00:00 hourly 0.9 https://trial.medpath.com/news/34ef97eb268d4b5b/axogen-raises-2025-revenue-growth-target-to-17-as-avance-nerve-graft-bla-approval-approaches 2025-08-05T13:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/48b6a7d5e91d2428/sensei-biotherapeutics-advances-vista-targeting-cancer-therapy-with-q2-2025-results-and-esmo-presentation 2025-08-05T13:34:42+00:00 hourly 0.9 https://trial.medpath.com/news/59030f0bee78f388/polpharma-biologics-and-fresenius-kabi-partner-on-vedolizumab-biosimilar-for-inflammatory-bowel-disease 2025-08-05T13:31:06+00:00 hourly 0.9 https://trial.medpath.com/news/a09810345b765c10/mcl-1-inhibitors-advance-toward-clinical-breakthrough-with-over-12-drugs-in-development-pipeline 2025-08-05T13:29:30+00:00 hourly 0.9 https://trial.medpath.com/news/8b48718f9dc72b2e/ethris-initiates-phase-2a-trial-of-novel-mrna-therapy-eth47-for-viral-triggered-asthma-exacerbations 2025-08-05T13:29:25+00:00 hourly 0.9 https://trial.medpath.com/news/4d91bbce9843e060/nucleus-network-acquires-hammersmith-medicines-research-to-create-global-early-phase-clinical-trial-network 2025-08-05T13:28:51+00:00 hourly 0.9 https://trial.medpath.com/news/fbf45046166e1fc6/fapon-biopharma-enrolls-first-patient-in-phase-i-trial-of-fp008-novel-anti-pd-1-fusion-protein-for-solid-tumors 2025-08-05T13:28:49+00:00 hourly 0.9 https://trial.medpath.com/news/5fc5999598901433/intranasal-stem-cell-therapy-shows-promise-for-newborn-brain-injury-in-passion-safety-trial 2025-08-05T13:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/53fc07c9066e2879/korean-biotech-hyundai-bioscience-reports-positive-phase-ii-results-for-oral-covid-19-treatment-cp-cov03 2025-08-05T10:58:54+00:00 hourly 0.9 https://trial.medpath.com/news/92f434e5caf83053/sandoz-plans-generic-semaglutide-launch-in-canada-with-up-to-70-price-reduction 2025-08-05T09:32:53+00:00 hourly 0.9 https://trial.medpath.com/news/24907d8b25023df9/taconic-and-cyagen-form-strategic-partnership-to-expand-access-to-16000-genetically-engineered-mouse-models 2025-08-05T09:30:54+00:00 hourly 0.9 https://trial.medpath.com/news/baea99167db4ebb3/tempest-therapeutics-advances-phase-3-trial-of-tpst-1120-combination-for-hepatocellular-carcinoma 2025-08-05T09:28:42+00:00 hourly 0.9 https://trial.medpath.com/news/560cdba797d6e448/health-canada-approves-dyanavel-xr-extended-release-amphetamine-for-adhd-treatment-in-adults-and-children 2025-08-05T08:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/2e11a95e0dba3ba1/metis-technologies-raises-rmb-400-million-series-d-to-advance-ai-driven-nanodelivery-platform 2025-08-05T05:30:04+00:00 hourly 0.9 https://trial.medpath.com/news/0fefe8e855009382/cyclacel-s-plogosertib-shows-promise-against-biliary-tract-cancer-in-preclinical-study 2025-08-05T05:29:54+00:00 hourly 0.9 https://trial.medpath.com/news/0896fe3c3ed9d9e4/real-world-study-confirms-safety-and-efficacy-of-trastuzumab-biosimilar-ct-p6-in-her2-positive-gastric-cancer 2025-08-05T05:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/d04196588834e9e4/sarilumab-demonstrates-significant-quality-of-life-improvements-in-polymyalgia-rheumatica-phase-3-trial 2025-08-05T05:04:31+00:00 hourly 0.9 https://trial.medpath.com/news/bdbb02d7fc7ec2ce/syndax-reports-strong-q2-2025-results-with-revuforj-revenue-growth-and-pending-fda-approval-for-npm1-aml 2025-08-05T01:33:06+00:00 hourly 0.9 https://trial.medpath.com/news/7bd0005247d3866a/breakthrough-study-reveals-hidden-cancer-cells-in-42-of-ovarian-cancer-patients-in-clinical-remission 2025-08-05T01:27:40+00:00 hourly 0.9 https://trial.medpath.com/news/c154a90f5ea204a0/grifols-alzheimer-vaccine-abvac40-demonstrates-53-reduction-in-cognitive-decline-risk-in-phase-2-trial 2025-08-05T01:27:31+00:00 hourly 0.9 https://trial.medpath.com/news/1e773ce416b8124e/vertex-pharmaceuticals-discontinues-vx-993-development-after-phase-2-failure-in-acute-pain 2025-08-05T01:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/63c157a2c9ddca74/first-commercial-brain-gene-therapy-treatments-delivered-in-us-using-clearpoint-neuro-s-smartflow-cannula 2025-08-05T01:26:58+00:00 hourly 0.9 https://trial.medpath.com/news/cbce12d609fe2657/real-world-study-confirms-safety-and-efficacy-of-aflibercept-biosimilar-pavblu-in-6313-patients 2025-08-05T01:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/bec281c5b09bfce6/redwire-launches-spacemd-to-commercialize-space-grown-pharmaceutical-crystals 2025-08-05T01:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/dc59eff83b66cc9d/sonelokimab-shows-promising-24-week-results-in-phase-2-psoriatic-arthritis-trial 2025-08-05T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/287bbc846af16a11/first-in-human-hiv-vaccine-trial-begins-in-africa-using-novel-gorilla-adenovirus-vector-platform 2025-08-04T21:34:16+00:00 hourly 0.9 https://trial.medpath.com/news/5ce12b9fa4ad0d5b/tg-therapeutics-reports-91-revenue-surge-driven-by-briumvi-multiple-sclerosis-treatment 2025-08-04T21:31:53+00:00 hourly 0.9 https://trial.medpath.com/news/4f619f40c4661ba5/agios-pharmaceuticals-addresses-safety-concerns-as-pyrukynd-receives-saudi-approval-for-thalassemia 2025-08-04T21:31:01+00:00 hourly 0.9 https://trial.medpath.com/news/1a9ac25a80ab742b/tearcare-system-demonstrates-cost-savings-and-superior-outcomes-compared-to-cyclosporine-in-dry-eye-treatment 2025-08-04T21:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/9d23a7660b69cd6c/rapid-dose-therapeutics-submits-quickstrip-nicotine-oral-film-for-health-canada-approval 2025-08-04T21:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/d5d6bee34edc5adf/car-macrophages-generated-in-situ-via-mrna-loaded-extracellular-vesicles-show-promise-against-lung-metastasis 2025-08-04T21:30:24+00:00 hourly 0.9 https://trial.medpath.com/news/9caac8343c1f0f14/combination-therapy-achieves-15-month-progression-free-survival-in-advanced-large-cell-neuroendocrine-lung-carcinoma 2025-08-04T21:30:11+00:00 hourly 0.9 https://trial.medpath.com/news/2cd01f2e4b836af1/xoma-acquires-struggling-biotechs-hillevax-and-lava-therapeutics-in-strategic-consolidation-move 2025-08-04T21:28:48+00:00 hourly 0.9 https://trial.medpath.com/news/496db5b53f375db4/agios-pharmaceuticals-faces-fda-delay-for-pyrukynd-thalassemia-approval-amid-safety-concerns 2025-08-04T21:28:20+00:00 hourly 0.9 https://trial.medpath.com/news/ade383b34c8cc1e7/bmi-organbank-receives-fda-breakthrough-device-designation-for-room-temperature-kidney-preservation-technology 2025-08-04T21:27:00+00:00 hourly 0.9 https://trial.medpath.com/news/de7a82b611f0fceb/roche-receives-fda-clearance-for-first-tags-powered-respiratory-test-detecting-four-major-viruses 2025-08-04T21:26:56+00:00 hourly 0.9 https://trial.medpath.com/news/473fafd26a858eb8/university-of-bath-develops-oral-delivery-system-for-injectable-protein-drugs 2025-08-04T21:26:51+00:00 hourly 0.9 https://trial.medpath.com/news/f4c2739e8ebe45c3/praxis-precision-medicines-reports-56-seizure-reduction-with-vormatrigine-despite-stock-decline 2025-08-04T21:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/a5152b80a3f57a09/tg-therapeutics-initiates-phase-3-trial-for-subcutaneous-briumvi-in-multiple-sclerosis 2025-08-04T17:42:08+00:00 hourly 0.9 https://trial.medpath.com/news/cef69a28a22cf15f/tharimmune-advances-th104-as-national-security-solution-against-weaponized-fentanyl-secures-5-47m-funding 2025-08-04T17:38:17+00:00 hourly 0.9 https://trial.medpath.com/news/00c6ac19c7b9f999/onemednet-expands-real-world-data-network-by-25-adding-5-billion-administrative-records 2025-08-04T17:35:58+00:00 hourly 0.9 https://trial.medpath.com/news/8c1acd4d0270eec0/sonnet-biotherapeutics-expands-son-1010-trial-after-promising-response-rate-in-platinum-resistant-ovarian-cancer 2025-08-04T17:35:56+00:00 hourly 0.9 https://trial.medpath.com/news/237b29db288d2ecc/pulsecare-medical-s-nxpfatm-receives-nmpa-approval-as-world-s-first-nanosecond-pulsed-field-ablation-system 2025-08-04T17:35:21+00:00 hourly 0.9 https://trial.medpath.com/news/da4512ed36cacc09/freya-pharma-launches-phase-ii-study-of-lybrido-for-female-sexual-dysfunction-using-novel-blood-flow-measurement 2025-08-04T17:34:53+00:00 hourly 0.9 https://trial.medpath.com/news/b1b56166d3cdf87b/transmedics-receives-fda-approval-for-largest-heart-transplant-preservation-trial 2025-08-04T17:32:32+00:00 hourly 0.9 https://trial.medpath.com/news/52741da96df523d5/inmune-bio-s-inkmune-therapy-meets-primary-endpoints-in-phase-1-2-prostate-cancer-trial 2025-08-04T17:32:30+00:00 hourly 0.9 https://trial.medpath.com/news/95b727b532cd8061/davion-healthcare-files-for-nasdaq-direct-listing-to-advance-non-invasive-medical-technologies 2025-08-04T17:16:00+00:00 hourly 0.9 https://trial.medpath.com/news/605fdba67f73ed1b/medicus-pharma-and-helixnano-partner-to-develop-needle-free-heat-stable-mrna-vaccines 2025-08-04T13:05:14+00:00 hourly 0.9 https://trial.medpath.com/news/6718a5bdc5bfe8a9/australian-researchers-identify-nod2-gene-variants-as-key-to-enhanced-cancer-immunotherapy-response 2025-08-04T13:04:59+00:00 hourly 0.9 https://trial.medpath.com/news/f8045fecb348fb79/atavistik-bio-doses-first-patient-in-phase-1-trial-of-atv-1601-for-akt1-e17k-mutant-solid-tumors 2025-08-04T13:04:42+00:00 hourly 0.9 https://trial.medpath.com/news/7674255f8f414643/guy-s-and-st-thomas-nhs-trust-expands-advanced-therapy-manufacturing-capacity-by-60-to-meet-growing-cell-and-gene-therapy-demand 2025-08-04T13:04:38+00:00 hourly 0.9 https://trial.medpath.com/news/9827bde1cd0f095b/tildrakizumab-demonstrates-sustained-efficacy-and-safety-in-elderly-psoriasis-patients-over-two-years 2025-08-04T13:04:21+00:00 hourly 0.9 https://trial.medpath.com/news/390e17a5512f7a7d/chocolate-compound-theobromine-combined-with-arainosine-outperforms-tamiflu-against-drug-resistant-flu-strains 2025-08-04T13:03:18+00:00 hourly 0.9 https://trial.medpath.com/news/b308bedbf8f5091a/microbiotica-completes-enrollment-in-phase-1b-trial-of-mb310-for-ulcerative-colitis 2025-08-04T13:02:07+00:00 hourly 0.9 https://trial.medpath.com/news/ffec2d96b3156549/neuroendocrine-tumor-pipeline-shows-strong-growth-with-75-therapies-in-development 2025-08-04T10:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/d48b4b117ad68738/certara-s-simcyp-simulator-becomes-first-pbpk-modeling-platform-to-receive-ema-qualification-for-eu-regulatory-submissions 2025-08-04T09:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/62ea403a7a32d2f4/phnyx-lab-secures-4m-to-advance-ai-powered-medical-writing-platform-for-life-sciences 2025-08-04T09:28:26+00:00 hourly 0.9 https://trial.medpath.com/news/66fd2f4c70deeb62/raytone-biotech-doses-first-patient-with-novel-tacrolimus-plug-for-dry-eye-disease 2025-08-04T09:26:49+00:00 hourly 0.9 https://trial.medpath.com/news/08dd8813cfc1bbb2/anbogen-receives-fda-clearance-for-phase-1-2-trial-of-abt-301-triplet-therapy-in-metastatic-colorectal-cancer 2025-08-04T09:26:47+00:00 hourly 0.9 https://trial.medpath.com/news/7f431511e0aed2a7/alveolus-bio-secures-strategic-investment-from-shilpa-medicare-to-advance-respiratory-therapeutics-platform 2025-08-04T05:07:36+00:00 hourly 0.9 https://trial.medpath.com/news/127dab3e734fd3aa/alphamab-oncology-receives-ind-approval-for-first-in-class-bispecific-adc-jskn022-targeting-pd-l1-and-integrin-avb6 2025-08-04T05:07:28+00:00 hourly 0.9 https://trial.medpath.com/news/3faa69ff51ead12f/university-of-michigan-develops-at-home-melanoma-detection-patch-using-microneedle-technology 2025-08-04T05:05:25+00:00 hourly 0.9 https://trial.medpath.com/news/f167260e99779200/green-space-exposure-during-pregnancy-and-early-childhood-reduces-risk-of-neurodevelopmental-disorders 2025-08-04T05:00:13+00:00 hourly 0.9 https://trial.medpath.com/news/46b3e0657d53ae14/dep-sn38-dendrimer-nanoparticle-shows-promise-in-advanced-solid-tumors-with-reduced-toxicity-profile 2025-08-04T01:27:59+00:00 hourly 0.9 https://trial.medpath.com/news/c2c584f563a23d40/australia-develops-world-first-mrna-vaccine-for-foot-and-mouth-disease-in-livestock 2025-08-03T22:03:20+00:00 hourly 0.9 https://trial.medpath.com/news/745f10f47427bed0/united-imaging-launches-fda-cleared-umr-ultra-3t-mri-system-with-dynamic-motion-visualization-technology 2025-08-03T22:00:36+00:00 hourly 0.9 https://trial.medpath.com/news/419cf29fc989902b/indian-regulators-scrutinize-biodeal-s-midazolam-nasal-spray-pricing-exemption-amid-nlem-inclusion-controversy 2025-08-03T14:10:05+00:00 hourly 0.9 https://trial.medpath.com/news/05c43ca63b41cf35/first-in-human-study-of-mrna-2416-shows-promise-in-advanced-solid-tumors-and-ovarian-cancer 2025-08-03T14:06:34+00:00 hourly 0.9 https://trial.medpath.com/news/b347b93cd942d695/luye-pharma-initiates-phase-1-trial-for-novel-triple-target-antidepressant-ly03021 2025-08-03T14:06:29+00:00 hourly 0.9 https://trial.medpath.com/news/95205b99b1283264/cdsco-panel-recommends-approval-for-vorasidenib-with-phase-iii-waiver-for-idh-mutant-gliomas-in-india 2025-08-03T09:57:15+00:00 hourly 0.9 https://trial.medpath.com/news/16fd7078e6033884/cdsco-requests-protocol-revisions-for-novartis-itu512-sickle-cell-disease-trial 2025-08-03T09:57:11+00:00 hourly 0.9 https://trial.medpath.com/news/c6a8893382161547/lg-group-invests-in-strand-therapeutics-mrna-cancer-platform-through-series-b-funding 2025-08-03T06:03:14+00:00 hourly 0.9 https://trial.medpath.com/news/e9b46449f0be5a0e/new-peritoneal-surface-malignancy-guidelines-address-critical-care-gaps-for-70000-us-patients-annually 2025-08-03T03:24:16+00:00 hourly 0.9 https://trial.medpath.com/news/e722e3e7d8480a9b/ice-t-conference-highlights-critical-need-for-standardized-car-t-cell-therapy-supportive-care-protocols 2025-08-03T03:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/b056805fcbe291f2/indian-clinical-trial-shows-one-third-of-type-2-diabetes-patients-achieve-drug-free-remission 2025-08-03T01:40:28+00:00 hourly 0.9 https://trial.medpath.com/news/3ff86545a2de74fa/aptinyx-prepares-for-fda-meeting-on-novel-ptsd-treatment-nyx-783 2025-08-03T01:39:11+00:00 hourly 0.9 https://trial.medpath.com/news/bacbc7f800136759/greek-led-clinical-trial-shows-40-reduction-in-death-risk-for-small-cell-lung-cancer-patients 2025-08-02T22:05:52+00:00 hourly 0.9 https://trial.medpath.com/news/0d4004395f8c9349/dr-reddy-s-semaglutide-launch-in-canada-faces-regulatory-delay-following-compliance-notice 2025-08-02T18:10:58+00:00 hourly 0.9 https://trial.medpath.com/news/be691bf9684ec0d9/blacksmith-medicines-advances-novel-antibiotic-fg-2101-targeting-drug-resistant-gram-negative-bacteria 2025-08-02T18:04:06+00:00 hourly 0.9 https://trial.medpath.com/news/8748acfdb098aa74/archimed-acquires-ai-powered-antimicrobial-stewardship-company-arkstone-medical-group 2025-08-02T18:04:01+00:00 hourly 0.9 https://trial.medpath.com/news/fd7fee06b65d617c/novel-car-nk-cell-therapy-and-chemotherapy-combinations-show-promise-for-pediatric-and-relapsed-aml-treatment 2025-08-02T18:03:44+00:00 hourly 0.9 https://trial.medpath.com/news/5ec622d3620f7b71/teodor-trial-launches-to-test-personalized-neoadjuvant-therapy-for-early-stage-breast-cancer 2025-08-02T18:02:56+00:00 hourly 0.9 https://trial.medpath.com/news/d48472a34497336c/myriad-genetics-secures-200-million-credit-facility-from-orbimed-to-fuel-growth-strategy 2025-08-02T14:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/7cbd31dfbe798642/novel-nanoparticle-formulations-enhance-paclitaxel-delivery-to-cancer-tumors 2025-08-02T14:07:58+00:00 hourly 0.9 https://trial.medpath.com/news/1022e409a3688113/phase-2-skyline-trial-shows-promising-results-for-gene-therapy-in-x-linked-retinitis-pigmentosa 2025-08-02T14:07:31+00:00 hourly 0.9 https://trial.medpath.com/news/d33c0a95b479e3f6/sava-technologies-achieves-10-day-continuous-glucose-monitoring-milestone-with-next-generation-microsensor-platform 2025-08-02T14:07:01+00:00 hourly 0.9 https://trial.medpath.com/news/097316de5222c01f/long-term-syfovre-data-shows-early-treatment-benefits-and-sustained-safety-in-geographic-atrophy 2025-08-02T10:11:24+00:00 hourly 0.9 https://trial.medpath.com/news/a009194a9f0d767b/federal-court-strikes-down-fda-s-narrow-interpretation-of-orphan-drug-exclusivity-in-neurelis-v-brenner 2025-08-02T05:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/5d89627beee1e8f1/systematic-review-reveals-significant-disparities-in-us-biologics-access-across-immunology-specialties 2025-08-02T03:24:37+00:00 hourly 0.9 https://trial.medpath.com/news/9f03e9dd3f321607/washington-research-foundation-awards-5-2m-to-launch-collaborative-clinical-trials-program-for-rare-cancer-therapeutics 2025-08-02T02:20:56+00:00 hourly 0.9 https://trial.medpath.com/news/abfe78f42ff914cf/purgo-scientific-appoints-james-bowman-as-ceo-to-advance-novel-drug-delivery-platform 2025-08-02T02:15:36+00:00 hourly 0.9 https://trial.medpath.com/news/65ed533d9c4b705b/hansa-biopharma-s-imlifidase-enables-gene-therapy-access-for-duchenne-patients-with-pre-existing-antibodies 2025-08-02T02:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/201c33934263b6bb/terbium-161-radioimmunotherapy-shows-superior-efficacy-against-ovarian-cancer-stem-cells-in-preclinical-study 2025-08-01T22:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/025700d6d8e54f18/allan-camaisa-joins-res-nova-biologics-advisory-board-to-advance-breast-cancer-immunotherapy 2025-08-01T22:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/d4b1d4610103b5e4/sucralose-artificial-sweetener-reduces-cancer-immunotherapy-effectiveness-through-gut-microbiome-disruption 2025-08-01T22:19:09+00:00 hourly 0.9 https://trial.medpath.com/news/8791345fa253633b/spine-biopharma-s-sb-01-fails-to-meet-primary-endpoint-in-phase-3-trial-for-chronic-low-back-pain 2025-08-01T22:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/30404161c73ee508/fda-issues-second-rejection-for-regeneron-s-lymphoma-therapy-odronextamab-due-to-manufacturing-issues 2025-08-01T22:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/bab08b4f4510335d/moderna-reports-41-revenue-decline-in-q2-2025-launches-1-5-billion-cost-cutting-initiative 2025-08-01T17:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/5c43f09ebb6d0f8e/ozempic-shows-anti-aging-effects-in-first-clinical-trial-reversing-biological-age-by-3-1-years 2025-08-01T17:22:31+00:00 hourly 0.9 https://trial.medpath.com/news/45594c06a629a994/allogene-therapeutics-modifies-alpha3-trial-design-following-patient-death-adopts-standard-lymphodepletion-protocol 2025-08-01T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/dc6f611b2eaebb22/novel-antibody-capture-system-enhances-targeted-mrna-delivery-with-8-fold-improved-binding-efficiency 2025-08-01T17:22:17+00:00 hourly 0.9 https://trial.medpath.com/news/0400bcbd0b382c26/everest-medicines-invests-30-9m-in-i-mab-following-promising-83-response-rate-for-gastric-cancer-bispecific-antibody 2025-08-01T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/846558af3a5b4b44/i-mab-raises-65-million-to-advance-givastomig-phase-2-trial-for-gastric-cancer 2025-08-01T17:19:02+00:00 hourly 0.9 https://trial.medpath.com/news/4f243adbd25308a6/mabwell-s-cdh17-targeting-adc-7mw4911-receives-dual-ind-acceptance-from-fda-and-nmpa 2025-08-01T17:18:54+00:00 hourly 0.9 https://trial.medpath.com/news/96e849624312862e/esteve-cdmo-acquires-chicago-based-regis-technologies-to-expand-us-manufacturing-capabilities 2025-08-01T17:16:19+00:00 hourly 0.9 https://trial.medpath.com/news/fd0c5882bcec677b/kazia-therapeutics-secures-2-million-private-placement-to-advance-brain-cancer-and-breast-cancer-drug-development 2025-08-01T17:16:10+00:00 hourly 0.9 https://trial.medpath.com/news/48c4ea38970b5c7e/fda-sets-2026-user-fee-rates-for-generic-and-animal-drug-programs-with-inflation-adjustments 2025-08-01T14:13:40+00:00 hourly 0.9 https://trial.medpath.com/news/5271013d584c7a6f/fda-mandates-comprehensive-safety-label-changes-for-all-opioid-pain-medications 2025-08-01T14:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/ac05679362b5e7f9/gsk-engages-trump-administration-in-drug-pricing-negotiations-following-strong-q2-performance 2025-08-01T14:10:04+00:00 hourly 0.9 https://trial.medpath.com/news/34c2e2c54a6dbeca/sanofi-acquires-rights-to-plozasiran-for-395-million-in-greater-china-deal-with-arrowhead 2025-08-01T14:09:14+00:00 hourly 0.9 https://trial.medpath.com/news/d77963f017e1e2fe/gene-therapy-for-x-scid-reveals-critical-role-of-virtual-memory-t-cells-in-early-human-immunity 2025-08-01T14:07:50+00:00 hourly 0.9 https://trial.medpath.com/news/85571f314c25818b/large-real-world-study-questions-effectiveness-of-immunoglobulin-replacement-therapy-in-cll-patients 2025-08-01T09:50:17+00:00 hourly 0.9 https://trial.medpath.com/news/b8145c157b01496b/dpiit-and-roche-india-sign-strategic-partnership-to-accelerate-healthcare-innovation-in-critical-therapeutic-areas 2025-08-01T09:49:51+00:00 hourly 0.9 https://trial.medpath.com/news/8e24d08f0864b54c/bd-advances-at-home-hpv-testing-with-ivdr-certification-and-fda-submission-for-cervical-cancer-screening 2025-08-01T05:30:32+00:00 hourly 0.9 https://trial.medpath.com/news/d8a88c143caa6842/knight-therapeutics-submits-minjuvi-supplemental-application-for-follicular-lymphoma-in-brazil 2025-08-01T05:30:30+00:00 hourly 0.9 https://trial.medpath.com/news/c84b9f053cf228cb/certara-appoints-ai-pioneer-dr-chris-bouton-as-cto-to-advance-next-generation-drug-development-platform 2025-08-01T05:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/4cc9cef360636b33/breakthrough-victoria-and-monash-university-invest-2-25m-in-three-medical-startups-targeting-rare-disease-and-autoimmune-conditions 2025-08-01T05:27:57+00:00 hourly 0.9 https://trial.medpath.com/news/2b4a3c0387ff88d0/zenara-pharma-secures-first-generic-sertraline-capsule-approval-with-180-day-market-exclusivity 2025-08-01T05:27:55+00:00 hourly 0.9 https://trial.medpath.com/news/4ba9cfc22235b398/chatgpt-reduces-clinical-trial-screening-time-from-40-minutes-to-under-3-minutes-but-human-oversight-still-required 2025-08-01T05:27:48+00:00 hourly 0.9 https://trial.medpath.com/news/acf45fbed650f8fd/preventive-cardiology-experts-call-for-enhanced-cardiovascular-risk-assessment-and-early-intervention-strategies 2025-08-01T05:27:45+00:00 hourly 0.9 https://trial.medpath.com/news/0394917d8c4b32b3/breast-cancer-treatment-de-escalation-advances-through-multi-institutional-clinical-trials 2025-08-01T05:27:38+00:00 hourly 0.9 https://trial.medpath.com/news/7f2270dace6cf07b/health-system-fragmentation-creates-barriers-to-timely-lung-cancer-biomarker-testing 2025-08-01T03:00:39+00:00 hourly 0.9 https://trial.medpath.com/news/b950f441315831fe/fda-approves-vostally-oral-solution-first-liquid-ramipril-formulation-for-hypertension-treatment 2025-08-01T01:40:30+00:00 hourly 0.9 https://trial.medpath.com/news/8a888032a8e00f72/maxcyte-partners-with-anocca-to-advance-tcr-t-cell-therapy-manufacturing-using-non-viral-gene-editing-platform 2025-08-01T01:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/11631ad7c197e3d6/danish-study-confirms-safety-of-jn-1-updated-covid-19-mrna-vaccines-in-real-world-analysis 2025-08-01T01:34:10+00:00 hourly 0.9 https://trial.medpath.com/news/c5ccd56428431e9b/mrna-therapy-reactivates-developmental-gene-to-repair-heart-damage-after-heart-attack 2025-08-01T01:34:05+00:00 hourly 0.9 https://trial.medpath.com/news/151692addca3ce8a/radius-pharmaceuticals-secures-patent-victory-for-tymlos-osteoporosis-treatment-through-2038 2025-08-01T01:33:37+00:00 hourly 0.9 https://trial.medpath.com/news/72f65ba1cef97855/genvira-and-labskin-secure-ps1-2-million-uk-canada-grant-for-melanoma-immunotherapy-development 2025-08-01T01:33:35+00:00 hourly 0.9 https://trial.medpath.com/news/362da9e21bc798ce/ucla-scientists-achieve-first-in-human-reprogramming-of-stem-cells-to-generate-renewable-cancer-fighting-t-cells 2025-08-01T01:33:28+00:00 hourly 0.9 https://trial.medpath.com/news/7a5c272817638a62/immunophotonics-completes-phase-1b-2a-trial-of-ip-001-immunotherapy-for-advanced-solid-tumors 2025-08-01T01:33:04+00:00 hourly 0.9 https://trial.medpath.com/news/8885600cf49b4d58/mitochondria-targeting-drugs-emerge-as-next-generation-obesity-treatments-to-address-glp-1-limitations 2025-08-01T01:30:59+00:00 hourly 0.9 https://trial.medpath.com/news/b6724756309236e2/serina-therapeutics-advances-once-weekly-injectable-vmat2-inhibitor-for-tardive-dyskinesia-treatment 2025-08-01T01:30:51+00:00 hourly 0.9 https://trial.medpath.com/news/a3d67465d3446e20/fda-approves-leqvio-as-first-line-monotherapy-for-cholesterol-management 2025-08-01T01:30:00+00:00 hourly 0.9 https://trial.medpath.com/news/5fa3f6bbe6f78250/vir-biotechnology-reports-positive-early-results-from-dual-masked-t-cell-engagers-trials 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/24ca2a58f0ba2e09/ich-opens-public-consultation-on-draft-q3e-guideline-for-extractables-and-leachables-in-drug-products 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/09fe6c4fadf8ffba/benralizumab-shows-promise-in-rare-eosinophilic-disorders-beyond-asthma-study-finds 2025-08-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe56549e9f0481ce/biocryst-names-charlie-gayer-as-new-ceo-following-jon-stonehouse-s-retirement-announcement 2025-07-31T21:43:32+00:00 hourly 0.9